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The non-receptor tyrosine kinase Src has been found to be overexpressed and activated in many 
human cancers, where it has been implicated in changes in cellular proliferation, adhesion, 
migration, apoptosis, angiogenesis, and tumour growth.  In addition, several other members of 
the Src family have also been implicated in various cancer phenotypes.  Our examination of a 
wide panel of colon, breast, and lung cancer cell lines revealed that not only Src, but also Yes, 
Fyn, Lyn, and Lck, were expressed at both the mRNA and protein levels in different 
combinations, and at varying levels, between cell lines.  When examined for kinase activity, it 
was discovered that only a subset of the expressed Src family members had detectable kinase 
activity within a given cell line.  To investigate the involvement of the Src family members in 
the proliferation, adhesion, migration, and colony forming ability of four selected cancer cell 
lines, both Src family kinase inhibitors, which inhibit the kinase activity of multiple Src family 
members, and RNA interference, which selectively decreases the expression of individual 
proteins, were used.  It was found that the involvement of these proteins in all of the cellular 
processes investigated was cell line-specific, with the greatest effects observed in HT29 cells, 
which have relatively high Src protein levels and kinase activity.  Furthermore, the 
consequences of Src family member inhibition were also inhibitor specific, as treatment with 
PP2 and SKI I generally had greater effects on the cellular processes examined than did 
treatment with SU6656 or SKI II.  It was also found that the inhibition of multiple Src family 
kinases by at least one of the inhibitors generally resulted in greater effects on the cancer cell 
phenotypes investigated than were observed when the expression of Src, Fyn, or Yes was 
decreased using RNA interference.  This suggests that multiple Src family members may need 
to be targeted in order to inhibit the increased proliferation, cell-matrix adhesion, migration, 
and colony forming ability exhibited by cancer cells.  The identification of the cancer cell 
phenotypes in which particular Src family members are involved is of interest, as these proteins 
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1.  REVIEW OF THE LITERATURE 
1.1.  INTRODUCTION 
     The non-receptor tyrosine kinase Src has been implicated in a wide variety of cellular 
phenotypes and has been found to contribute to the development and progression of a large 
number of different cancers, including colon, breast, pancreatic, brain, lung, and ovarian 
cancers, as well as melanomas and hematopoietic cancers (Summy and Gallick, 2003; Lieu and 
Kopetz, 2010).  In cancer cells, increased Src activity has been implicated in changes in 
proliferation, cellular adhesion, migration, apoptosis, angiogenesis, and tumour growth 
(Thomas and Brugge, 1997; Irby and Yeatman, 2000; Summy and Gallick, 2003, Yeatman, 
2004; Lieu and Kopetz, 2010).  However, Src is only the prototype member of the Src family of 
nine non-receptor tyrosine kinases.  Some of the other Src family kinases (SFKs), notably Yes, 
Fyn, Lyn, and Hck, have also been implicated in the development and progression of human 
cancers (Lieu and Kopetz, 2010).  As such, the Src family has become an attractive target in 
cancer therapy, and a number of Src-directed chemical inhibitors are either currently in use or 
are undergoing clinical trials for the treatment of both hematopoietic cancers and various solid 
cancers (Wheeler et al., 2009; Lieu and Kopetz, 2010).  As multiple SFKs may be co-expressed 
within a given cell, it is of interest to determine what cellular events the individual SFKs are 
involved in.  The goal of this work was therefore to investigate the involvement of the 
individual SFKs in cancer cell phenotypes in selected human cancer cell lines by using RNA 
interference (RNAi), as well as commercially available SFK inhibitors.  The work presented 
herein provides further insight into the involvement of the ubiquitously expressed SFKs, Src, 
Yes and Fyn, in the proliferation, adhesion, migration and colony forming ability of selected 
cancer cell lines. 
     The following literature review will focus on the development and progression of cancer, 
with an emphasis on colon cancer, as well as the involvement of the SFKs in several cancer cell  
phenotypes.  Chemical SFK inhibitors currently used in cancer therapy, as well as those 
undergoing clinical trials, will also be discussed. 
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1.2.  CANCER 
     Cancer is a disease characterized by uncontrolled cell growth.  This disease can develop in 
many different cell types; there are more than one hundred different cancers affecting different 
organs currently known.  Furthermore, there may also be distinct subtypes of cancer within a 
given organ, each of which potentially requires a different form of treatment.  This results in 
cancer being an extremely complex disease both in its diagnosis and treatment (Hanahan and 
Weinberg, 2000).  Cancer is also a disease with significant mortality; as many as seven million 
deaths worldwide were attributed to this disease in 2001 alone (Danaei et al., 2005). 
     A large percentage of people will develop some form of cancer over their lifetime and, 
although cancer can strike any person at any age, most cancers develop in the elderly.  It is 
estimated that 40% of women and 45% of men in Canada will develop cancer in their lifetime, 
and one in four Canadians will die from this disease (Canadian Cancer Society’s Steering 
Committee: Canadian Cancer Statistics, 2009).  Although cancer can develop in a large number 
of organs, over half of cancers affecting men and women in Canada can be attributed to three 
types; namely, prostate cancer, lung cancer, and colorectal cancer in men, and breast cancer, 
lung cancer, and colorectal cancer in women.  Lung cancer is the leading cause of cancer-
related death in both men and women in Canada, while colorectal cancer is responsible for the 
second most deaths (Canadian Cancer Society’s Steering Committee: Canadian Cancer 
Statistics, 2009).  Cancer is therefore a disease with a serious impact on society.   
     Both genetic and behavioural risks can contribute to the development of cancer, which 
occurs when cells gain a growth advantage through the mutation of different genes.  Individuals 
may be genetically predisposed to developing cancer if they have inherited germline mutations 
of particular genes.  For example, mutations in Breast Cancer (BRCA) 1 and BRCA2 genes are 
inherited in a dominant fashion in hereditary breast and ovarian cancers (Ford et al., 1998), 
while mutation in adenomatous polyposis coli (APC) is observed in one form of hereditary 
colon cancer (Nakamura et al., 1992).  The presence of such mutations results in an increased 
risk of developing cancer in affected individuals.  A large number of cancers may also develop 
as a result of environmental and behavioural risks.  It is estimated that modifiable behaviours 
contributed to 35% of all cancer deaths in 2001, with the major behaviours being smoking, 
alcohol use, a low intake of fruits and vegetables, and being overweight or obese (Danaei et al., 
2005).  The most obvious example of the impact of behaviour on cancer incidence is likely the 
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link between smoking and cancer; it is estimated that 21% of cancer deaths may be attributed to 
smoking worldwide (Danaei et al., 2005).  Some cancers can also develop following infection 
with particular viruses or bacteria.  For example, the expression of human papilloma virus viral 
proteins can cause transformation leading to cervical cancer (Syrjänen and Syrjänen, 1985), 
while Helicobacter pylori infection can contribute to the development of gastric cancers 
(Loffeld et al., 1990).  Behavioural, environmental, and genetic factors can therefore all 
contribute to cancer development. 
     Although cancer remains a disease with significant mortality, the large amount of research 
that has gone into understanding it has lead to various interventions capable of decreasing 
cancer incidence and mortality.  For instance, the development of vaccines such as those for 
hepatitis B, which has been implicated in liver cancer, and human papilloma virus, which is a 
significant cause of cervical cancer, should lead to a decreased incidence of specific cancers.  
Furthermore, the implementation of programmes to increase awareness and encourage the 
modification of behavioural risk factors that can lead to cancer should also result in a decreased 
incidence of this disease in general.  The development of better detection methods and 
increased screening should also lead to earlier detection and thus better prognoses due to earlier 
interventions.  These advances, coupled to more effective chemotherapeutic and radiation 
therapies, should result in further decreases in the incidence and mortality of this disease in the 
future.  
 
1.2.1.  Cancer development and progression 
1.2.1.1.  Initial cancer cell growth 
     Cellular growth and death are normally tightly regulated.  Cancer may develop when these 
processes become deregulated and there is an accumulation of genetic and chromosomal 
changes that result in a proliferative advantage (reviewed in Sadikovic et al., 2008).  Both 
chromosomal instability, which can result in abnormalities in both the number and structure of 
chromosomes, and microsatellite instability, which refers to point mutations that occur as a 
result of defects in DNA repair, can increase the likelihood of cancer developing.  However, 
cancer does not develop as often as may be suggested by the mutation rate; evidence suggests 
that more than one mutation is required within a given cell in order for tumourigenesis to occur.  
Not only do tumour cells generally exhibit several genetic alterations ranging from point 
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mutations to chromosome deletions, but lesions that represent intermediate stages in the 
transformation from normal cells to pre-malignant states to invasive tumours have also been 
identified (Foulds, 1954).  Several types of cancer also occur in an age-dependent manner, 
suggesting that mutations must accumulate over time within a cell in order for it to undergo 
tumourigenesis.  Indeed, it has been observed that four to seven mutations occur in the course 
of transformation (Renan, 1993).  Therefore, although cells harbouring mutations are usually 
detected and undergo cell death, the cells that are able to evade this process may develop 
further mutations that lead to tumourigenesis. 
     The mutation or altered expression of three types of genes in particular can lead to 
transformation; namely, oncogenes, tumour suppressor genes, and stability genes (reviewed in 
Vogelstein and Kinzler, 2004).  Any alteration in the expression or activity of oncogenic 
proteins or tumour suppressors, be it through mutation of the gene or altered expression levels, 
can lead to the development of cancer.  Oncogenes code for proteins that promote cell survival 
and proliferation.  Therefore, mutations that either lead to the constitutive expression of the 
gene product, such as through gene amplification, or in the activation of their protein product, 
such as may occur due to chromosomal translocations or the mutation of residues that regulate 
the activity of the gene product, can lead to the transformation of a cell (Vogelstein and 
Kinzler, 2004; Sadikovic et al., 2008).  For instance, the oncogene k-ras is commonly mutated 
in cancers such that it remains in an active conformation, resulting in abnormal cell 
proliferation (Bos, 1989).  The increased signalling that results from the higher activity of 
oncogenic proteins may ultimately lead to tumourigenesis. 
     Tumour suppressors, in contrast, normally function to prevent uncontrolled cell growth and 
cellular survival.  Therefore, unlike oncogenes, which can lead to cancer through their 
activation, mutations of tumour suppressor genes that inhibit the activity or expression of their 
protein products can provide the cell with a selective growth advantage, resulting in 
transformation (Vogelstein and Kinzler, 2004).  For instance, the classic example of a tumour 
suppressor protein, p53, has been found to be mutated in 50% of cancers (Soussi and Wiman, 
2007).  In colon cancer, the loss of p53 function frequently occurs through the missense 
mutation of one allele combined with the deletion of the other allele (Baker et al., 1989).  
Indeed, the portion of chromosome 17p that contains the p53 gene has been found to be deleted 
in over 75% of colon cancers (Vogelstein et al., 1988).  As p53 normally functions to initiate 
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cell cycle arrest, senescence, or apoptosis in response to DNA damage or other cellular stresses, 
it is not surprising that the mutation of the p53 gene can lead to cellular transformation (Aylon 
and Oren, 2007).  The loss or mutation of genes coding for p53 and other tumour suppressors is 
a common occurrence in tumourigenesis. 
     The loss of either the activity or expression of proteins involved in DNA damage repair can 
also contribute to cellular transformation (Vogelstein and Kinzler, 2004).  Stability genes, 
which include mismatch repair (MMR) genes, nucleotide excision repair genes, and base-
excision repair genes, code for proteins that act to repair DNA damage that occurs either 
through normal DNA replication, or through exposure to DNA damaging agents (reviewed in 
Friedberg, 2003).  As the protein products of these genes are responsible for maintaining the 
genetic material of a cell with as few mutations as possible, there is an increased likelihood of 
mutations in other genes upon loss of function, including oncogenes and tumour suppressor 
genes (Vogelstein and Kinzler, 2004).  The accumulation of these mutations can subsequently 
lead to transformation.  
     Epigenetic changes, or heritable changes in gene expression that do not affect the gene 
sequence itself, are also capable of conferring a growth advantage on a cell and can lead to 
cellular transformation.  Such changes are common in cancer, and include alterations in DNA 
methylation, histone modification, and microRNA expression (reviewed in Sawan et al., 2008).  
For instance, in non-cancerous cells, the majority of the CpG islands associated with promoters 
are unmethylated, allowing for transcription of the associated genes, while hypermethylation of 
these regions is generally associated with gene silencing (reviewed in Sadikovic et al., 2008).  
However, cancer cells can have significant disruptions in DNA methylation and both 
hypermethylation of promoter regions and global hypomethylation are common (Ehrlich, 
2002).  This can lead to the development of cancer, as hypermethylation of the promoter 
regions of tumour suppressor genes results in the decreased expression of tumour suppressor 
proteins, while hypomethylation can lead to the increased expression of oncogenic proteins 
(Vogelstein and Kinzler, 2004).  Alterations in the post-translational modifications of histones 
can also affect the expression of particular genes by altering the access of transcription factors 
and other proteins to their promoter regions (Sawan et al., 2008).  Therefore, both mutations 
and epigenetic modifications that lead to the abnormal expression or activity of oncogenes, 
tumour suppressor genes, or stability genes, can provide a cell with a growth advantage that 
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results in transformation.  Although hereditary predispositions to cancer can result if these 
mutations or epigenetic changes are present in the germline and are passed to offspring, they 
also commonly occur in somatic cells and lead to sporadic cancers.  
 
1.2.1.2.  Cancer cell characteristics 
     Transformed cells are phenotypically distinct from the normal cells from which they are 
derived (reviewed in Hanahan and Weinberg, 2000).  These differences can include the ability 
to regulate their own growth and proliferation, insensitivity to growth inhibition signals, and an 
ability to evade apoptosis signals.  In addition, cancer cells are also able to undergo an 
unlimited number of cell divisions and replicate at an elevated rate.  Finally, a subset of cancer 
cells is able to promote angiogenesis and undergo metastasis.  These characteristics will be 
discussed in the following section.  
 
1.2.1.2.1.  The enhanced growth of cancer cells      
     Normally, cells require growth signals to undergo proliferation, a dependency that acts to 
regulate cellular growth within a tissue.  Tumour cells, however, are much less dependent on 
exogenous growth signals.  Although paracrine signalling is likely also involved in signalling 
the majority of cancer cells to proliferate (reviewed in Hanahan and Weinberg, 2000), many 
tumour cells are able to secrete many of their own growth factors and signal in an autocrine 
manner.  This allows cancer cells to grow in the absence of signalling molecules from the 
normal surrounding tissue (Joslin and Lauffenburger, 2006).  Some tumour cells can also 
overcome the dependence upon growth factors by overexpressing growth receptors, which 
allows low levels of growth factors that would not normally result in the induction of signalling 
pathways to be detected, resulting in proliferation (Hanahan and Weinberg, 2000).  Similarly, 
some cancer cells also express integrins that, upon binding the extracellular matrix (ECM), are 
capable of activating signalling pathways that result in cellular proliferation (reviewed in 
Lukashev and Werb, 1998; Giancotti and Ruoslahti, 1999).  In addition to increased pro-growth 
signalling, cancer cells can also become insensitive to anti-growth signals (Hanahan and 
Weinberg, 2000).  The ability to grow in the presence of anti-growth signals, as well as a 
decreased dependence upon pro-growth signals, provides cells with a proliferative advantage 
and contributes to cancer cell growth. 
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     The ability to evade programmed cell death, or apoptosis, is also a hallmark of cancer cells 
that, along with increased rates of proliferation, contributes to their ability to expand in number 
(Hanahan and Weinberg, 2000).  Normally, cells monitor themselves for abnormalities 
including DNA damage, aberrant signalling, an insufficiency of survival factors, loss of cell-
cell or cell-ECM contacts, or hypoxia, and will undergo apoptosis if they are detected 
(reviewed in Evan and Littlewood, 1998).  Once triggered, apoptosis results in a disruption of 
the cell membrane, the breakdown of the cytoplasmic and nuclear skeletons and degradation of 
the chromosomes, the loss of cytosol and, finally, the fragmentation of the nucleus (Kerr et al., 
1972).  In this way, damaged cells are prevented from further proliferating.  Cancer cells, 
however, are able to expand even when damaged, which allows them to accumulate further 
mutations and form tumours. 
     Senescence, the state reached by a cell once it has gone through the maximum number of 
divisions possible and stops dividing, is a property of all normal cells.  The number of divisions 
possible for a cell to make is determined by the length of the telomeres located at the ends of 
chromosomes; as DNA polymerase is unable to replicate the ends of chromosomes, 50 to 200 
base pairs are lost from the telomeres following every cell division (Raynaud et al., 2008).  
Once the telomeres have been degraded, the maximum number of divisions by a cell has been 
reached and cells normally enter senescence, thereby ensuring that the multiplication of a given 
cell is limited (Hayflick, 1965).  However, cancer cells are able to undergo further divisions by 
maintaining their telomeres, a phenomenon that is observed in most cancers (Shay and 
Bacchetti, 1997).  This is accomplished in the majority of cancer cells by upregulating the 
expression of telomerase, the enzyme responsible for adding nucleotide repeats onto the ends of 
telomeres (Counter et al., 1992).  Alternately, telomeric DNA may be exchanged 
interchromosomaly through recombination (Bryan et al., 1995; Bryan and Reddel, 1997).  The 
maintenance of telomere length allows cancer cells to undergo an essentially limitless number 
of cell divisions, thereby allowing them to further expand in number.  Therefore, the 
characteristics of cancer cells provide them with autonomy from environmental signals, allow 
them to evade apoptosis, and confer upon them limitless replicative potential, which lead to 
tumour growth.  Once a tumour has reached a certain size, however, these abilities are no 
longer sufficient for its survival; the growth of larger tumours requires angiogenesis.  
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1.2.1.2.2.  The ability of cancer cells to undergo angiogenesis  
     Angiogenesis, the process whereby new blood vessels are formed, is involved in 
physiological processes such as embryonic development, wound healing, and tissue 
regeneration, as well as in pathological tumour growth and metastasis.  The ability to induce 
angiogenesis is important in tumour growth since the size of a tumour is limited by a lack of 
oxygen and nutrients.  Initially, small tumours are able to use the existing vasculature of the 
affected individual in order to obtain sufficient oxygen and nutrients; however, after reaching a 
size of approximately 150 µm this becomes insufficient for the tumour to survive (Awwad et 
al., 1986), causing tumour cells to grow along existing blood vessels (Holash et al., 1999).  
However, for a tumour to grow larger than approximately 1 mm in diameter, the cells must 
acquire the ability to induce blood vessel formation (Gimbrone et al., 1972).  As angiogenesis 
is normally tightly regulated by the balance of pro- and anti-angiogenic factors, cancer cells can 
induce this process through changes in the expression levels of these factors.  For instance, 
increased levels of the pro-angiogenic factors vascular endothelial growth factor (VEGF) 
(Senger et al., 1986) and/or fibroblast growth factor (FGF) (Takahashi et al., 1992) are secreted 
by tumours when compared to normal tissue, while the expression of various inhibitors of 
angiogenesis, such as "-interferon and thrombospondin-1, may be downregulated (Volpert et 
al., 1995).  Secreted pro-angiogenic factors induce the surrounding endothelial cells to move 
towards the source of these factors and form blood vessels that subsequently provide the 
tumour with oxygen and nutrients and, ultimately, allow it to grow larger.   
 
1.2.1.2.3.  The ability of cancer cells to invade and metastasize 
     Once a primary tumour has been established, a subset of tumour cells may move to a 
secondary site by either invading adjacent tissues or through the process of metastasis, whereby 
cancer cells spread to distant locations in the body by moving through the bloodstream, the 
lymphatic system, or the body cavity (reviewed in Hanahan and Weinberg, 2000; 
Oppenheimer, 2006; Geiger and Peeper, 2009).  This process requires that cancer cells detach 
from the primary tumour, invade into either lymph or blood vessels, and move through these 
vessels to distant areas of the body.  Once the cells have reached a suitable site, they must then 
extravasate from the vessels and into the tissue of the secondary site, and, finally, establish 
themselves in this site (Geiger and Peeper, 2009).  Only a small number of cells from a primary 
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tumour will acquire this ability (Fidler and Kripke, 1977; Talmadge et al., 1982); cells that are 
able to invade or metastasize have altered expression of cell adhesion molecules, such as E-
cadherin, integrins, and cell-cell adhesion molecules (CAMS), which results in a loss of 
adhesion that allows them to move away from the tumour (Hanahan and Weinberg, 2000).  The 
loss of adhesion is a hallmark of cells undergoing the endothelial to mesenchymal transition 
(EMT), or de-differentiation, that is commonly observed in metastasis (Geiger and Peeper, 
2009).  Another hallmark of cells that have the ability to invade or metastasize is the enhanced 
secretion of proteases into the extracellular environment (Jechlinger et al., 2003).  These 
proteases facilitate invasion by degrading the surrounding extracellular matrix (ECM).  
Proteases secreted by surrounding inflammatory and stroma cells may also contribute to 
invasion in this manner (Egeblad and Werb, 2002).  Therefore, both the loss of adhesion and 
the secretion of proteins that affect the surrounding environment allow tumour cells to become 
more invasive, leading to metastasis.   
     Once cells have moved away from the primary tumour to a secondary site, they may then 
adhere and grow to form a tumour in this new site (Oppenheimer, 2006).  The ability of 
tumours to form at a secondary site is dependent upon the microenvironment of the secondary 
organ, and, indeed, there is some selectivity in metastasis (Kaplan et al., 2005), with metastatic 
cells often forming secondary tumours in the liver, lungs, lymph nodes, bone marrow, and 
brain.  Furthermore, primary tumours from a particular organ will often metastasize to the same 
secondary site within different patients.  For example, breast cancer cells frequently metastasize 
first to the lymph nodes and then to the liver, lungs, and bone; colon cancers commonly 
metastasize to the liver; and lung cancers preferentially metastasize to the lymph nodes and 
then the brain (Tierney et al., 2009).  Metastasis is of great clinical importance, as up to 90% of 
cancer deaths are caused by metastases rather than the primary tumour (Hanahan and 
Weinberg, 2000).  
 
1.2.2.  Colon cancer 
     One cancer in which the SFKs have strongly been implicated is colorectal cancer.  
Colorectal cancer, like other cancers, is a disease of uncontrolled cell growth that can affect 
both the rectum and colon.  The colorectal mucosa is made up of an epithelium separated from 
the base of the colon by a lamina propria, which is a layer of loose connective tissue, and a thin 
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layer of smooth muscle known as the muscularis mucosae (reviewed in Ponz de Leon and Di 
Gregorio, 2001).  The colon epithelium is formed by a single layer of columnar cells, through 
which water and ions are absorbed, and goblet cells, which synthesize, store and secrete mucin.  
These cells are continually sloughed off and replaced every four to six days by cells produced 
at the base of the colorectal crypts that form the interior of the colon (Lipkin et al., 1963).  The 
colorectal crypts are also made up of a single layer of columnar epithelial cells that contain 
absorptive and goblet cells, as well as undifferentiated precursor cells (Ponz de Leon and Di 
Gregorio, 2001).  As new cells are continually differentiating from these colon stem cells, it has 
been hypothesized that the disruption of their normal proliferation can lead to the development 
of colon cancer (Wang et al., 2006).  
     One of the earliest detectable abnormalities in the colon is the formation of clusters of 
mucosal cells with an abnormally large layer of epithelia known as aberrant crypt foci (ACF) 
(Roncucci et al., 1991).  A small number of ACF will further progress to form adenomatous 
polyps, which are clusters of cells arising from uncontrolled crypt cell division.  Although the 
majority of these polyps will not develop into cancer, a small number may become malignant.  
Indeed, it is believed that the majority of colon cancers develop from adenomatous polyps 
(Winawer et al., 1997), and the detection and removal of these polyps can prevent the 
formation of colon cancer (Winawer et al., 1993). 
      
1.2.2.1.  Epidemiology of colon cancer 
     There are large geographical variations in the incidence of colon cancer; China and South 
American countries have a relatively low incidence, while western industrialized nations have a 
much higher incidence (Parkin et al., 2005).  Indeed, colorectal cancer is one of the most 
common cancers in the western world.  Approximately half of the population of western 
countries will develop a colorectal tumour by the time they reach 70 years of age; however, of 
these, only 10% will develop malignancies (Kinzler and Vogelstein, 1996).  Although the 
majority of pre-cancerous polyps do not develop into malignant tumours, colorectal cancer 
remains a disease with significant mortality.  For instance, colorectal cancer is the third most 
common cancer in both males and females in Canada, with 22 000 new cases diagnosed and 
approximately 9000 deaths estimated in 2009 (Canadian Cancer Society’s Steering Committee: 
Canadian Cancer Statistics, 2009).  This corresponds to 13.5% and 12.1% of all cancers 
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diagnosed in men and women, respectively, while 12.4% of all cancer deaths in men and 11.8% 
in women can be attributed to colorectal cancer.  Therefore, as in other western nations, colon 
cancer is a disease with serious incidence and mortality in Canada.  
     Although there is a genetic basis for the development of colon cancer, environmental factors 
play a role as well, possibly by affecting the risk of genetic mutations.  Interestingly, there is an 
increase in the incidence of colon cancer among populations that have adopted a western diet 
after immigrating from areas of low incidence to areas of high incidence (King et al., 1985; Lee 
et al., 2007).  This further supports the idea that diet plays a significant role in the development 
of this disease.  In addition to diet, there are also a host of other risk factors associated with 
colon cancer.  These include: age (Gloeckler Ries et al., 2003), inflammatory bowel disease 
(Ekbom et al., 1990), having first-degree relatives with colon cancer (Bonelli et al., 1988), or 
having a hereditary syndrome associated with colon cancer.  Gender is also a factor, as men 
have a higher incidence of colon cancer than women (Gloeckler Ries et al., 2003).  As with 
other cancers, tobacco use (Chao et al., 2000), alcohol consumption (Cho et al., 2004), and low 
physical activity (Colditz et al., 1997) have also been found to be significant risk factors for 
colon cancer.  Cumulatively, these behavioural and environmental factors, as well as genetic 
risk factors, all contribute to the likelihood of an individual developing colon cancer. 
 
1.2.2.2.  The genetic basis of colon cancer 
     One of the most frequently mutated genes found in colon cancer is that of the tumour 
suppressor APC; mutations in this gene can be found in up to 70% of sporadic colon cancers 
(Powell et al., 1992; Suraweera et al., 2006).  Indeed, mutations of the APC gene can be found 
as early as in ACF and are common in dysplastic polyps, suggesting that the mutation of this 
gene may be one of the initial steps in adenoma formation (Jen et al., 1994).  Normally, APC 
acts as a suppressor of Wnt signalling by catalyzing the degradation of "-catenin.  The most 
common APC mutations are nonsense mutations that truncate the APC protein amino-terminal 
to the "-catenin interacting domain, resulting in elevated levels of free cytosolic "-catenin.  
This allows the stabilized "-catenin to translocate to the nucleus where it acts along with T-cell 
factors to activate various transcription factors involved in cellular proliferation (Molatore and 
Ranzani, 2004).  APC also has additional functions in regulating cellular adhesion, apoptosis, 
and chromosomal segregation that can further affect transformation (Fodde et al., 2001; Kaplan 
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et al., 2001; Qian et al., 2007).  Mutation of the APC gene is therefore a significant event in the 
transformation of colon cells. 
     In addition to APC, there are several other genes that are also frequently mutated in colon 
cancer.  For instance, the protein product of the oncogene k-ras has been found to be activated 
in approximately 50% of colon cancers (Vogelstein et al., 1988).  The activation of this protein 
results in increased cellular proliferation through the Ras-Raf-Mitogen activated protein kinase 
(MAPK) pathway, leading to clonal expansion.  Mutation of p53 has also been found in over 
50% of colon cancers and is an important event in the transition from late adenoma to full-
fledged carcinoma (Rodrigues et al., 1990; Kikuchi-Yanoshita et al., 1992).  Indeed, 
progression from adenoma to colon cancer is a multistep process requiring the mutation of 
several genes, often including those encoding k-Ras and p53. 
     Although the majority of colorectal cancers are spontaneous, there are two genetically 
inherited forms: Familial Adenomatous Polyposis (FAP) and Hereditary Nonpolyposis 
Colorectal Cancer (HNPCC) (reviewed in Kinzler and Vogelstein, 1996; Rustgi, 2007).  FAP, 
which is caused by a germline mutation of the tumour suppressor gene APC, is inherited in an 
autosomal, dominant fashion and is estimated to affect approximately 1 in 7000 to 1 in 13 000 
people (Bisgaard et al., 1994; Kinzler and Vogelstein, 1996).  People with this condition 
develop hundreds to thousands of benign adenomatous polyps, usually by the time they have 
reached thirty years of age.  Although these polyps are in and of themselves not harmful, the 
large number of polyps increases the likelihood that one or more may become malignant to the 
point where the development of cancer is inevitable (Rustgi, 2007).  The age at which colon 
cancer develops in people with FAP is also much earlier than in the general population, usually 
occurring by forty years of age.  
     The other form of genetically inherited colon cancer, HNPCC, is caused by germline 
mutations in essential components of the DNA MMR complex; over 90% of these are found in 
human mutS homologue 2 (hMSH2) and human mutL homologue 1 (hMLH1).  MMR 
inactivation results in a nearly 1000-fold increase in the spontaneous mutation rate, thereby 
accelerating the time in which colon cancer develops to under 36 months.  Over their lifetimes, 
people who harbour these mutations have an 80% risk of developing colon cancer (Rustgi, 
2007).  Mutations in MMR genes that result in microsatellite instability, such as those found in 
HNPCC can also be found in approximately 15% of sporadic colon cancers (Suraweera et al., 
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2002).  Therefore, although mutations in APC and/or MMR components are found in both 
sporadic and inherited colon cancers, genetically inherited forms of colorectal cancer result in 
the development of cancer at a much younger age than occurs in the general population. 
  
1.2.2.3.  Detection, staging, and treatment of colon cancer 
     Adenomatous polyps, the precursors to colon tumours, are largely asymptomatic and rarely 
cause detectable symptoms (Cappell, 2005).  Although early stage colorectal cancer is also 
largely asymptomatic, late stage colon cancer commonly presents with symptoms such as 
abdominal pain, changes in bowel habits, weight loss, and blood in the stool (Falterman et al., 
1974; Beard et al., 1995).  Other symptoms can include nausea, malaise, anorexia, and 
abdominal distention, although these are less common.  The symptoms experienced by a given 
patient also depend upon the location and size of the tumour, and whether the cancer has 
metastasized (Cappell, 2005).  Since these symptoms often do not present until a more 
advanced, incurable stage, it is difficult to detect colon cancer by clinical means.  Therefore, it 
is suggested that mass screening of the population be undertaken in order to detect colon cancer 
at an early stage, when it is largely curable (Winawer et al., 1997; Smith et al., 2003).  As 
colon cancer risk is age related, with over 95% of cases occurring after fifty years of age, this 
screening generally begins at fifty (Harford, 2006).  Screening allows colon cancer to be 
detected at earlier stages than would otherwise be likely (Mandel et al., 1999). 
     Screening for colon cancer can be carried out using a number of methods, although fecal 
occult blood testing (FOBT) and/or colonoscopy are generally used.  FOBT examines stool 
samples for the presence of blood.  However, the sensitivity and specificity of FOBT are less 
than ideal because not only does colon cancer cause bleeding only intermittently, but 
microscopic bleeding in the colon can also result from a number of other causes (Winawer et 
al., 1997).  Therefore, any patient with a positive FOBT is referred for colonoscopy, which is 
both highly sensitive and specific (Harford, 2006).  Indeed, colonoscopy is capable of detecting 
not only colon cancers, but also large polyps (> 1.0 cm) with high sensitivity, and even small 
polyps (< 0.6 cm) with moderate sensitivity (Rex et al., 1997).  Another advantage of 
colonoscopy is that it is possible to remove polyps and take biopsy samples for pathological 
examination during the procedure (Cappell, 2005).  It is suggested that individuals over the age 
of fifty have a colonoscopy every ten years in order to screen for colon cancer.  Currently, there 
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are also investigations into a number of other screening methods to detect colon cancer in its 
early stages, such as fecal DNA and immunochemical tests, as well as the use of computed 
tomography (CT) colonography (reviewed in Harford, 2006).  New screening methods will 
hopefully allow more colon cancers to be detected at an early stage. 
     It is important to properly stage colon cancer in order to determine a prognosis, as well as 
the correct course of treatment.  Staging can be done preoperatively using CT scan, urinalysis, 
complete blood count, and by assessing liver and kidney function (Hawk et al., 2005).  
Following surgical staging, colorectal cancer can be classified into four stages using the 
tumour, node, metastasis (TNM) staging system.  This staging system differentiates the extent 
of invasion, whether lymph nodes are involved, and if metastasis has occurred (Table 1.1).  The 
stage at which colon cancers are detected also determines the course of treatment.  For instance, 
colon cancers detected in stage I, where the tumour has invaded only the submucosa or 
muscularis, may be cured with surgery alone.  However, once the cancer has metastasized, and 
is in stage IV, there is a very poor prognosis (Hawk et al., 2005).  While surgery may still be 
used to treat the disease, chemotherapy with the cancer drug 5-fluoracil (5-FU) may be given as 
a palliative therapy when this is no longer a treatment option.  This can increase survival and 
quality of life; however, the majority of patients will die within two years of developing 
metastatic colon cancer (Markowitz et al., 2002).  Unfortunately, the majority of people with 
colon cancer are only diagnosed once the cancer has progressed to the later stages of the 
disease (Hawk et al., 2005).  Given the high mortality of colon cancer when detected at later 












1.3.  SRC FAMILY KINASES 
1.3.1.  Historical overview 
     Peyton Rous first noted how tumours could be induced in chickens when exposed to a 
“filterable agent” derived from a chicken sarcoma in 1911 (Rous, 1911).  This agent was later 
found to be a virus, which became known as the Rous Sarcoma Virus (RSV).  Support for the 
idea that RSV was involved in cancer came in 1955, when it was demonstrated that cells in a 
tumour induced by RSV infection not only survived the infection but secreted an infectious 
virus, suggesting that the virus was involved in maintaining the malignant state of the tumour 
(Rubin, 1955).  Despite initial skepticism in the scientific community, the discovery that 
tumours can result from viral infection later resulted in the awarding of the Nobel Prize to Rous 
in 1966 (Martin, 2004).   
     The transforming gene of RSV was not identified to be viral Src (v-Src) until 1970 (Martin, 
1970).  The presence of such a gene within the genome of RSV was suggested by the finding 
that the RNA genomes of replicating, transformation competent strains of RSV were larger 
than those of non-transforming strains.  This suggested that a gene missing from the 
transformation defective strains was responsible for transformation (Duesberg and Vogt, 1970).  
This was indeed the case, and oligonucleotide fingerprinting was used to identify a marker for 
the transforming gene close to the 3’ end of the viral RNA (Wang et al., 1976).  At the same 
time, a v-Src deletion mutant was used to generate a complimentary DNA probe specific for 
Src that was found to recognize not only v-Src, but also a homologous sequence in normal 
avian DNA (Stehelin et al., 1976).  Furthermore, this sequence was also found to be conserved 
in vertebrate DNA.  This normal cellular gene, or cellular Src (c-Src), was the first proto-
oncogene, or cellular homologue of a retroviral transforming gene, identified.  The discovery 
that retroviral oncogenes have a cellular origin led to the second Src-related Nobel Prize being 
awarded to Bishop and Varmus in 1989 (Martin, 2004).  Upon sequencing the c-Src gene, it 
was discovered that it differs from v-Src by a carboxy-terminal deletion and a number of point 
mutations that would later be found to be important in regulating the activity of the Src proteins 
(Shalloway et al., 1981; Takeya and Hanafusa, 1983).   
     Although the v-Src gene was identified in 1970, it was not until 1977 that the v-Src protein 
was isolated by using the serum from rabbits infected with RSV to immunoprecipitate v-Src 
from transformed fibroblasts (Brugge and Erikson, 1977).  It was discovered shortly after v-Src 
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was immunoprecipitated from cell extracts that this protein was a kinase (Collett and Erikson, 
1978; Levinson et al., 1978).  In fact, v-Src was the first identified tyrosine kinase, as prior to 
this discovery it was thought that only threonine and serine residues could be phosphorylated 
(Hunter and Sefton, 1980).  Upon investigation, c-Src was also found to have kinase activity, 
although this was much lower than that exhibited by v-Src (Collett et al., 1978; Oppermann et 
al., 1979).  The decreased kinase activity of c-Src correlated with the decreased transforming 
ability of this protein in comparison to v-Src; although the expression of v-Src causes 
transformation when it is expressed in cells (Erikson et al., 1980), c-Src was found to have 
much lower transforming ability in both mammalian cell lines and chicken embryo fibroblasts 
(Parker et al., 1984; Shalloway et al., 1984; Iba et al., 1984).  Despite this, some cells were 
found to undergo phenotypic changes consistent with transformation when c-Src was expressed 
at high levels (Johnson et al., 1985).  Therefore, due to its role in cancer, Src has historically 
been of great interest, and continues to be of interest.  For the remainder of this work, c-Src will 
be referred to simply as Src. 
 
1.3.2.  Src family protein structure 
     There are eight members of the Src family of proteins expressed in mammals.  These 
proteins share a common domain structure of six different functional regions, and range in size 
from 52 to 62 kDa (Figure 1.1) (reviewed in Brown and Cooper, 1996; Thomas and Brugge, 
1997).  The N-terminal domain of these proteins is a Src homology (SH) 4 domain of 15 to 17 
residues in length, which may be post-translationally modified with fatty acids.  These fatty 
acids are important in the localization of the SFKs within the cell (Silverman and Resh, 1992; 
Silverman et al., 1993).  For instance, when myristoylated on Glycine-2, the SFKs can be found 
associated with cellular membranes or in the cytosol, while unmyristoylated SFKs do not bind 
membranes and remain unbound in the cytosol (Resh, 1994).  The SH4 domains of all SFKs, 
with the exception of Src and Blk, also contain cysteine residues that may be reversibly 
palmitoylated post-translationally, which acts to stabilize the SFKs at the membrane (Koegl et 
al., 1994).  
     C-terminal to the SH4 domain is the unique domain (Figure 1.1), so named as it is the least 
conserved domain among the SFKs.  These domains range in size from 50 to 80 amino acids 

















Figure 1.1.  Src family kinase domain structure.  The SFKs share a common domain 
structure, with an SH4 domain followed by a unique domain, SH3 and SH2 domains and a 
kinase domain.  The important regulatory tyrosines (Y) of Src, Y530 and Y419, are shown; the 
other SFKs have corresponding regulatory tyrosines.  The domain structure of v-Src is also 
shown.  Of note is that the v-Src protein is lacking the regulatory Y530 at the c-terminal end of 
the protein.   
 
 
for the specific interactions of each SFK with particular receptors and other protein targets.  For 
instance, it has been shown that Lck associates with the T-cell receptors CD4 and CD8# 
through this domain (Veillette et al., 1988; Shaw et al., 1989).  Fyn also associates with the 
cytoplasmic chains of the T-cell receptor through its unique domain (Timson Gauen et al., 
1992).  Therefore, it is likely that the unique domain plays a role in specifying the substrates of 
the different SFKs.   
     A non-catalytic SH3 domain of approximately 50 amino acids follows the unique domain 
(Figure 1.1).  SH3 domains are found in many signalling molecules and are involved in both 
intra- and inter-molecular interactions.  The SH3 domains of different proteins bind different 
consensus sequences; the SH3 domains of the SFKs bind proline-rich regions with the 
consensus sequence of P-X-X-P (Alexandropoulos et al., 1995), where the specificity of the 
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interaction is determined by the amino acids adjacent to the proline residues (Rickles et al., 
1995).  The SH3 domains of the SFKs are involved in both regulating the catalytic activity of 
these proteins through intramolecular interactions, and mediating intermolecular interactions 
with other protein substrates (Ingley, 2008).   
     The SH2 domain that follows the SFK SH3 domain is another protein binding domain of 
approximately 100 amino acids that can recognize and bind a short amino acid sequence 
containing a phosphotyrosine residue.  Like SH3 domains, SH2 domains are also found in 
different protein tyrosine kinases and preferentially bind different consensus sequences 
(Thomas and Brugge, 1997).  The specificity of individual SH2 domains is determined by the 
three to five amino acids following the tyrosine residue (Songyang et al., 1993), whereby one 
of the two hydrophobic binding pockets present in the SH2 domain binds the phosphotyrosine 
and the second interacts with the third amino acid following this residue (Eck et al., 1993; 
Waksman et al., 1993).  The SFKs preferentially bind the sequence pY-E-E-I (Songyang et al., 
1993).  Following the SH2 domain is an SH2-kinase linker region that functions as a SH3 
binding site and is involved in maintaining the SFKs in an inactive state. 
     The final domain of the SFKs is a 250 amino acid SH1 kinase domain, which is responsible 
for the catalytic activity of these proteins.  SH1 kinase domains, which contain subdomains 
including an ATP binding pocket, are well conserved in all tyrosine kinases (Brown and 
Cooper, 1996).  Despite the conserved nature of this domain, the consensus sequence 
phosphorylated by this domain varies between proteins; the SFKs preferentially phosphorylate 
the consensus sequence EEEIY
G
/EEFD (Songyang et al., 1995).  The SFK kinase domain also 
contains a regulatory tyrosine residue that is necessary for the activation of the Src kinases 
(Smart et al., 1981; Brown and Cooper, 1996).  A short regulatory tail of 15 to 17 amino acids 
that contains another phosphorylation site important in negatively regulating the kinase activity 
of the SFKs is also present at the carboxy terminal end of the SFKs (Cooper et al., 1986). 
 
1.3.3.  Src family regulation 
     The kinase activity of the SFKs is regulated by the phosphorylation state of key regulatory 
tyrosines, as well as by intramolecular interactions involving the SH3, SH2, and C-terminal 
domains (reviewed in Thomas and Brugge, 1997).  The key tyrosine (Tyr) residues important in 
regulating the kinase activity of human Src are Tyr 530, which is found in the C-terminal 
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negative regulatory tail of the protein, and Tyr 419, which is located in the kinase domain; the 
other family members have corresponding residues.  Normally, the majority of Src present in a 
cell has been phosphorylated on Tyr 530 by the Carboxy-terminal Src kinase (Csk) (Nada et 
al., 1991; Okada et al., 1991), or its homologue Csk homology kinase (Chk) (Davidson et al., 
1997).  When Tyr530 is phosphorylated, the SFKs are held in an inactive, closed conformation 
where phosphorylated Tyr 530 is bound by the SH2 domain in an intramolecular interaction 
(Xu et al., 1997), and the SH3 domain interacts with the linker region found between the SH2 
and the kinase domains (Figure 1.2).  The dephosphorylation of Tyr 530, however, disrupts the 
intramolecular associations holding the protein in the inactive conformation, which leads to its 
activation (Cooper and King, 1986).  Indeed, the mutation or loss of Tyr 530 can lead to the 
constitutive activation of Src (Cartwright et al., 1987).  Not surprisingly, v-Src, which lacks the 
C-terminal regulatory tail present in its cellular homologue, is also constitutively active 
(Takeya and Hanafusa, 1983).   












Figure 1.2.  Src family kinase activation.  Src is normally held in an inactive state in the cell 
(left panel), whereby Y530 is phosphorylated and is bound by the SH2 domain.  The linker 
region between the SH2 domain and the kinase domain also associates with the SH3 domain 
when Src is in the closed conformation, thereby holding it in an inactive state.  Possible 
mechanisms of activation are shown in the middle panel.  When Y530 is de-phosphorylated 
and the intramolecular associations of the SH2 and SH3 domains are disrupted, Src is in an 
active state.  The autophosphorylation of Y419 results in full activation of Src.  The other SFKs 
are regulated in the same manner, with corresponding regulatory tyrosines.  (Reproduced from 
Thomas and Brugge, 1997). 
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     The interaction of the SFKs with other proteins can also disrupt the intramolecular 
associations that hold the SFKs in an inactive state, thereby also leading to SFK activation.  For 
example, the SFKs bind substrates such as focal adhesion kinase (FAK) (Cobb et al., 1994; 
Thomas et al., 1998), p130
Cas
 (Burnham et al., 2000), and platelet-derived growth factor 
receptor (PDGFR) (Kypta et al., 1990; Alonso et al., 1995) through their SH2 and SH3 
domains.  As these intermolecular associations have higher affinity for these domains than the 
intramolecular associations maintaining the SFK in an inactive conformation, the 
intramolecular interactions are disrupted (Bjorge et al., 2000a).  Therefore, both the 
dephosphorylation of Tyr 530 and the interaction of the SFKs with other proteins can lead to 
the activation of the SFKs. 
     In addition to the dephosphorylation of Tyr 530 and the disruption of the SFK 
intramolecular interactions, the autophosphorylation of the other regulatory tyrosine residue, 
Tyr 419, is necessary for full activation of the SFKs.  The phosphorylation of this residue  
causes it to be displaced from the substrate binding pocket, thereby allowing the SFKs to bind 
substrates (Xu et al., 1997, 1999).  Therefore, the SFKs are inactive and in the closed 
conformation when Tyr 530 is phosphorylated, Tyr 419 is dephosphorylated, and the SH2 and 
SH3 domains are engaged in intramolecular interactions.  They are fully active when the SH2 
and SH3 domain intramolecular interactions are disrupted, Tyr 530 is dephosphorylated, and 
Tyr 419 is phosphorylated (Figure 1.2) (Kmiecik and Shalloway, 1987).  The phosphorylation 
states of both Tyr 530 and Tyr 419 consequently dictate the level of SFK activity (Ingley, 
2008).   
     As the phosphorylation states of key regulatory tyrosines are important in the regulation of 
SFK activity, phosphatases which dephosphorylate Tyr 419 or Tyr 530 play an important role 
in regulating the activity of these proteins.  The dephosphorylation of Tyr 530 leading to 
increased SFK activity can be accomplished through the action of a number of phosphatases, 
including protein tyrosine phosphatase (PTP) # (Harder et al., 1998), PTP1B (Bjorge et al., 
2000b), Src homology region 2 domain-containing phosphatase (SHP-1) (Somani et al., 1997), 
and SHP-2 (Peng and Cartwright, 1995; Walter et al., 1999), among others, whereas the 
dephosphorylation of Tyr 419 leads to decreased SFK activity (reviewed in Roskoski, 2005).  
The activity level of the SFKs therefore depends upon regulation by kinases and phosphatases, 
as well as on the formation and disruption of intermolecular interactions. 
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     The involvement of the SFKs in different signalling pathways can also be regulated by the 
localization of these proteins within a cell.  For instance, the majority of the Src protein present 
in fibroblasts is held in an inactive state in the perinuclear region, in either endosomes or in 
association with the microtubule-organizing centre (Kaplan et al., 1992), while constitutively 
active forms of Src can be found primarily in association with the cytoskeleton (Hamaguchi 
and Hanafusa, 1987).  Indeed, inactive Src is maintained in the perinuclear region until it is 
activated, at which time it is translocated in endosomes to the plasma membrane (Sandilands et 
al., 2004).  Upon activation, Src can therefore be found both in endosomes (de Diesbach et al., 
2008) and at the cell surface, where it associates with peripheral membrane associated focal 
adhesions (Kaplan et al., 1994).  This relocation brings Src closer to specific substrates at the 
plasma membrane, where Src is able to interact with integrins, growth factor receptors, and 
other signalling molecules that were unavailable in the perinuclear space (Sandilands et al., 
2004).  The localization of active Src into distinct cellular compartments can therefore lead to 
differential signalling, as different substrates become available.  This may also provide one way 
in which specificity in signalling between the SFKs is achieved, as the subcellular localizations 
and trafficking of the various SFKs differs, presumably because of the differing acylations of 
the family members (de Diesbach et al., 2008; Sato et al., 2009).  Src, which is only 
myristoylated, is transported to the plasma membrane by endosomes.  In contrast, Lyn and Yes, 
which are monopalmitoylated, are transported through the secretory pathway, via the Golgi, 
while the dual palmitoylated Fyn is directly targeted to the plasma membrane (Kasahara et al., 
2007; Sato et al., 2009).  This raises the possibility that the specific functions of the SFKs may 
be directed, in part, through their distinct localizations within the cell by allowing interactions 
with the substrates located at those distinct sites (Sato et al., 2009).  The involvement of the 
SFKs in signalling pathways is therefore regulated both by the phosphorylation state of the 
given SFK and the specific protein substrates with which it interacts. 
 
1.3.4.  Src family members 
     The SFKs are involved in signalling in response to interactions with a wide variety of 
molecules, including growth factor and immune receptors, cytokines, G-protein-coupled 
receptors, and adhesion molecules such as integrins (reviewed in Parsons and Parsons, 2004).  
Therefore, it is perhaps not surprising that this family of proteins has been implicated in a wide 
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variety of cellular processes, including proliferation, differentiation, adhesion, migration, cell 
survival, and invasion (reviewed in Brown and Cooper, 1996), and that the aberrant activation 
of the SFKs has been found in a wide variety of diseases, including cancer (Ishizawar and 
Parsons, 2004), neurodegenerative diseases (Ho et al., 2005), and epilepsy (Sanna et al., 2000). 
     Although the SFKs share the same basic domain structure and are often co-expressed within 
a given cell type, the different SFKs also have distinct features.  Each of the SFKs that will be 
examined further in this work will therefore be discussed briefly, including their expression 
patterns and the phenotypes observed in knockout mice lacking a single SFK.  Important 
























1.3.4.1.  Src kinase 
     The prototype member of the Src family is Src, a 60 kDa non-receptor tyrosine kinase.  
Although Src is ubiquitously expressed, it is expressed at particularly high levels in platelets 
(Golden et al. 1986), neurons (Cotton and Brugge, 1983), and osteoclasts (Horne et al., 1992).  
In addition to the ubiquitously expressed isoform of Src, there are also two neuron specific 
isoforms that result from differential splicing of extra exons into the SH3 domain (Brugge et 
al., 1985; Martinez et al., 1987; Pyper and Bolen, 1990). 
     A great deal of insight into the cellular functions of the SFKs has come from studies of 
knockout mice.  Despite being implicated in a variety of cellular processes, including 
proliferation, differentiation, and migration, the only readily observable phenotype of src
-/-
 
mice is the development of osteopetrosis, a defect in bone resorption that leads to an 
overgrowth of bone (Soriano et al., 1991).  This is perhaps not surprising as Src is required for 
the normal differentiation and function of osteoclasts, which act to resorb bone (Lowe et al., 
1993).  More recently, src
-/-
 mice have also been found to have a defect in lactation, implicating 
Src in mammary gland development as well (Watkin et al., 2008).  These findings suggest that 
although Src is expressed in most cells and is involved in many cellular processes, it is not 
necessary for the majority of them.      
 
1.3.4.2.  Yes kinase 
     Like Src, the 62 kDa Yes kinase is ubiquitously expressed, although it is found in 
particularly high levels in fibroblasts, endothelial cells, and portions of the brain (Sudol et al., 
1988; Lowell and Soriano, 1996).  Yes and Src share the greatest sequence homology of the 
SFKs, with 90% homology of the kinase domain and 80% homology overall (Kitamura et al., 
1982).  
     Despite its ubiquitous expression, yes
-/-
 knockout mice do not show any readily observable 
phenotype (Lowell and Soriano, 1996).  Indeed, the only phenotypic change in yes
-/-
 mice is 
decreased transport of Immunoglobulin A (IgA) across epithelial cells, which is important in 
the immune response to pathogens entering the body through mucosal surfaces (Luton et al., 
1999).  However, Yes likely has at least some role in many of the cellular events regulated by 
Src and the other SFKs, as its expression appears to be able to compensate for the loss of other 
family members. 
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1.3.4.3.  Fyn kinase 
     Like Src and Yes, Fyn is ubiquitously expressed.  However, there are two 59 kDa isoforms 
of Fyn: Fyn (T) is specific to hematopoietic cells, while Fyn (B) is expressed in other cell 
types.  These isoforms are due to alternative splicing of the Fyn gene in the seventh exon, 
which codes for the kinase domain (Cooke and Perlmutter, 1989).  Fyn is involved in a diverse 
set of cellular functions through its ability to bind and phosphorylate a large number of 
different intracellular signalling molecules.  In particular, Fyn has been implicated in cellular 
adhesion, T-cell signalling, and in brain functions (Resh, 1998).  Evidence for the involvement 
of Fyn in brain functions has come from the study of Fyn knockout mice, where a significant 
decrease in myelination has been reported (Umemori et al., 1994).  fyn
-/-
 knockout mice also 
have abnormal hippocampal development and defects in learning and memory functions, as 
well as defects in thymocyte signalling (Grant et al., 1992; Stein et al., 1992).  
  
1.3.4.4.  Lyn kinase 
     Lyn is generally considered to be expressed mainly in immune cells.  In particular, Lyn is 
the most highly expressed SFK in B-cells (Xu et al., 2005).  Lyn is involved in both activating 
and inhibiting the activation of these cells, depending on the stimulus involved, as well as the 
developmental state of the cell (reviewed in Scapini et al., 2009).  Lyn is also expressed in 
other cell types, including myeloid cells (Rider et al., 1994) and in the brain (Umemori et al., 
1992).  There are two co-expressed isoforms of Lyn that result from alternative splicing within 
the unique domain; one of the isoforms is 53 kDa while the other is 56 kDa (Stanley et al., 
1991; Yi et al., 1991).  
     Lyn knockout mice have impaired B-cell function and develop lethal autoimmune disease.  
Although the population of B-cells present in the bone marrow of lyn
-/-
  mice is comparable to 
that observed in lyn
+/+
 mice, the number of peripheral B-cells is decreased by over 50% (Hibbs 
et al., 1995; Nishizumi et al., 1995).  B-cells from lyn
-/-
 mice are also hyper-responsive to B-
cell signalling, as Lyn is involved in downregulating this process.  This is thought to result in 
abnormal B-cell selection, which leads to the production of self antibodies and the subsequent 
development of autoimmune disease (Xu et al., 2005).  
     Despite originally being thought to have expression restricted to cells of lymphoid origin, 
Lyn has more recently been found to be expressed in epithelial cells.  For instance, Lyn is 
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expressed in cultured airway smooth muscle cells (Pertel et al., 2006), as well as in normal 
prostate epithelia.  Indeed, Lyn is important in prostate epithelium development, and lyn
-/-
 mice 
have abnormal prostate gland morphogenesis (Goldenberg-Furmanov et al., 2004).  It is likely 
that Lyn has important functions in other epithelial tissues as well.  
 
1.3.4.5.  Other Src family members 
     The expression of the other SFKs, Lck (56 kDa), Hck (59 kDa), Fgr (58 kDa), and Blk (56 
kDa), is mainly restricted to hematopoietic cells, although Hck and Fgr are also expressed at 
high levels in osteoclasts in mice (reviewed in Lowell and Soriano, 1996).  Hck and Fgr are, 
however, expressed primarily in neutrophils, monocytes and macrophages, while Fgr is also 
expressed in mature B-cells (Brown and Cooper, 1996).  These two proteins, as well as Lyn, 
have also been found to be involved in a variety of intracellular signalling pathways in myeloid 
cells, including cytokine receptor signalling (Corey et al., 1993; Corey et al., 1994; Anderson 
and Jorgensen, 1995), fc fragment of IgG receptor (Fc$R) signalling (Hamada et al., 1993; 
Wang et al., 1994), and the lipopolysaccharide response (Stefanova et al., 1993).  Of the two 
other SFKs, Lck is expressed mainly in T-cells and natural killer cells, while Blk is mainly 
expressed in B-cells.  Interestingly, while lck
-/-
 mice exhibit a block in T-cell development, as 







 mice do not show any observable phenotypic changes (Lowell and Soriano, 1996).  
The non-ubiquitous SFKs are, however, important in signalling in various immune cells.   
 
1.3.5.  Src family redundancy 
     As the SFKs are often co-expressed, the possibility exists that they have redundant or 
compensatory functions.  Some of the best evidence to support this has come from studies 
involving Src family knockout mice, which suggest that there is indeed a great deal of 
functional overlap between the SFKs (Lowell and Soriano, 1996).  As in humans, the SFKs 
Src, Yes, Fyn, Lyn, Lck, Hck, Fgr, and Blk are expressed in mice.  While Src, Yes, Fyn, and 
Lyn are expressed in a wide variety of tissues, with particularly high levels of these proteins 
found in neurons and hematopoietic cells, the expression of the other four SFKs is more 
restricted to hematopoietic cells (Lowell and Soriano, 1996).  Surprisingly, as discussed in the 
previous section, all of the single Src family knockout mice are viable and exhibit only 
 26 
relatively mild phenotypes.  Given the wide expression of these proteins and their involvement 
in both development and a number of other cellular processes, this suggests that there may be 
functional overlap between the SFKs.   
     In addition to knockout mice lacking single SFKs, mice in which different combinations of 
the SFKs have been knocked out have been developed.  When contrasted to the phenotypic 
changes observed in single knockout mice, it is obvious that the defects in these mice are much 















 double knockout mice die perinatally (Stein et al., 1994).  




 mice are viable, they exhibit much 
more severe defects than their corresponding single knockouts; these mice have enlarged 
spleens and severe renal disease due to glomerulosclerosis (Stein et al., 1994).  These findings 
suggest that there is significant functional overlap between the SFKs, and that they are able to 
compensate for the loss of activity of other family members.  In mice that have had multiple 
SFKs knocked out, the SFKs that could normally compensate for this loss are also absent, 
leading to a more severe phenotype (Lowell and Soriano, 1996).  Redundancy in specific 
signalling pathways in which the SFKs are involved has also been found, where the same 
stimulus results in the activation of more than one SFK.  For example, Src, Yes, and Fyn have 
all been found to be activated following the stimulation of PDGFR (Kypta et al., 1990).  SFK 
redundancy is also complicated by the fact that a single SFK may be activated by multiple 
different stimuli, and that, in addition to any redundant functions, the SFKs may have unique 
functions in different cell types (Lowell and Soriano, 1996).   
     Further evidence suggesting that the SFKs are able to compensate for the loss of one of the 
family members has come from examining the expression of the other SFKs in the different 
knockout mice.  For instance, the level and activity of Src is increased in neurons from fyn
-/-
 
mice, suggesting that Src may be able to compensate for the loss of Fyn by phosphorylating 
various substrates that would normally be phosphorylated by Fyn (Stein et al., 1994).  
Macrophages from hck
-/-
 mice also have increased Lyn activity (Lowell et al., 1994), while the 
level of Hck is increased in osteoclasts from src
-/-





knockout mice exhibit a much more severe osteopetrosis than do the single knockout mice, 




(Lowell et al., 1996).  It is therefore likely that the SFKs share many redundant functions in 
several tissues, in addition to any individual functions that they may have.  
 
1.4.  SRC FAMILY KINASES IN CANCER 
1.4.1.  Src family kinase involvement in cancer 
     Src has been found to be overexpressed and/or activated in a number of cancers, including 
those of the colon, breast, pancreas, lung, ovaries, stomach and liver, as well as chronic 
myelogenous leukemia (CML) and multiple myeloma (Budde et al., 1994; Muthuswamy et al., 
1994; Verbeek et al., 1996; Lutz et al., 1998; Masaki et al., 1999; Masaki et al., 2000, Masaki 
et al., 2003; Wiener et al., 2003).  In addition, many of the other SFKs have also been 
implicated in various human epithelial and lymphoid cancers.  Not surprisingly, the more 
ubiquitously expressed SFKs, such as Src, Yes and Fyn, are involved in both solid and 
hematopoetic cancers, while those with expression restricted to cells of lymphoid origin are 
involved mainly in leukemias and lymphomas.  The involvement of the different SFKs in 
selected human cancers, as well as evidence implicating these proteins in changes in tumour 
cell growth and survival, cellular adhesion, migration, angiogenesis, and metastasis (reviewed 
in Irby and Yeatman, 2000), will be discussed in the following section. 
 
1.4.1.1.  Src family kinase expression and activity in colon cancer 
     Although Src has been implicated in a variety of human cancers, its involvement in colon 
cancer progression is likely the most extensively characterized.  Src activation has been 
reported in up to 80% of colon tumours, with the level of activation correlating with colon 
tumour progression (Talamonti et al., 1993).  In other words, although Src kinase activity is 
increased early on in the development of colon cancer, it is even higher in later stages of cancer 
progression.  Indeed, even in the normal colon epithelia, the actively dividing crypt cells have 
higher levels of Src activity than the more differentiated cells (Cartwright et al., 1993).  In 
addition, the level of Src activity is further elevated in the colonic polyps that are precursors to 
colon carcinoma; the polyps with less potential for malignancy have lower activity than the 
large benign polyps with the greatest potential to develop into a malignancy (those larger than 2 
cm with villous structure and severe dysplasia), while malignant polyps have the highest 
activity (Cartwright et al., 1990).  This suggests that Src activation may be an early event in the 
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transformation from normal colon cells to carcinoma cells.  Further to this, Src protein levels 
and kinase activity have been found to be higher in primary tumours when compared to the 
polyps (Talamonti et al., 1993).  Src expression and activity in liver metastases from primary 
colon tumours have also been examined, as the liver is the most frequent site of metastasis from 
colon cancer, and not only are significant increases in both Src activity and protein levels 
observed when compared to the normal colonic mucosa, but the liver metastases have 
significantly higher Src activity than the primary tumours (Talamonti et al., 1993).  Taken 
together, these studies demonstrate that Src activity increases as colon cancer progresses from 
pre-malignant polyps to liver metastases.    
     The increased level of Src kinase activity in the later stages of colon cancer cannot be 
accounted for by the increased level of Src protein expressed in these stages alone, suggesting 
that Src activity may be regulated by other mechanisms than simply protein level (Talamonti et 
al., 1993).  One explanation for this could be the presence of an activating mutation, and, in 
1999, it was reported that a mutation resulting in the truncation of Src at codon 531 was present 
in 12% of the advanced human colon cancers tested that was absent in both normal tissue 
samples and in the early stage, primary colon cancers investigated (Irby et al., 1999).  
However, this finding has been controversial, as no other group has been able to repeat these 
results (Daigo et al., 1999; Nilbert and Fernebro et al., 2000) and, to date, there has been no 
other activating Src mutation identified.  Mutations, therefore, are not likely an important 
mechanism of Src activation in colon cancer cells.  Regardless, Src kinase activity in primary 
colorectal cancer has been found to correlate to poor patient prognosis (Aligayer et al., 2002), 
and increased Src expression and activity in primary colon tumours appears to be independent 
of age and sex of the patient, stage, or tumour location (Talamonti et al., 1993).      
     Other SFKs have also been found to be highly expressed and activated in a subset of colon 
cancer cell lines and primary colon cancers when compared to non-cancerous colon cells (Park 
et al., 1993).  Like Src, Yes activity has been found to increase with colon cancer progression 
(Park et al., 1993; Peña et al., 1995).  Lck is also expressed in a small subset of colon cancer 
cell lines.  Although Lck expression is regulated by both a proximal and distal promoter in 
hematopoietic cells (Takadera et al., 1989), it is expressed exclusively from the proximal 
promoter in colon cancer cells (Nakamura et al., 1996; McCracken et al., 1997).  Finally, 
although Lyn has traditionally been thought of as being expressed primarily in B-cells, it has 
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been implicated in colon cancer cell migration in response to cluster of differentiation 44 
(CD44) (Subramaniam et al., 2007), as well as in the development of chemoresistance through 
the induction of the phosphoinositide 3’-kinase (PI3K)/Akt cell survival pathway (Bates et al., 
2001).  Therefore, Lyn may also play a role in the development of colon cancer through its 
ability to suppress apoptosis.  These findings suggest that several of the other SFKs, in addition 
to Src, have a role in colon cancer. 
 
1.4.1.2.  Src family kinase expression and activity in other cancers 
     Src is also overexpressed and active in many other human cancers in addition to colon 
cancer, including breast cancer and lung cancer.  For instance, Src activity is higher in breast 
cancer tissue than in normal breast tissue (Finn, 2008), while Src expression and activity are 
also increased in malignant lung tissue.  One study found Src levels to be elevated in 60% of 
the lung tumour biopsies investigated (Mazurenko et al., 1992).  More recently, Src expression 
and activity have been found to be increased in adenocarcinomas of the lung when compared to 
the surrounding lung tissue, with the highest Src activity observed in larger tumours (Masaki et 
al., 2003).  A further study also found Src activation to be significant in squamous cell lung 
tumours (Zhang et al., 2007).  Therefore, Src likely plays a role in breast and lung cancers, as 
well as in colon cancer. 
     Src expression and activity have also been found to be increased in a number of other 
cancers.  For instance, despite a lack of Src expression in normal ovarian epithelial cells, Src is 
overexpressed and activated in late-stage ovarian tumours, as well as in a number of human 
ovarian cancer cell lines (Wiener et al., 2003).  Similarly, Src, as well as Lyn and Fgr, are 
expressed at high levels in prostate cancer, although these SFKs have also been found to be 
expressed at lower levels in primary cell cultures derived from the prostate (Goldenberg-
Furmanov et al., 2004; Nam et al., 2005).  The level of Src protein expressed in neuroblastoma 
cell lines is also higher than in primary cultures derived from normal central nervous system 
tissues, while Src expression in neuroendocrine tumours has been found to increase with the 
differentiation state of the tumour (O’Shaughnessy et al., 1987).  Finally, Src has been found to 
be overexpressed and activated in pancreatic carcinoma cell lines (Lutz et al., 1998).  The high 
levels of Src activity in these cancers suggest that this protein is involved in the progression of 
a large number of different cancers. 
 30 
     The other SFKs are also overexpressed and activated in different cancers.  For instance, 
although Src activity is not increased in melanoma cells, Yes has been found to have higher 
activity in both human melanomas and malignant melanoma cell lines than in melanocytes 
(Loganzo et al., 1993).  The SFKs have also been found to be active in glioblastomas, and 
increases in Lyn activity, in particular, have been reported.  In one study, it was found that 
although Lyn activity accounted for only approximately 30% of the total SFK activity in the 
normal brain, neoplastic brain, and anaplastic astrocytoma samples examined, over 90% of the 
Src kinase activity in glioblastoma cells was due to Lyn (Stettner et al., 2005).  In a more recent 
study, Src, Fyn, Yes, Hck, and Blk were also found to be overexpressed in glioblastomas, while 
Lyn and Hck expression was found to be restricted mainly to mesenchymal glioblastomas (Lu 
et al., 2009).  Such findings suggest that the various SFKs are involved in a number of different 
human cancers.  
 
1.4.2.  Effects of Src family kinase expression on tumour growth 
     Evidence implicating the SFKs in a number of cancer cell phenotypes has come from 
examining tumour specimens, as well as from tissue culture studies and in vivo models of 
various cancers.  Many of these studies have either varied the expression level of Src and/or the 
other SFKs, or have inhibited their kinase activity.  For instance, HT29 colon cancer cells 
expressing antisense against Src have decreased proliferation when compared to the parental 
cell line (Staley et al., 1997).  The breast cancer cell line MCF7 also has decreased 
proliferation, as well as altered migration, attachment, and cell spreading when Src activity is 
decreased either through the expression of a dominant-negative form of Src, or the presence of 
small interfering RNAs (siRNAs) targeting Src (González et al., 2006).  Lyn has also been 
implicated in the proliferation of hematopoietic cancer cells.  For instance, Lyn is constitutively 
active in leukemia cells, and the proliferation of these cells has been shown to be inhibited 
when Lyn expression is reduced using antisense RNA (Roginskaya et al., 1999).  Lyn siRNA 
has also been found to cause breakpoint cluster region (BCR)- c-Abl (Abl) oncogene precursor 
blast cells to have decreased proliferation and to undergo apoptosis, while normal 
hematopoietic cells are unaffected (Ptasznik et al., 2004), suggesting that Lyn may be a valid 
target for therapy in chronic myelogenous leukemia (CML).  In contrast, no changes in 
proliferation, adhesion, or wound migration were observed in SKOv-3 ovarian cancer cells 
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when Src levels were decreased using antisense, although the anchorage-independent growth of 
these cells was significantly reduced (Wiener et al., 1999).  A decrease in anchorage-
independent growth, along with an increase in apoptosis, was also observed in breast and colon 
cancer cell lines in which Src levels were decreased using siRNA (Zheng et al., 2008).  
Interestingly, siRNAs targeting either Fyn or Yes had no effect on the anchorage-independent 
growth of the breast cancer cells investigated in this study, indicating that Src alone may be 
involved in cell survival following loss of adhesion in these cell lines (Zheng et al, 2008).  
Taken together, these studies suggest that the involvement of the SFKs in cancer phenotypes 
such as proliferation and survival may depend on the type of cell and the SFK being 
investigated. 
     In addition to proliferation and cell survival, Src has also been found to be important in later 
stages of cancer progression; namely, angiogenesis, invasion, and metastasis (reviewed in 
Yeatman, 2004).  Several studies examining the ability of cells with decreased Src kinase 
activity to form tumours when injected into mice have been carried out.  For instance, not only 
were HT29 colon cancer cells with decreased Src expression due to antisense found to have 
decreased proliferation, but the tumours formed following the injection of these cells into nude 
mice also grew much more slowly than would be expected from the decrease in cell 
proliferation observed in tissue culture (Staley et al., 1997).  In addition, the tumours that did 
form from these cells were decreased in size even after a year (Ellis et al., 1998), thereby 
suggesting that Src plays an important role in the growth of colon tumours.  Similarly, when 
MCF7 breast cancer cells expressing a dominant-negative form of Src were injected into mice, 
it was observed that although there was no significant change in the number of tumours, they 
grew more slowly due to both a decrease in proliferation and an increase in apoptosis of the 
tumour cells (González et al., 2006).  Decreased tumour size and metastasis were also observed 
in an orthotopic mouse model of pancreatic cancer created by injecting mice with L3.6 pl 
pancreatic cells transfected with an siRNA targeting Src, although neither effects on 
proliferation nor a decrease in tumour number were observed (Trevino et al., 2006).  Similarly, 
tumour size and metastasis were again observed to be reduced when mice bearing tumours 
formed from L3.6. pl cells were treated with the Src/Abl selective inhibitor BMS-354825 
(Trevino et al., 2006).  Pancreatic cancer cells either treated with the clinically relevant SFK 
inhibitor dasatinib or with an siRNA-mediated decrease in the expression of Src have also been 
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shown to have decreased proliferation, migration, and invasion, while dasatinib treatment also 
inhibited the growth of pancreatic tumours in vivo (Nagaraj et al., 2010).  Finally, when ovarian 
cancer cells expressing antisense targeting Src were injected into nude mice there was a 
dramatic reduction in both vascularization and tumour development (Wiener et al., 1999).  
Taken together, these studies provide strong evidence that although cells with decreased SFK 
activity are able to form tumours in in vivo mouse models of cancer, the growth of these 
tumours is significantly impeded, suggesting that the SFKs are intimately involved in later 
stages of cancer progression. 
 
1.4.3.  Src family kinase involvement in cellular processes in cancer cells 
     As the SFKs are involved in a variety of cellular processes, it is perhaps not surprising that 
the overexpression of these proteins can lead to the aberrant signalling of multiple pathways 
within a cell.  However, rather than through activation by mutation, the SFKs appear to be 
involved in signalling in cancer cells mainly through their association with other proteins that 
are themselves abnormally activated or expressed.  Indeed, the SFKs can be activated 
downstream of various receptor tyrosine kinases (RTKs), G-protein-coupled receptors, 
cytokines, steroid receptors, CAMS, and integrins (reviewed in Ishizawar and Parsons, 2004).  
Therefore, if any of these proteins are more highly expressed or activated in cancer cells than in 
non-cancerous cells it can lead to the abnormal activation of the SFKs and the subsequent 
initiation of various signalling pathways involved in cancer development and progression.  The 
involvement of the SFKs in proliferation, survival, adhesion, migration, angiogenesis, and 
metastasis will be discussed in the following section. 
  
1.4.3.1.  Src family kinase involvement in proliferation and cell cycle progression 
     The SFKs have been implicated in the proliferation of both cancer and normal cells in 
response to a number of stimuli, including the stimulation of both integrins and growth factor 
receptors.  Indeed, some growth factors, such as platelet derived growth factor (PDGF), colony 
stimulating factor type 1 (CSF-1), fibroblast growth factor (FGF), and epidermal growth factor 
(EGF), require SFKs in order to induce fibroblasts to undergo DNA synthesis (Roche et al., 
1995b).  The SFKs are not required for such a response to lysophophatidic acid (LPA) and 
bombesin, however (Roche et al., 1995b; Kilkenny et al., 2003).  When growth factor receptors 
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are stimulated by growth factors, the SFKs may associate with the activated receptors through 
their SH2 domains, leading to their activation and association with focal adhesion kinase 
(FAK) (Bromann et al., 2004; Yeatman, 2004).  The non-receptor tyrosine kinase FAK is a 
particularly important SFK substrate, as it, along with the SFKs, is involved in regulating cell 
cycle progression, as well as survival, adhesion, and migration (Schaller, 2001).  Integrin 
stimulation can also contribute to cellular proliferation by activating FAK.  Following an 
association with integrins, the regulatory Tyr 397 of FAK is autophosphorylated, which creates 
a binding site for the SH2 domain of the SFKs (Schaller et al., 1994; Eide et al., 1995).  This 
binding results in the activation of the SFK, which enhances FAK activity and provides 
docking sites for other signalling proteins by phosphorylating FAK at several additional 
tyrosine residues (Chaudhary et al., 2002; Mitra et al., 2005).  Src-FAK signalling, whether in 
response to growth factors or integrin stimulation, subsequently results in the induction of a 
variety of interconnected signalling pathways that have consequences for cellular proliferation, 
survival, adhesion, migration, and invasion (Ishizawar and Parsons, 2004).  Of these, the 
activation of the Ras-extracellular signal-regulated kinase (ERK)-MAPK signalling pathway in 
response to Src-FAK signalling is a major way in which SFK activation leads to cellular 











Figure 1.3.  Src family kinase signalling pathways involved in proliferation and survival.  
Upon stimulation of integrins or RTKs, SFKs and FAK associate, leading to their activation.  
SFK-FAK activation can result in the activation of both the Ras-ERK-MAPK pathway, which 
is involved in cellular proliferation, and the PI3K-AKT pathway, which is involved in cellular 
survival.  Alternately, a subset of integrins is able to activate Fyn directly, leading to the 
activation of the adaptor protein Shc and the induction of the Ras-ERK-MAPK pathway. 
(Modified from Kim et al., 2009b). 
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activated independently of Src-FAK signalling by a subset of integrins that are able to bind the 
SH3 domain of Fyn directly (Wary et al., 1998).  Fyn subsequently recruits and activates Shc, 
which acts as a protein adapter leading to the activation of Ras.  The activation of the Ras-
ERK-MAPK signalling pathway, leading to cellular proliferation, is therefore a major role of 
the SFKs in cancer cells. 
     The SFKs also control proliferation and progression through the cell cycle by modulating 
the activity of proteins such as p27 and various cyclins at different points in the cell cycle.  p27 
normally regulates cellular proliferation by inhibiting the kinase activity of cyclin-Cdk2, which 
is a complex that acts to prevent entry into the S phase of the cell cycle (Chu et al., 2007).  The 
phosphorylation of p27 by Src results in accelerated p27 proteolysis, which allows a 
progression to S phase and DNA synthesis (Chu et al., 2007).  Lyn and Yes have also been 
found to phosphorylate p27, suggesting that other SFKs may also be involved in regulating cell 
cycle progression in this manner (Chu et al., 2007).  In addition to downregulating p27 
expression, Src also causes the upregulation of a number of cyclins, which are proteins 
involved in controlling cell cycle progression.  For instance, the transformation of cells with v-
Src results in the upregulation of cyclins D1, E, and A, which causes cells to leave quiescence 
and enter S phase (Riley et al., 2001).  Therefore, in addition to activating the Ras-ERK-MAPK 
pathway, the SFKs are involved in regulating cell cycle progression by affecting the expression 
of various other proteins involved in this process.  
     Yes and Fyn, in addition to Src, are also activated at mitosis and have been shown to be 
involved in the transition from G2 to M phase in fibroblasts.  Interestingly, there appears to be 
functional redundancy between these family members, as although treatment of fibroblasts with 
an antibody that neutralizes Src alone did not cause cell cycle arrest, one that neutralizes Src, 
Yes, and Fyn was found to inhibit cell division (Roche et al., 1995a).  This suggests that the 
various SFKs can compensate for the loss of function of another family member, at least in 
proliferation.  However, Src and Yes are likely regulated differently during mitosis, as the 
specific activity of Src has been found to increase two to threefold during mitosis in HT29 
colon cancer cells, while Yes protein levels and activity decrease during this period as a 
consequence of both increased degradation and decreased synthesis (Park et al., 1995).  
Nevertheless, multiple SFKs are likely involved in signalling leading to cellular proliferation.  
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1.4.3.2.  Src family kinase involvement in cell survival 
     The ability of cells to survive signals that would otherwise cause their death is another 
important property of cancer cells.  Normally, the viability of a cell is monitored intracellularly, 
and if abnormalities such as DNA damage, an insufficiency of survival factors, aberrant 
signalling caused by oncogenes, or hypoxia are detected, the apoptosis pathway is activated 
(Evan and Littlewood, 1998).  In addition, apoptosis may be triggered if survival signals 
normally present due to cell-extracellular matrix and cell-cell adhesion are absent (Giancotti 
and Ruoslahti, 1999).  Resistance to anoikis, or detachment-induced apoptosis, is a property of 
many epithelial cancers that has implications in tumour cell survival and metastasis.   
     The involvement of the SFKs in anoikis was initially suggested by the finding that the 
transformation of epithelial cells with v-Src could prevent them from undergoing this process 
(Frisch and Francis, 1994).  A number of more recent studies in various cell lines have also 
implicated the SFKs in anoikis.  For instance, both Src and Fyn have transiently increased 
kinase activity in intestinal epithelial cells following detachment (Loza-Coll et al., 2005).  Src 
activity is also higher in lung tumour cells that are resistant to anoikis than in those that are 
susceptible (Wei et al., 2004).  Furthermore, it has also been observed that colon cancer cell 
lines with naturally lower levels of Src kinase activity have an increased susceptibility to 
anoikis when compared to cells with higher levels of Src kinase activity (Windham et al., 
2002).  The finding that colon cancer cells with naturally higher levels of Src kinase activity 
could be made more susceptible to anoikis by either decreasing Src expression or treating the 
cells with a SFK inhibitor provides more direct evidence for the involvement of the SFKs in 
anoikis resistance (Windham et al., 2002).  Similarly, the treatment of osteosarcoma cells with 
a SFK inhibitor has also been shown to restore the sensitivity of these cells to anoikis, further 
confirming the involvement of the SFKs in this process (Diaz-Montero et al., 2006).  Taken 
together, these studies strongly suggest that the increased SFK activity found in cancer cells 
contributes to anoikis resistance and the survival of these cells.  
     One way in which the SFKs contribute to cell survival is through the activation of the PI3K-
Akt pathway.  This pathway is activated in response to Src-FAK signalling following integrin 
or RTK stimulation, and results in the suppression of apoptosis, leading to cell survival (Figure 
1.3) (Siesser and Hanks, 2006).  Evidence for the involvement of the PI3K-Akt pathway in 
anoikis resistance following Src activation has come from studies where the treatment of cells 
 36 
with SFK inhibitors prevented the activation of this pathway in response to cell detachment 
(Loza-Coll et al., 2005; Diaz-Montero et al., 2006).  It has also been found that inhibiting PI3K 
results in cells regaining sensitivity to anoikis (Diaz-Montero et al., 2006), further supporting 
the involvement of this pathway in anoikis resistance.  In addition to the activation of the PI3K 
pathway, the SFKs Fyn and Yes may also play a role in anoikis through the phosphorylation of 
the 135 kDa CUB-domain-containing protein 1 (CDCP1); the phosphorylation of this protein is 
associated with an increased resistance to anoikis (Uekita et al., 2007).  At least some of the 
SFKs therefore have a role in cancer progression through their ability to confer resistance to 
anoikis upon cells that have lost attachment.  As this is necessary for cancer cells to invade and 
metastasize, this is yet another way in which the SFKs contribute to cancer progression. 
 
1.4.3.3.  Src family kinase involvement in adhesion 
     The SFKs, in particular Src and Fyn, are involved in cellular adhesion to both the 
extracellular matrix (ECM) and to other cells.  The actin cytoskeleton of cells is linked to the 
ECM through the integrin family of transmembrane receptors in points of interaction known as 
focal adhesions (Danen and Yamada, 2001).  Integrins do not themselves possess kinase 
activity; however, signals may be transmitted into cells in response to interactions with the 
ECM through the activation of integrin-associated proteins present within the focal adhesions, 
such as the SFKs.  As integrins can interact with a variety of proteins, as well as the actin 
cytoskeleton, their stimulation can initiate a number of signalling events that can regulate 
cellular proliferation, survival, adhesion, and migration in both normal and cancerous cells 
(reviewed in Gabarra-Niecko et al., 2003).  Important components of focal adhesions, which 
can be composed of over 50 different proteins, include the SFKs and the non-receptor tyrosine 
kinase FAK (Zamir and Geiger, 2001).  Upon integrin stimulation, FAK is recruited to the sites 
of integrin clustering by integrin-associated proteins such as paxillin, and a FAK-Src signalling 
complex is formed, as discussed previously.  Src is subsequently able to phosphorylate other 
proteins involved in integrin-mediated signalling and cytoskeletal events, including FAK itself, 
p130
Cas
, paxillin, and cortactin (Vuori et al., 1996; Klinghoffer et al., 1999; Volberg et al., 
2001), which can lead to changes in the actin cytoskeleton that result in the disruption of the 
focal adhesions.  Indeed, Src has been found to be integral to the phosphorylation of other 
proteins following integrin stimulation as few proteins are phosphorylated in response to this 
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stimulation in fibroblasts lacking Src, Yes, and Fyn (Klinghoffer et al., 1999).  Src inhibition 
has also been found to correlate to decreased phosphorylation of Src substrates, such as FAK 
and p130
Cas
, in a variety of cell lines (Shin et al., 2004; Brábek et al., 2005; Shor et al., 2007; 
Park et al., 2008; Vultur et al., 2008).  The high SFK activity observed in cancer cells therefore 
has implications in the adhesion of these cells to the ECM.  
     The SFKs are also involved in cell-cell adhesion.  The points of contact between two cells 
are known as adherens junctions, one of the major components of which are transmembrane 
proteins known as cadherins.  The extracellular domain of these proteins can adhere to 
cadherins on other cells, while the cytoplasmic domain binds to "-catenin, thereby linking 
cadherins to the actin cytoskeleton.  The SFKs are also components of adherens junctions; Src, 
Yes, and Lyn have been identified in the adherens junctions of rat hepatocytes, while Src and 
Yes are also enriched in those of cultured hepatocytes, primary cultured keratinocytes, and 
kidney epithelial cells (Tsukita et al., 1991).  Activated SFKs are able to induce the endocytosis 
of E-cadherin, leading to the disruption of cadherin/catenin complexes, and, subsequently, to 
decreased adhesion and enhanced migratory and invasive capacity of the cells (Figure 1.4) 
(Avizienyte et al., 2002; Irby and Yeatman, 2002).  The phosphorylation of p120-catenin, 
which is a cytoplasmic protein involved in adhesion through its association with the cadherins, 
by Src can also lead to cadherin turnover, further implicating these proteins in adhesion 
(Reynolds et al., 1989, 1994; Reynolds and Roczniak-Ferguson, 2004) (Figure 1.4) (Shibamoto 
et al., 1995).  SFK involvement in this loss of cell-cell adhesion is supported by the finding that 
treatment of colon cancer cell lines with a SFK inhibitor results in increased cell-cell adhesion 
(Calcagno et al., 2005).  Furthermore, both the expression of a dominant-negative Src protein 
and treatment with a SFK inhibitor have been shown to restore adhesion in colon cancer cell 
lines expressing an active form of Src (Irby and Yeatman, 2002).  The treatment of 
keratinocytes with a SFK inhibitor, or the overexpression of a dominant-negative Src, were also 
able to induce and stabilize cell-cell contacts, thereby suggesting that the catalytic activity of at 
least one of the SFKs is required for the disassembly of adherens junctions (Owens et al., 
2000).  The finding that keratinocytes from fyn
-/-
 mice have defects in the formation of cell-cell 
adherens junctions in vitro also demonstrates the involvement of SFKs in cell-cell adhesion.  




 mice exhibit this defect, suggesting that 
Fyn in particular is involved cell-cell adhesion, at least in these cells (Calautti et al., 1998). 
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Figure 1.4.  Src family kinase signalling pathways involved in adhesion, migration, and 
metastasis.  Src and FAK become activated in response to integrin stimulation, leading to the 
phosphorylation of several other components of focal adhesions, including p130
Cas
, paxillin, 
and cortactin.  This can lead to focal adhesion turnover, resulting in increased cellular 
migration and metastasis.  Active SFKs are also able to phosphorylate E-cadherin and p120 
catenin, which leads to the disruption of the cadherin/catenin complex through the endocytosis 
of E-cadherin, the subsequent loss of cell-cell adhesion, and enhanced migration and invasion. 
(Modified from Yeatman, 2004 and Kim et al., 2009b). 
 
 
Therefore, the SFKs have been implicated in both the loss of cell-cell contacts through the 
disruption of adherens junctions, as well as in cellular adhesion to the ECM through their role 
in focal adhesion disassembly, and are, in consequence, intimately involved in cellular 
adhesion. 
 
1.4.3.4.  Src family kinase involvement in migration 
     As SFK activity is required for both the disruption of integrin-dependent cellular adhesions 
(Fincham and Frame, 1998; Cary et al., 2002; Brunton et al., 2005), and cadherin-mediated 
cell-cell contacts (Owens et al., 2000), it is not surprising that the SFKs also play an important 
role in cellular migration, as well as in adhesion.  The SFKs affect cellular migration through 
their interactions with a variety of proteins, including kinases, integrins, actins, GTPase 
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activating proteins, and scaffolding proteins.  As with adhesion signalling, the Src-FAK 
association is particularly important for migration; when FAK is activated following integrin 
stimulation it acts to recruit the SFKs to transient signalling complexes that induce migration 
through a number of signalling pathways that regulate the formation and disassembly of focal 
adhesions (Mitra and Schlaepfer, 2006).  Indeed, the autophosphorylation of FAK on Tyr 397 
and subsequent association with either Src or Fyn is required for cells that are overexpressing 
FAK to have increased migration on fibronectin (Cary et al., 1996).  Interestingly, although the 
catalytic activity of Src has been shown to be necessary for migration in response to integrin 
signalling, the scaffolding functions of Src are not required (Cary et al., 2002).  Indeed, the 
elevated expression and activity of Src and/or FAK in cancer cells likely leads to their 
increased migration by activating pathways that facilitate focal adhesion turnover.  
     Some of the Src-FAK substrates involved in migration are the scaffolding proteins p130
Cas
 
and paxillin, both of which are involved in cytoskeleton organization, adhesion, and cellular 
migration (Schaller, 2001; Huang et al., 2002), and cortactin, which is also involved in 
cytoskeleton organization (Figure 1.4) (Wu and Parsons, 1993; Huang et al., 1998; Huang et 
al., 2003).  For example, Src-FAK activation has been found to result in the increased 
phosphorylation of FAK, paxillin, and p130
Cas
 in response to vascular endothelial growth factor 
receptor (VEGFR) stimulation (Lesslie et al., 2006), while the expression of a kinase inactive 
Src results in decreased phosphorylation of paxillin and cortactin (Kilarski et al., 2003).  As 
these adaptor proteins are involved in recruiting further downstream effector molecules that 
lead to focal adhesion turnover, the SFKs have an important role in the increased migratory 
capacity of cancer cells. 
 
1.4.3.5.  Src family kinase involvement in angiogenesis 
      The SFKs are also involved in angiogenesis, or the formation of new blood vessels from the 
existing vasculature.  This is a multistep process that requires the proliferation, migration, 
differentiation, and invasion of endothelial cells, all of which are regulated, at least in part, by 
the SFKs (reviewed in Ferrara and Kerbel, 2005).  The SFKs are involved in angiogenesis 
through two separate mechanisms (Figure 1.5).  Firstly, they are involved in regulating the 
expression of angiogenic growth factors and cytokines such as VEGF (Summy et al., 2005) and 
















Figure 1.5.  Src family kinase involvement in angiogenesis and metastasis.  The SFKs are 
involved in regulating angiogenesis and metastasis through their effects on both tumour cells 
and endothelial cells.  By activating transcription factors such as STAT3, activated SFKs 
promote the expression of pro-angiogenic factors such as VEGF and IL-8 in tumour cells.  
These factors are secreted by the tumour cells and are able to interact with receptors on the 
surrounding endothelial cells, as well as on the tumour cells themselves.  This results in SFK 
activation, and the subsequent increased proliferation and migration of the endothelial cells 
results in the growth of blood vessels towards the tumour.  In addition, the vascular 
permeability of the endothelial cell layer is increased as a result of this signalling, thereby 
facilitating metastasis.  (Modified extensively from Kim et al., 2009b). 
 
 
factors into the area surrounding the tumour subsequently results in the stimulation of the 
surrounding endothelial cells, which leads to the induction of capillary growth towards the 
tumour.  Secondly, as the SFKs have a role in the signalling pathways that are initiated in 
response to these pro-angiogenic factors in both endothelial cells and the tumour cells 
themselves, they have a further role in this process.  Therefore, the SFKs are involved not only 
in the production of pro-angiogenic factors but also in the cellular responses to these factors 
and, as such, play an important role in angiogenesis.   
     One of the best-characterized ways in which the SFKs are involved in angiogenesis is 
through the regulation of VEGF expression, particularly in response to hypoxia, or a lack of 
 41 
oxygen (reviewed in Lesslie and Gallick, 2005).  The SFKs regulate VEGF expression by 
activating the STAT transcription factors in response to RTK stimulation (Silva, 2004); STAT3 
is a direct transcriptional activator of VEGF expression (Figure 1.5) (Niu et al., 2002; Wei et 
al., 2003).  The expression of VEGF varies directly with the level of Src activity, whereby 
increased Src activity induces the upregulation of VEGF expression, while the repression of Src 
results in the downregulation of VEGF expression (Fleming et al., 1997).  Therefore, as there is 
an increase in Src activity in response to hypoxia, there is a corresponding increase in VEGF 
expression that leads to angiogenesis (Mukhopadhyay et al., 1995b).  Similarly, the expression 
of v-Src has been found to result in increased levels of VEGF being expressed in response to 
hypoxia (Mukhopadhyay et al., 1995a).  Src has also been shown to be required for the 
induction of VEGF expression in response to hypoxic conditions in prostate and pancreatic cell 
lines (Gray et al., 2005), and in Müller cells (Werdich and Penn, 2006).  Interestingly, there is 
no increase in Fyn or Yes activity in response to hypoxia, which suggests that Src may be the 
primary SFK involved in the regulation of VEGF expression (Mukhopadhyay et al., 1995b). 
     Several studies have also shown that decreased Src activity results in decreased VEGF 
expression within a cell.  For instance, an antisense strategy targeting Src, but not Yes, has been 
found to result in decreases in both constitutive and hypoxia-induced VEGF expression in 
colon cancer cells (Ellis et al., 1998).  VEGF expression was likewise inhibited in ovarian 
tumour cells expressing a Src antisense construct (Wiener et al., 1999).  Similarly, the 
expression of either a dominant-negative Src or treatment with a tyrosine kinase inhibitor have 
been shown to result in decreased VEGF expression in response to hypoxia in U87 glioma cells 
and 293 kidney cells (Mukhopadhyay et al., 1995b).  Finally, a subcutaneous mouse model of 
colon cancer formed using Src antisense clones has also been found to exhibit decreased 
vascularity when compared to that observed in control mice injected with parental cells, 
suggesting that Src is involved in regulating angiogenesis in vivo as well (Ellis et al., 1998).  
Cumulatively, these studies strongly support a role for Src in the expression of VEGF, and, as 
VEGF is secreted by many solid tumours and is important in mediating tumour angiogenesis, 
as well as the proliferation, migration, differentiation and vascular permeability of endothelial 
cells (Leung et al., 1989; Neufeld et al., 1999; Lesslie et al., 2006), the involvement of the 
SFKs in regulating its expression is a significant way in which they contribute to angiogenesis.   
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     The second way in which the SFKs are involved in angiogenesis is through their role in 
signalling pathways initiated by the stimulation of angiogenic growth factor receptors, such as 
VEGFR, in both endothelial cells and tumour cells (Lesslie and Gallick, 2005; Kim et al., 
2009b).  When these receptors are activated on endothelial cells by growth factor or cytokine 
binding, the SFKs become activated, which leads to the initiation of signalling cascades that 
result in cellular proliferation and migration, as well as the formation of new blood vessels 
(Kim et al., 2009b).  As VEGFRs are also expressed on the surface of tumour cells, it is likely 
that autocrine signalling through this receptor also plays a role in cancer progression, whereby 
the biological effects of Src activity are amplified in the tumour cell in response to VEGF 
stimulation (Figure 1.5) (Park et al., 2007).  The SFKs are therefore important components of 
signalling pathways that can lead to angiogenesis in both tumour cells and the surrounding 
endothelial cells.  Consequently, not only would SFK inhibition decrease the progression of 
primary tumours, but it would also impede signalling between the tumour cells and the 
surrounding cells by preventing the expression of pro-angiogenic factors by the tumours.  As 
such, SFK inhibitors could be a valuable therapy for inhibiting tumour growth.   
 
1.4.3.6.  Src family kinase involvement in invasion and metastasis 
     Metastasis is the process whereby cancer cells detach from a primary tumour and move 
through the bloodstream, the lymphatic system, or the body cavity to a distant site within the 
body, in which they establish a secondary tumour.  Since cancer cells must develop the ability 
to migrate and spread before they are able to metastasize, and the SFKs are integral to both the 
loss of stable cell-cell contacts and cell-ECM adhesion, as well as to migration, it is not 
surprising that the SFKs are involved in metastasis (Figure 1.4) (reviewed in Shah and Gallick, 
2007).  Indeed, the level of Src activity has been shown to correlate to the ability of tumour 
cells to metastasize.  For instance, mice injected with breast cancer cells overexpressing a 
constitutively active Src developed significantly increased bone lesions, in both size and 
number of osteoclasts, while those overexpressing a dominant-negative mutant had reduced 
bone metastasis (Myoui et al., 2003).  SFK activity has also been found to correlate with the 
metastatic potential of HuO9 osteosarcoma cells; Fyn in particular was found to have increased 
autophosphorylation in highly metastatic sublines of this cell line (Azuma et al., 2005).  
Therefore, the level of SFK activity within cancer cells impacts their metastatic potential.   
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     SFK signalling in the endothelial cells surrounding a tumour has also been shown to be 




 mice in which VEGF-expressing tumour 
cells have been injected intravenously have significantly fewer lung and liver metastases when 
compared with control mice (Weis et al., 2004).  Similarly, src
-/-
 mice have also been shown to 
have less tumour-induced vascular permeability and significantly fewer lung metastases 
following both subcutaneous and intravenous injection with lung tumour cells (Criscuoli et al., 
2005).  Interestingly, the subcutaneous growth of tumour cells was unaffected in the knockout 
mice, suggesting that although Src activity was not required for tumour cell growth, its activity 
in endothelial cells is necessary for metastasis (Criscuoli et al., 2005).  Taken together, these 
studies indicate that the SFKs need to be active in the endothelial cells surrounding a tumour 
for metastasis to occur.  As there is increased space between endothelial cells following SFK 
activation, this is likely due to their involvement in inducing the increased vascular 
permeability of the endothelial cell layer, which allows tumour cells to intravasate more easily 
into the vascular space (Figure 1.5) (Kim et al., 2009a).  Following the dissemination of the 
tumour cells through the vascular system, the extravasation from the vessels at a secondary site 
where they are able to establish metastases is also facilitated by increased vascular permeability 
(Kim et al., 2009a). 
     Further to decreasing adhesion and increasing the migratory capacity of cancer cells, the 
SFKs also contribute to metastasis through upregulating the expression of proteinases.  For 
instance, FAK-Src signalling contributes to an invasive phenotype by activating p130
Cas
, which 
results in the induction and activation of the matrix metalloproteinases MMP-2 and MMP-9 
(Van Slambrouck et al., 2007).  The upregulation of these proteinases facilitates invasion by 
degrading the basement membrane.  Therefore, the SFKs are involved in promoting invasion 
and metastasis in multiple ways, further supporting their importance in later stages of tumour 
progression.  
 
1.5. SRC FAMILY KINASE INHIBITORS 
     As the SFKs are involved in a number of different pathways important in tumour 
progression, they are an attractive target for the treatment of cancer.  In particular, cancers that 
have very poor prognoses and high mortality, such as pancreatic cancer, could benefit from 
SFK inhibition.  Efforts have therefore been made in order to develop clinically relevant 
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chemical inhibitors capable of inhibiting the SFKs.  Although the first SFK inhibitors, such as 
herbimycin A and genistein, were non-specific, a great deal of progress has been made and 
several SFK inhibitors are currently in clinical trials (Wheeler et al., 2009; Lieu and Kopetz, 
2010; Saad and Lipton, 2010).   
     One major hurdle to the use of SFK inhibitors as a cancer therapy is the specificity, or lack 
thereof, of these drugs.  As all protein tyrosine kinases share similar SH1, SH2, and SH3 
domain structures, inhibitors developed targeting these regions often have significant off-target 
effects on other tyrosine kinases.  For instance, the clinically relevant SFK inhibitors dasatinib 
and 4-Anilino-3-quinolinecarbonitrile (SKI-606) inhibit Abl kinase in addition to the SFKs, 
while dasatinib also inhibits EGFR (Cao et al., 2008).  Another significant problem with cancer 
treatment is the development of resistance to anti-cancer drugs.  The SFKs have themselves 
been implicated in this phenomenon; therefore, the use of SFK inhibitors in combination with 
other chemotherapeutic agents has promise in cancer therapy, as this would prevent the 
activation of the SFKs in response to other chemotherapy drugs.  SFK inhibition may therefore 
prove to be a particularly valuable cancer therapy. 
 
1.5.1. Structures, targets and clinical trials 
     The most effective SFK inhibitors are ATP mimics that are competitive for the ATP binding 
sites of the SFKs.  Compounds with several different types of scaffolding structures have been 
found to inhibit the SFKs in this fashion, with differing levels of specificity; 
pyrazolopyrimidines (Hanke et al., 1996), pyrrolopyrimidines, pyrido-pyrimidinones, 
indolinones, naphthyridinones, aminopyridopyrimidinyl urea, quinazolines and quinolines are 
all capable of inhibiting the SFKs (reviewed in Tsygankov and Shore, 2004).  All of the ATP-
binding site inhibitors have a heteroaromatic ring system that is capable of hydrophobic 
interactions with the kinase domain (Cao et al., 2008).  Although the kinase domains of 
different proteins are somewhat conserved, differences in these domains allow chemical 
inhibitors to inhibit particular tyrosine kinases more efficiently than others.  For instance, 
adjacent to the ATP binding site in the kinase domain is a hydrophobic pocket.  As the structure 
of the hydrophobic pocket varies between kinases, and some small molecules, including SFK 
inhibitors, are able to bind both the hydrophobic pocket and the ATP binding site, this provides 
one way in which these inhibitors are selective (Chong et al., 2005).  Even so, chemical 
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inhibitors are not completely specific due to similarities in the ATP-binding site of different 
kinases, and often have off-target effects.  For instance, some SFK inhibitors are unable to 
specifically inhibit a given SFK; rather, they can inhibit the kinase activity of multiple family 
members (Hanke et al., 1996; Liu et al., 1999; Blake et al., 2000). 
     One of the most widely used SFK inhibitors in preclinical research is 4-amino-5-(4-
chorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) (Figure 1.6).  This compound, along 
with 4-Amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP1), was originally 
found to be an ATP-competitive inhibitor selective for the SFKs (Hanke et al., 1996).  
However, these compounds have also been found to inhibit other tyrosine kinases including the 
EGF receptor and Janus Kinase 2 (Jak2) (Chen et al., 2006).  The other SFK inhibitor most 
commonly used in preclinical studies is 2-Oxo-3(4,5,6,7-tetrahydro-1H-indol-2-ylmethylene)-
2,3-dihydro-1H-indole-5-sulfonic acid dimethylamide (SU6656) (Figure 1.6).  This inhibitor is 
another ATP-competitive small molecule inhibitor that inhibits Src, Fyn, Yes, and Lyn, 
although it is a poor inhibitor of Lck.  SU6656 does not, however, significantly inhibit PDGFR, 
which allows it to be used to investigate SFK involvement in the pathways induced in response 
to the stimulation of this receptor (Blake et al., 2000).  In addition to these two SFK inhibitors, 
two other commercially available SFK inhibitors have been used in the studies discussed in this 
thesis; namely, 4-(4’-phenoxyanilino)-6.7-dimethoxyquniazoline, or Src Kinase Inhibitor I 
(SKI I) and the substituted triazoloquinoline-1-thione compound Src Kinase Inhibitor II (SKI 
II), which are available from Merck (Figure 1.6).  SKI I interacts with both the peptide binding 
site and the ATP binding site of multiple SFKs, and also inhibits VEGFR and c-fms at higher 
concentrations (Tian et al., 2001), while SKI II inhibits both the SFKs and Csk (Kilimnik  et 
al., 2003).  Therefore, although SFK inhibitors also inhibit proteins other than the SFKs, their 
non-specific effects are dependent upon the particular SFK inhibitor being used. 
     There are several SFK inhibitors currently in clinical trials or in use as cancer therapies.  For 
example, the SFK inhibitor dasatinib, from Bristol-Myers Squibb, is an orally available 
chemical inhibitor of several SFKs, as well as Bcr-Abl, and is currently the only SFK inhibitor 
approved for the treatment of chronic myelogenous leukemia (CML) and Philadelphia positive 
acute lymphoblastic leukemia (Wheeler et al., 2009).  In addition, there are also phase I and II 
clinical trials currently underway examining the use of this drug in non-Hodgkin’s lymphoma, 
































Figure 1.6.  The structures of selected Src family kinase inhibitors.  PP2, SU6656, SKI I, 
and SKI II are available commercially, while Dasatinib and SKI-606 are clinically relevant Src 
kinase inhibitors currently undergoing clinical trials. 
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and prostate cancers (Wheeler et al., 2009).  Dasatinib is of particular interest as it has been 
found to have minimal effects on normal hematopoietic cells (Alvarez et al., 2006).  SKI-606 
(Figure 1.6), also known as bosutinib, is also an orally available, dual Src-Abl kinase inhibitor, 
produced by Wyeth Pharmaceuticals, Inc., that is capable of inhibiting multiple SFKs (Alvarez 
et al., 2006).  Like dasatinib, there are currently several clinical trials underway in order to 
investigate the use of SKI-606 in the treatment of a variety of cancers, including those that are 
unresponsive to standard treatments, as well as metastatic cancers (Wheeler et al., 2009).  As 
some of the cancers being investigated are difficult to treat using current chemotherapeutic 
drugs, the development of effective SFK inhibitors would be of great use. 
 
1.5.2. Preclinical studies of clinically relevant Src family kinase inhibitors 
     A variety of SFK inhibitors have been used to examine the effect of SFK inhibition on 
various cancer cell phenotypes in preclinical studies.  Similar to what has been observed in 
other investigations into the involvement of the SFKs in cellular processes in cancer cell lines, 
studies using SFK inhibitors have found the SFKs to be primarily involved in migration and 
invasion.  For instance, the SFK inhibitor PP2, which has been used extensively in preclinical 
investigations of the SFKs, has been shown to decrease the ability of breast cancer cells to form 
colonies in soft agar, as well as tumours in nude mice (Ishizawar et al., 2004).  This was 
supported by similar findings when cells overexpressing a catalytically inactive Src were used 
(Ishizawar et al., 2004).  Clinically relevant SFK inhibitors have also shown effects when used 
in cell culture.  For instance, the treatment of melanoma cells (Buettner et al., 2008), bone and 
soft tissue sarcoma cell lines (Shor et al., 2007), malignant pleural mesothelioma cell lines 
(Tsao et al., 2007), and prostate cancer cell lines (Nam et al., 2005; Park et al., 2008) with 
dasatinib results in an inhibition of adhesion, migration, and invasion.  Dasatinib treatment has 
also been shown to result in the increased apoptosis and decreased invasion of glioblastoma 
cells, which was confirmed by silencing the expression of either Src or Fyn (Lu et al., 2009).  
Similarly, the treatment of breast cancer cell lines with SKI-606 also results in the decreased 
motility and invasive potential of these cells (Vultur et al., 2008).  Therefore, clinically relevant 
SFK inhibitors have significant effects on the adhesion, migration, and colony forming ability 
of various cell lines in vitro.     
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     In contrast to the effects of various SFK inhibitors on migration and invasion, the effects of 
SFK inhibitor treatment on cellular proliferation are varied, and SFK inhibition does not impact 
the cellular proliferation of certain cell lines.  For instance, the proliferation and survival of 
melanoma cells was found to be unaffected by treatment with dasatinib (Buettner et al., 2008).  
Dasatinib treatment also did not affect the proliferation of ten of twelve colon cancer cell lines 
tested in another study (Serrels et al., 2006).  Similarly, despite its ability to inhibit migration 
and invasion, SKI-606 did not affect either the proliferation or survival of selected breast 
cancer cell lines (Vultur et al., 2008), nor did it have an antiproliferative effect on HT29 or 
Colo 205 colon cancer cell lines (Golas et al., 2005).  However, the proliferation of some cell 
lines has been reported to be reduced following SFK inhibitor treatment.  For instance, the SFK 
inhibitor PD173955 causes an arrest in the mitotic progression of a variety of cancer cell lines 
(Moasser et al., 1999), while SKI-606 has been found to inhibit the proliferation of CML cells 
in culture (Golas et al., 2003).  Finally, the inhibition of Lyn with a sequence based peptide 
inhibitor in hormone-refractory prostate cancer cell lines has also been shown to decrease the 
proliferation of these cells (Goldenberg-Furmanov et al., 2004).  Therefore, the involvement of 
the SFKs in cellular proliferation may be somewhat cell specific.   
     SFK inhibitor treatment has also been found to impact tumour growth in vivo.  In a study 
investigating the effects of dasatinib on prostate cancer growth, both tumour growth and the 
development of lymph node metastasis were inhibited in an orthotopic nude mouse model 
(Park et al., 2008).  SKI-606 has also been shown to be effective in decreasing tumour growth 
(Golas et al., 2005); daily oral administration of this drug to mice bearing xenografts of the 
CML cell line K562 resulted in the complete regression of the xenografts (Golas et al., 2003).  
Similarly, the inhibition of Lyn kinase using a peptide inhibitor has also been found to result in 
both apoptosis and tumour regression in nude mice bearing tumours formed from prostate 
cancer cell lines (Goldenberg-Furmanov et al., 2004).  Together, these preclinical studies 
demonstrate that SFK inhibition has significant effects on multiple cancer cell phenotypes, 
further supporting a potential clinical benefit of using SFK inhibitors to treat cancer. 
 
1.5.3. Drug resistance 
     A portion of a cancer cell population may develop resistance to chemotherapeutic agents 
following their extended use.  This is a serious problem, as it results in the expansion of a 
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population of cells that are able to evade the toxic effects of these previously effective drugs.  
The SFKs have been implicated in the development of chemoresistance of both solid cancers 
and CML (Shah and Gallick, 2007).  For instance, resistance to various anticancer agents such 
as gleevec, gemcitabine, and taxol has been found to correlate with increased Src activation, 
suggesting that SFK inhibitors may be particularly useful in cancer therapy  (Summy and 
Gallick, 2006).  Src activity also correlates directly with pancreatic cancer cell chemoresistance 
to gemcitabine; inhibiting Src in these cells results in an increase in gemcitabine-induced 
apoptosis (Duxbury et al., 2004a).  This was further supported by the finding that treatment of 
these pancreatic cancer cells with siRNA directed against Src likewise resulted in increased 
gemcitabine sensitivity (Duxbury et al., 2004b).  Fyn has also been found to have a role in 
imatinib resistance, as both PP2 treatment and siRNA directed against Fyn result in a re-
sensitization of CML cells to imatinib (Grosso et al., 2009).  As the use of SFK inhibitors in 
conjunction with other cancer drugs sensitizes the target cells to these agents, combined 
therapies using SFK inhibitors may be more effective than current treatments as they could 
result in greater initial cell death, and thereby prevent, or at least postpone, the development of 
a resistant phenotype.   
     The usefulness of SFK inhibitors in combined therapies has been demonstrated both in vitro 
and in vivo.  The drug 5-fluorouracil (5-FU) is commonly used to treat different types of cancer 
such as pancreatic and colon cancer; however, as with other cancer drugs, the development of 
resistance to 5-FU is a problem.  As the treatment of 5-FU resistant pancreatic cancer cells with 
a combination of 5-FU and PP2 has a synergistic effect on the ability of 5-FU to induce 
apoptosis in these cells, it suggests that SFK inhibitors could be useful for combating 
chemoresistance (Ischenko et al., 2007).  In vivo tumour growth and metastasis were also 
decreased in mice treated with a combination of PP2 and 5-FU (Ischenko et al., 2007).  
Similarly, treatment of a mouse model of colorectal liver metastasis with dasatinib combined 
with the cytotoxic drug oxaliplatin has also been found to result in synergistic effects leading to 
decreased tumour growth (Kopetz et al., 2009).  Indeed, inhibiting the SFKs in conjunction 
with other targets appears to be able to sensitize cancer cells to these drugs, leading to cell 
death.  Therefore, the use of SFK inhibitors in conjunction with other therapies, such as other 






2.  SPECIFIC AIMS AND HYPOTHESIS 
     Given that a number of the SFKs are overexpressed and activated in a variety of different 
cancers and cancer cell lines, it is likely that these proteins have redundant or complementary 
functions in regards to cancer cell phenotypes.  In particular, the ubiquitously expressed SFKs, 
Src, Fyn, and Yes, are often co-expressed.  However, studies often only investigate the 
involvement of Src in cancer cell phenotypes by either specifically increasing or decreasing the 
level of Src expression, and do not examine the involvement of the other SFKs.  Conversely, 
while a large number of studies have used SFK inhibitors to examine the effects of SFK 
inhibition on a variety of cancer cell phenotypes, this approach results in the inhibition of 
multiple SFKs.  This prevents the involvement of the individual SFKs in cellular processes 
from being elucidated.  Therefore, although many of the SFKs have been implicated in various 
cancers, the involvement of the individual SFKs in given cancer cell phenotypes is not clear.  It 
is of interest to identify which SFKs in particular are involved in these processes, as this could 
provide valuable insight into the suitability of these proteins for more targeted cancer therapies. 
 
HYPOTHESIS:  Multiple Src family members contribute to cancer cell phenotypes such as 
cellular proliferation, adhesion, migration, and tumour formation, within a given cell line.   
 
SPECIFIC AIMS: 
1.  To examine the expression and activity of the individual SFKs in a wide panel of human 
cancer cell lines.   
2.  To use a systematic approach to investigate the role of the SFKs in the cellular proliferation, 
adhesion, migration, and colony forming ability of four selected cancer cell lines.   
3.  To compare the changes in proliferation, adhesion, migration, and colony forming ability 
that result from inhibiting multiple SFKs using SFK inhibitors to those resulting from RNAi-







3. MATERIALS AND METHODS 
3.1. Reagents, Kits, Equipment and Distributors 
 Commercially available reagents and kits were used in the studies described in this 
thesis.  These products and their respective distributors are outlined in the following tables:  
Table 3.1. Reagents, Table 3.2. Kits, Table 3.3. Equipment and Software, Table 3.4. 
Antibodies.  The addresses of the distributors used may be found in Table 3.5.   
 
Table 3.1.  Reagents and Distributors 
Reagent  Distributor Name 
[#-32P] dCTP PerkinElmer Life Sciences Inc. 
Acetic acid (glacial) BDH 
2-Butanol (water saturated) Sigma-Aldrich Co. 
Acetic acid (glacial) BDH 
Acrylamide EM Sciences 
Actinomycin D Sigma-Aldrich Co. 
Agarose EMD Chemicals Inc. 
Ammonium persulfate EM Sciences 
Ampicillin EMD Chemicals Inc. 
ATP Sigma-Aldrich Co. 
"-glycerophosphate Sigma-Aldrich Co. 
"-mercaptoethanol EMD Chemicals Inc. 
Bacto agar BD Biosciences 
BioMax XAR film Kodak 
Biotrace NT membrane Pall 
Bis-acrylamide EM Sciences 
Boric acid Sigma-Aldrich Co. 
Bovine serum albumen EMD Chemicals Inc.  
Bromophenol blue BDH  
Calcium chloride dihydrate BDH  
Calf Intestinal Alkaline Phosphatase New England Biolabs Ltd.  
Carbenicillin EMD Chemicals Inc. 
CellTitre 96 Aqueous One Solution Promega 
Chloroform EMD Chemicals Inc. 
Collagen Invitrogen 
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Crystal violet Sigma-Aldrich Co. 
Diethyl pyrocarbonate Sigma-Aldrich Co. 
Disodium hydrogen phosphate  EMD Chemicals Inc. 
DL-Dithiothreitol Sigma-Aldrich Co. 
DMEM Invitrogen – Gibco Cell Culture Systems 
DMEM-F12 Invitrogen – Gibco Cell Culture Systems 
DMSO Sigma-Aldrich Co. 
dNTPs New England Biolabs Ltd.  
EDTA EMD Chemicals Inc. 
Ethanol EMD Chemicals Inc. 
Ethidium bromide BDH  
Express Hyb BD Biosciences 
Fat-free skim milk powder Carnation 
Fetal Bovine Serum HyClone  
Fibronectin Sigma-Aldrich Co. 
Formaldehyde EMD Chemicals Inc. 
Formamide BDH  
Fyn EST (7997662) ATCC 
GeneScreen Plus Hybridization Transfer 
Membrane  
PerkinElmer Life Sciences, Inc.  
Glycerol EMD Chemicals Inc. 
Glycine EMD Chemicals Inc. 
Guanidinium thiocyanate BDH 
Hexadimethrine bromide Sigma-Aldrich Co. 
Humulin Eli Lilly Canada Inc. 
Hydrochloric acid EMD Chemicals Inc. 
Insulin-Transferrin -Selenium-G Supplement Invitrogen--Gibco Cell Culture Systems 
Isoamyl alcohol BDH  
Isopropanol EMD Chemicals Inc. 
Lck EST (6883710) ATCC 
Lipofectamine   Invitrogen 
Lipofectamine 2000 Invitrogen 
Lipofectamine RNAiMAX Invitrogen 
Lyn EST (5509761) ATCC 
Magnesium chloride BDH  
Manganese chloride tetrahydrate  BDH  
McCoy's 5A Invitrogen – Gibco Cell Culture Systems 
Methanol EMD Chemicals Inc. 
Molecular Imager FX Imaging Screen K Bio-Rad Laboratories Ltd. 
Morpholinopropanesulfonic acid Sigma-Aldrich Co. 
N-lauroyl sarcosine Sigma-Aldrich Co. 
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N,N,N',N'-Tetramethylethylenediamine EMD Chemicals Inc. 
Odyssey Blocking Buffer Li-Cor Biosciences 
Opti-MEM I Reduced Serum Medium Invitrogen--Gibco Cell Culture Systems 
Paraformaldehyde Sigma-Aldrich Co. 
Penicillin-Streptomycin  Invitrogen – Gibco Cell Culture Systems 
Phenol (water saturated) EMD Chemicals Inc. 
Potassium acetate BDH  
Potassium chloride EMD Chemicals Inc. 
Potassium dihydrogen phosphate EMD Chemicals Inc. 
PP2 EMD Chemicals Inc. 
Prestained Protein Marker Fermentas 
Protease Inhibitor Cocktail Sigma-Aldrich Co. 
Protein G Agarose, Fast Flow Millipore 
Puromycin  Sigma-Aldrich Co. 
Restriction endonucleases New England Biolabs Ltd.  
RPMI–1640 Invitrogen – Gibco Cell Culture Systems 
Rubidium chloride EMD Chemicals Inc. 
Sodium acetate  BDH  
Sodium bicarbonate EMD Chemicals Inc. 
Sodium carbonate EMD Chemicals Inc. 
Sodium chloride EMD Chemicals Inc./Sigma 
Sodium citrate BDH  
Sodium deoxycholate Sigma-Aldrich Co. 
Sodium dihydrogen phosphate  BDH  
Sodium dodecyl sulfate Sigma-Aldrich Co. 
Sodium hydroxide BDH  
Sodium orthovanadate Sigma-Aldrich Co. 
Sodium phosphate (dibasic) EMD Chemicals Inc. 
Sodium phosphate (monobasic) EMD Chemicals Inc. 
Src Kinase Inhibitor I EMD Chemicals Inc. 
Src Kinase Inhibitor II EMD Chemicals Inc. 
SU 6656 EMD Chemicals Inc. 
Tris EMD Chemicals Inc. 
Triton X-100 BDH 
Trypsin-EDTA 1X Invitrogen – Gibco Cell Culture Systems 
Tween 20 Sigma-Aldrich Co. 
UV Stratalinker 2400 Stratagene 
Western Lightning Chemiluminescence Reagent 
Plus 
PerkinElmer Life Sciences Inc. 
X-OMAT Blue XB- film Kodak 
Yes EST A50(7497767) ATCC 
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Table 3.2.  Commercial Kits and Distributors 
Commercial Kit Distributor Name 
EndoFree Plasmid Maxi Kit Qiagen Inc. 
QIAquick Gel Extraction Kit Qiagen Inc.  
QIAquick Nucleotide Removal Kit Qiagen Inc. 
Ready-To-Go DNA Labeling Beads 
(-dCTP) 
GE Healthcare 
Total Protein Kit, Micro Lowry Sigma 
Tyrosine Kinase Activity Assay Millipore 
 
Table 3.3.  Equipment and Software and Distributors 
Equipment and Software Distributor Name 
Biofuge 13 microcentrifuge Thermo Electron Corporation - Heraeus  
CO2 Incubator 3326 Forma Scientific, Inc.  
Coolpix 990 Digital Camera Nikon 
Coulter Counter ZM  Coulter Electronics, Ltd. 
Eclipse TE300 Nikon 
Gel Doc 2000 Bio-Rad Laboratories Ltd. 
Gene Amp PCR System 2700 Applied Biosystems Canada 
Horizontal Gel Electrophoresis System Owl Separation Systems 
IEC Micromax RF  Fisher Scientific 
ImageJ Software National Institutes of Health 
Isotemp Incubator 230D Fisher Scientific Company 
J2-MI highspeed centrifuge Beckman Coulter Canada, Inc. 
JA-10 rotor Beckman Coulter Canada, Inc. 
Micro Hybridization Incubator Model 2000 Robbins Scientific 
Microplate Reader Model 3550 Bio-Rad Laboratories Ltd. 
Mini-PROTEAN II Cell BioRad Laboratories Ltd. 
Molecular Imager FX Bio-Rad Laboratories Ltd. 
Odyssey Infrared Imaging System Li-Cor Biosystems 
Odyssey Software Li-Cor Biosystems 
ORBIT Incubator Shaker  Lab-Line 
Quantity One Software, Version 4 Bio-Rad Laboratories Ltd. 
Semi-dry Transfer Apparatus Owl Separation Systems 
SmartSpec 3000 Spectrophotometer  Bio-Rad Laboratories Ltd. 
Sorvall H1000B Du Pont Canada, Inc. 
Sorvall RT6000D Du Pont Canada, Inc. 
SpectraMax 340 PC Molecular Devices Corporation 
UV Stratalinker 2400 Stratagene 
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Table 3.4.  Antibodies and Distributors 
Wn, Western Blot; IP, Immunoprecipitation; Wn 2°, Western Blot secondary antibody 
Antibody Type Distributor 
Catalogue 
Number Use 
v-Src (Ab-1) Mouse monoclonal (327) Calbiochem OP07 Wn, IP 
Yes Rabbit polyclonal IgG Upstate 06-514 Wn 
c-Yes (C-4) Rabbit polyclonal IgG Santa Cruz sc-14 IP 
Fyn (15) Mouse monoclonal IgG1 Santa Cruz sc-434 Wn 
Fyn (FYN-01) Mouse monoclonal IgG Santa Cruz sc-51598 Wn 
Fyn (FYN3) Rabbit polyclonal IgG Santa Cruz sc-16 IP 
Lyn (H-6) Mouse monoclonal IgG2a Santa Cruz sc-7274 Wn, IP 
Lck (3A5) Mouse monoclonal IgG2b Santa Cruz sc-433 Wn, IP 
Actin (Ab-1) Mouse monoclonal (JLA20) Calbiochem CP01 Wn 
Goat anti Mouse  IgG HRP conjugated Santa Cruz sc-2005 Wn 2° 
Goat anti Rabbit IgG HRP conjugated Santa Cruz sc-2004 Wn 2° 
Goat anti Mouse IRDye 800 CW Li-Cor Biosystems 926-32210 Wn 2° 
Goat anti Rabbit IRDye 800 CW Li-Cor Biosystems 926-32211 Wn 2° 
Goat anti Rabbit IRDye 680 Li-Cor Biosystems 926-32221 Wn 2° 
 
Table 3.5.  siRNA and shRNA Sequences and Distributors 




Control siRNA #1 


















Yes Silencer Validated 
siRNA 690 





None Open Biosystems RHS4430 



















Table 3.6.  Names and Addresses of Distributors 
Distributor Name Address 
American Type Culture Collection 
(ATCC) 
ATCC, Manassas, VA, USA 
Applied Biosystems Canada Applied Biosystems Canada, Streetsville, ON, 
Canada 
BD Biosciences BD Biosciences, Mississauga, ON, Canada 
BDH Inc. BDH Inc., Toronto, ON, Canada 
Beckman Coulter Canada, Inc.  Beckman Coulter Canada, Inc., Mississauga, 
ON, Canada  
Bellco Glass Bellco Glass, Vineland, NJ, USA 
Bio-Rad Laboratories Ltd.  Bio-Rad Laboratories Ltd., Mississauga, ON, 
Canada 
Calbiochem EMD Biosciences Inc., La Jolla, CA, USA 
Coulter Electronics Ltd.  Coulter Electronics Ltd. Luton, Beds., England 
Dharmacon Thermo Scientific, Dharmacon, Inc., Lafayette, 
CO, USA 
Du Pont Canada, Inc. Du Pont Canada, Inc., Mississauga, ON, Canada 
Eli Lilly Canada Inc. Eli Lilly Canada Inc., Scarborough, ON, Canada 
EMD Chemicals Inc. EMD Chemicals Inc., Gibbstown, NJ, USA 
Eppendorf AG Eppendorf AG, Hamberg, Germany 
Fermentas Canada Inc.  Fermentas Canada Inc., Burlington, ON, Canada 
Fisher Scientific Company Fisher Scientific Company, Nepean, ON, Canada 
Forma Scientific, Inc.  Forma Scientific, Inc., Marietta, OH, USA 
GE Healthcare Bio-Sciences Inc. GE Healthcare Bio-Sciences Inc., Baie d'Urfe, 
QC, Canada 
HyClone HyClone, Logan, UT, USA 
Invitrogen Canada Inc. Invitrogen Canada Inc., Burlington, ON, Canada 
Kodak Kodak Eastman Company, Rochester, NY, USA 
Millipore Millipore, Billerica, MA, USA 
New England Biolabs, Ltd.  New England Biolabs, Ltd., Pickering, ON, 
Canada 
Open Biosystems Thermo Scientific Open Biosystems, Huntsville, 
AL, USA 
Owl Separation Systems Owl Separation Systems, Portsmouth, NH, USA 
Pall Canada, Ltd. Pall Canada Ltd., Ville St. Laurent, QC, Canada 
PerkinElmer Life Sciences, Inc.  PerkinElmer Life Sciences, Inc., Boston, MA, 
USA 
Promega  Promega, Madison, WI, USA 
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Qiagen Inc.  Qiagen Inc., Mississauga, ON, Canada 
Roche Diagnostics Roche Diagnostics, Laval, QC, Canada 
Santa Cruz Santa Cruz Biotechnology Inc., Santa Cruz, CA, 
USA 
Sigma-Aldrich Co. Sigma-Aldrich Co., Oakville, ON, Canada 
Stratagene Stratagene, La Jolla, CA, USA 
Thermo Electron Corporation - Heraeus  Thermo Electron Corporation, Waltham, MA, 
USA  
US Biomax, Inc. US Biomax, Inc., Rockville, MD, USA 
 
 
3.2. Tissue Culture and Cell Lines 
3.2.1. Cell lines and standard tissue culture conditions 
 All cell lines used throughout these studies were obtained from the American Type 
Culture Collection (ATCC) and grown at 37° in a Forma Scientific CO2 incubator, model 3326, 
with 5% CO2.  The four cell lines used extensively in this work are all adherent epithelial 
cancer cell lines: HT29 colorectal adenocarcinoma cells, HCT116 colorectal carcinoma cells, 
SW480 Dukes’ type B colorectal adenocarcinoma cells, and HepG2 hepatocellular carcinoma 
cells.  The colon cancer cell lines Colo 201, Colo 205, Colo 320, DLD-1, and HCT-15 were 
grown in RPMI-1640 media containing 10% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin (P/S), while HCT116 cells were grown in McCoy’s 5A medium with 
10% FBS and 1% P/S.  HT29, KM12C, LS174 T, LS180, SW480, SW620 and WiDr colon 
cancer cell lines were all grown in Dulbecco's Modified Eagle's Medium (DMEM) containing 
10% FBS and 1% P/S.  LoVo colon cancer cells were grown in DMEM F12 media with 10% 
FBS and 1% P/S.  The breast cancer cell line Hs578T was grown in DMEM, while MDA-MB 
231 and MDA-MB 435 cells were grown in RPMI-1640 and T47D cells were grown in RPMI-
1640 medium supplemented with 0.2 units/mL humulin.  All media for the breast cancer cell 
lines contained 10% FBS and 1% P/S.  The HepG2 cell line was grown in DMEM or DMEM-
F12, while the myeloid cell line U937 was grown in RPMI-1640, all containing 10% FBS and 
1% P/S.  The normal lung cell lines CCD-16Lu and CCD-19Lu were both maintained in #-
MEM supplemented with 2 mM L-glutamine and Earle’s balanced salt solution, 10% FBS and 
1% P/S.  The lung cancer cell lines were maintained as follows: HCC827, NCI-H1395, NCI-
H727 and NCI-H23 in RPMI-1640 containing 4.5 g/L glucose and NCI-H1993 in RPMI-1640 
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with no additional supplements.  NCI-H2009 cells were grown in DMEM-F12 supplemented 
with 5 µg/mL insulin, 0.01 mg/mL transferrin, 30 nM sodium selenite, 10 nM hydrocortisone, 
10 nM "-estradiol, 5% FBS and 1% P/S.  All other lung cell lines were maintained in media 
containing 10% FBS and 1 % P/S.  The HEK 293T cells used for viral packaging were 
maintained in DMEM containing 10% FBS.  In order to expand or seed adherent cells, they 
were first washed with phosphate-buffered saline (PBS) (8 g sodium chloride (NaCl), 0.2 g 
potassium chloride (KCl), 1.44 g disodium hydrogen phosphate (Na2HPO4), 0.24 g potassium 
dihydrogen phosphate (KH2PO4) in 1 L water), detached from their culture dishes using 
Trypsin-ethylenediamine tetracetic acid (EDTA) and split at a ratio consistent with that 
recommended by ATCC.  Cells used in proliferation, migration, adhesion, and colony forming 
assays were grown to at least 75 % confluency prior to seeding, in order to maintain 
consistency. 
 
3.2.2. Src family kinase inhibitor treatments 
 Cells were trypsinized and seeded into plates a minimum of 24 hours prior to treatment 
with SFK inhibitors or the control DMSO.  The SFK inhibitors were mixed into culture media 
at the indicated concentrations prior to treating the cells. To treat, cells were washed once with 
sterile PBS, following which the culture media containing the SFK inhibitors was added to the 
cells. 
 
3.3. siRNA Transfection of Cultured Cells 
3.3.1. Standard forward transfection conditions 
 Briefly, 24 hours before transfection HepG2 cells were trypsinized and counted using a 
Coulter Counter ZM and 5.0 x 10
5
 cells seeded per well of a 24 well plate in media containing 
FBS but without P/S. Transfection mixes were made by first diluting the indicated 
concentration of siRNA in 50 µL OPTI-MEM serum free media  for transfection in 24 well 
plates.  Five µL of Lipofectamine 2000 was added to equivalent volumes of OPTI-MEM in 
separate sterile tubes and allowed to incubate at room temperature for 15 minutes before the 
addition of the siRNA dilutions. The mixtures were gently mixed by pipetting up and down and 
allowed to incubate for a further 15 minutes. The media on the cultured cells was changed to 
fresh media containing FBS prior to the transfection mixes being added dropwise to the wells.  
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To transfect cells in different sizes of well volumes were adjusted accordingly.  The siRNAs 
commonly used in these studies may be found in Table 3.5. 
 
3.3.2. Standard reverse transfection conditions 
 Transfection mixes were made up directly in the tissue culture plates being used. In 
general, 50 nM siRNA was mixed into 500 µL OPTI-MEM media in a 35 mm well, followed 
by 5 µL Lipofectamine RNAiMAX.  The transfection mix was allowed to incubate for 15 to 20 
minutes prior to the addition of cells.  Cells were trypsinized and counted using a Coulter 
Counter ZM and 6.0 x 10
5
 HepG2 cells seeded directly into the wells containing transfection 
mix so that they would be approximately 50% confluent the following day.  Untreated control 
wells without siRNA or transfection reagent, as well as mock transfected wells (containing no 
siRNA), were also seeded at the same time. 
 
3.4. Creation of shRNA Knockout Cell Lines 
3.4.1. Preparation of competent Top10 cells 
     Top10 Escherichia coli cells were grown in 5 mL Luria Broth (LB) overnight at 37°C with 
shaking.  This whole culture was used to inoculate 100 mL of LB and the culture was grown 
until an optical density (OD) 550 nm of approximately 0.4 was reached before being 
centrifuged at 1300 x g for 15 minutes at 4°C.  The pellet was subsequently resuspended in 30 
mL of RF1 Buffer, pH 5.8 (100 mM rubidium chloride (RbCl), 50 mM manganese chloride 
tetrahydrate (MnCl2-4H20), 30 mM potassium acetate (KOAc), 10 mM CaCl2 dihydrate 
(CaCl2-2H2O), 15% (w/v) glycerol).  Following a 15 minute incubation on ice the cells were 
recentrifuged and resuspended in 7.2 mL RF2 Buffer, pH 6.8 (10 mM N-
morpholinopropanesulfonic acid (MOPS), 10 mM RbCl, 75 mM CaCl2-2H20, 75 mM 
glycerol).  Cells were again incubated on ice for 15 minutes, aliquoted and flash frozen.  Cells 
were stored at -80°C until use. 
 
3.4.2. Transformation of competent Top10 cells 
     Top10 supercompetent cells were transformed with the lentiviral packaging vectors psPAX2 
and pMD2.G or the control short hairpin RNA (shRNA) vector pGIPZ by incubating the dried 
plasmids in distilled water for 30 minutes prior to either 1 µl or 5 µL being added directly to 
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100 µL Top10 cells.  The cells were incubated on ice for 5 minutes before being plated on LB 
plates containing 50 µg/mL carbenicillin.  psPAX2, pMD2.G, and pGIPZ vectors were 
generous gifts from Dr. Calley Hirsch (MD Anderson Cancer Center).  Alternately, the shRNA 
constructs targeting the Src family members were obtained directly from Open Biosystems in 
competent cells (Table 3.5).  These cells were plated directly onto LB plates with 100 !g/mL 
carbenicillin and grown overnight.   
 
3.4.3. Plasmid preparations 
     Three mL of LB containing 50 µg/mL carbenicillin were inoculated with a single colony 
from the LB plates grown overnight.  These starter cultures were allowed to grow in a 37°C 
shaking incubator for approximately eight hours before being diluted 1:400 in 200 mL LB 
containing carbenicillin.  Cultures were grown overnight and centrifuged at 6000 x g for 15 
minutes at 4°C.  Plasmids were subsequently isolated using the Qiagen Endofree Plasmid Maxi 
Kit as per the manufacturer’s instructions. 
 
3.4.4. Viral packaging 
 Briefly, transfection mixes were made containing 1.5 µg of shRNA vector, 1 µg psPAX2 and 
0.5 µg pMD2.G.  To create multiple knockdown cell lines cells were co-transfected with 1.5 µg 
of each shRNA vector.  Vectors were mixed with 36 µL of Lipofectamine and incubated for 15 
minutes prior to being mixed into OPTI-MEM serum free media.  The entire mix was added to 
a 10 cm plate of 50% confluent HEK 293T cells grown in DMEM containing 10% FCS.  After 
5 hours, the media was changed to DMEM containing 20% FCS without P/S and cells grown 
under regular conditions for 48 hours.  All culture media was collected and replaced with fresh 
DMEM containing 20% FCS.  The collected media was kept at 4°C overnight.  Media 
containing virus was harvested again at 72 hours post transfection and added to the 48 hour 
harvest.  The harvested media was centrifuged at 1300 x g for 20 minutes prior to the 
supernatant being aliquoted into small volumes and kept at -80°C.  
 
3.4.5. Transduction and selection of target cell lines 
     Cells were seeded so that they were approximately 50% confluent at the time of 
transduction.  Twenty four hours after seeding, the cellular media was removed, the cells 
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washed with PBS and the viral supernatant added directly to the target cells in the presence of 8 
µg/mL hexadimethrine bromide.  After six hours, additional DMEM containing 10% FCS and 
P/S was added.  Twenty-four hours following transduction the cells were split into larger plates 
and grown under normal conditions for 48 hours after which fresh media containing puromycin 
was added.  The initial puromycin concentration depended upon cell line: 10 µg/mL for HT29 
was added, 5 µg/mL for SW480 cells, 1 µg/mL for HCT116, and 2 µg/mL for HepG2 cells.  
Once cells had become sufficiently confluent, higher puromycin concentrations of up to 50 
µg/mL were used.  Media was changed every three or four days to contain fresh puromycin 
until no untransduced cells remained in culture, as determined using a fluorescent microscope. 
 
3.5. RNA Isolation from Cultured Cells 
     RNA was isolated from confluent cultured cells according to the guanidinium thiocyanate 
protocol (Chomczynski and Sacchi, 1987).  Following PBS wash, cell lysates were harvested in 
Solution D buffer (4 M guanidinium thiocyanate, 25 mM sodium citrate (Na3C6H5O7), 0.5% 
(%w/v) N-lauroyl sarcosine) using a rubber policeman.  Sodium acetate (NaOAc, 2 M), pH 4.0 
was added and the samples vortexed prior to and following the addition of water saturated 
phenol and cloroform:isoamyl alcohol (at a 49:1 ratio).  Samples were incubated on ice for 15 
minutes, during which they were vortexed every 5 minutes, and the samples centrifuged at 12 
000 x g for 5 minutes at room temperature.  Following the transfer of the aqueous layer to a 
clean microfuge tube, an amount of isopropanol equal to 75% of the aqueous layer volume was 
added and the sample vortexed prior to being incubated at -20°C overnight.  Samples were 
centrifuged at 12 000 x g for 15 minutes, and the pellet dried and resuspended in Solution D 
containing "-mercaptoethanol.  Cold 95% ethanol was added and the sample incubated at -
20°C for a minimum of 1 hour before the samples were centrifuged at 12 000 x g for 20 
minutes at room temperature.  The resulting pellet was washed once with 70% ethanol before 
being dried and resuspended in RNA Storage Buffer (0.1 M EDTA in water containing 0.1% 
(v/v) diethyl pyrocarbonate).  The RNA concentration of each sample was determined by 
measuring the absorbance at 260 nm (A260).  Only samples with an A260:A280 ratio of more than 




3.6. Northern Blot 
3.6.1. Northern Blot electrophoresis and gel transfer 
     A 1% agarose gel was made in MOPS running buffer (0.2 M MOPS, 0.05 M sodium 
acetate, 0.01 M EDTA) containing 6% (v/v) formaldehyde and poured into an RNase free 
electrophoresis apparatus.  Samples were prepared in Northern Juice (50.7% (v/v) formamide, 
11.3% (v/v) 10X MOPS, 6.8% (v/v) formaldehyde, 5.6% (v/v) glycerol in diethyl 
pyrocarbonate treated H2O containing 0.1 mM EDTA) to contain 12 µg of mRNA.  Each 
sample was incubated at 65°C for 5 minutes prior to the addition of 6 x DNA gel loading buffer 
containing ethidium bromide.  The gel was electrophoresed in 1 x MOPS running buffer.  
Following electrophoresis, the gel was incubated in 50 mM sodium hydroxide (NaOH), washed 
in dH2O, neutralized in 100 mM Tris, pH 8.0, and washed again in dH2O for 20 minutes each.  
RNA was transferred overnight in 50 mM sodium phosphate solution, pH 7.0 onto a 
GeneScreen Plus hybridization transfer membrane.  Following transfer, the membrane was 
cross-linked using a UV Stratalinker 2400. 
 
3.6.2. Northern Blot probes 
     Probes used for Northern Blotting were generated by using endonuclease restriction 
enzymes to create DNA fragments, as described in Molecular Cloning: A Laboratory Manual 
(Sambrook et al., 1989).  The probes were subsequently extracted by gel extraction using the 
QIAquick Gel Extraction Kit.  The Src probe was generated by digesting the Src(wt) Y530 
pcDNA 3.1 plasmid with KpnI and NcoI.  A probe to detect c-Yes was created by digesting the 
Yes EST with BamHI and HincIII to produce a 560 base pair (bp) cDNA fragment.  Probes to 
detect Fyn, Lyn, and Lck were also generated by digesting their corresponding EST with 
restriction enzymes: the Fyn EST was digested with KpnI to create a 431 bp fragment, the Lyn 
EST was digested with SacI and HindIII, creating a 523 bp fragment, and the Lck EST was 
digested with RsrII and NcoI, which resulted in a 500 bp probe being produced.  Probes were 
labelled with [#-
32
P] using Ready-To-Go DNA Labeling Beads  
(-dCTP) according to manufacturer’s instructions, and unincorporated nucleotides were 




3.6.3. Northern Blot hybridization and detection 
     Membranes were pre-hybridized in ExpressHyb hybridization solution for 1 hour at 65° in a 
Micro Hybridization Incubator Model 2000 prior to the addition of the probe.  Following the 
addition of the [#-
32
P]-labelled probe, the hybridization reaction was allowed to proceed 
overnight at 65°C before the membrane was washed with a series of three 20 minute washes 
with decreasing concentrations of SSC buffer: Wash Buffer 1 (0.3 M sodium chloride (NaCl), 
30 mM sodium citrate, 1% sodium dodecyl sulfate (SDS), Wash Buffer 2 (75 mM NaCl, 7.5 
mM sodium citrate, 1% SDS), and Wash Buffer 3 (30 mM NaCl, 3 mM sodium citrate, 1% 
SDS).  Following washing, the membrane was wrapped in saran wrap and exposed to a 
Molecular Imager FX Imaging Screen K before the image was viewed using a Molecular 
Imager FX phosphoimager.  The membrane was also generally used to expose BioMAX XAR 
film in the presence of an intensifier screen. 
 
3.7.  Protein Isolation from Cultured Cells and Protein Concentration Determination 
3.7.1.  In 2X sample buffer 
     Cells were grown in tissue culture plates or dishes. Once they had grown to the desired 
confluency or for the desired time the plates were washed once with PBS and 2 x SDS Sample 
Buffer (10% (v/v) glycerol, 5% (v/v) "-mercaptoethanol, 2% (w/v) SDS, 65 mM Tris-HCl (pH 
7.0), and 0.05% (w/v) bromophenol blue) was added directly to the plate.  To examine SFK 
expression in panels of cell lines, each cell line was grown until it just reached confluency, in 
order to maintain consistency.  Protein was harvested by scraping and the samples were boiled 
and resuspended further by running through a 27 " gauge needle several times before protein 
concentration was determined.  Samples were stored at -80°C. 
 
3.7.2.  In RIPA buffer 
     Cells were grown in tissue culture plates or dishes until either the desired confluency or time 
was reached.  For kinase assays, all cell lines were grown until they were near confluency prior 
to harvesting.  Cells were washed once with cold PBS and RIPA buffer (150 nM NaCl, 25 mM 
Tris-HCl pH 7.2, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 2 mM EDTA and 1 
mM fresh dithiothreitol (DTT)) added directly to the plate.  Cells were harvested by scraping 
and samples were kept at -80°C until use. 
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3.7.3. Lowry protein assay 
     The protein concentration of all samples was determined using the commercially available 
Micro Lowry Total Protein Kit according to the manufacturer’s instructions.   
 
3.8. Western Blot 
3.8.1. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
     SDS-PAGE was carried out following the method of Laemmli (1970).  In general, the 
western gels used were a 5% acrylamide stacking gel (29.2% acrylamide:0.8% bis acrylamide, 
130 mM Tris-HCl, 0.1% (w/v) SDS, 0.1% (w/v) ammonium persulfate, 0.04% (w/v) TEMED) 
and a 10% SDS-polyacrylamide resolving gel (10% acrylamide:bis acrylamide (29.2%:0.8%), 
375 mM Tris-HCl pH 8.8, 0.1% (v/v) SDS, 0.1% (w/v) ammonium persulfate and 0.04% (w/v) 
N,N,N’,N’-tetramethylethylenediamine (TEMED).  Protein samples were boiled for 5 minutes 
and an equal concentration of protein loaded into the gel; in general, 30 µg of protein was used.  
Electrophoresis was carried out in SDS Gel Running Buffer (25 mM Tris-HCl, 200 mM 
glycine, 0.1% (w/v) SDS).  The resulting gel was soaked for 15 minutes in Transfer Buffer (48 
mM Tris, 39 mM glycine, 20 % methanol, 0.0375% SDS) and transferred to a BioTrace NT 
nitrocellulose blotting membrane using an OWL semi-dry transfer apparatus. 
 
3.8.2. Western Blot procedure 
     Membranes were rinsed in TBST (10 mM Tris, 15 mM NaCl, 0.5% (v/v) TWEEN-20) and 
blocked in 5% (w/v) fat-free skim milk powder in TBST for a minimum of 1 hour at room 
temperature to overnight at 4°C before being incubated in primary antibody diluted in blocking 
solution.  Following four washes with TBST, membranes were incubated in horseradish 
peroxidase (HRP) conjugated secondary antibody again diluted in blocking solution for 1 hour 
at room temperature (Towbin et al., 1979).  Following a second set of four washes in TBST, 
membranes were incubated in Western Lightning chemiluminescent reagent for 1 minute.  The 
membrane was subsequently exposed to X-OMAT Blue film for varying lengths of time and 
the film developed.  Antibodies could subsequently be stripped from the membrane by 
incubating it in Stripping Buffer (62.5 mM Tris, 2% (v/v) SDS, 0.7% (v/v) "-mercaptoethanol), 
allowing the membrane to be blotted with different antibodies, if desired.  Antibodies used in 
these studies may be found in Table 3.4. 
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3.8.3. Analysis of Western Blots with Li-Cor technology 
     Western blots developed using the Li-Cor system were carried out as above, except that 
membranes were washed in PBS or PBST (PBS with Tween 20) instead of TBST, and were 
blocked in Li-Cor Blocking Buffer.  Antibodies were also diluted in Li-Cor Blocking Buffer 
containing 0.05% Tween 20.  Secondary antibodies conjugated to infrared dyes were used, 
allowing the signal to be detected using the Li-Cor Odyssey Infrared Imaging System.  Band 
intensities were determined using the Li-Cor Odyssey software.  
 
3.9. Immunohistochemical Staining of Lung Cancer Tissue Array 
     A lung cancer tissue microarray containing 50 cases in duplicate was obtained from US 
Biomax, Inc..  Ten adenocarcinoma cases, ten squamous carcinoma, and eight small cell 
carcinoma cases were represented, along with multiple other types, as well as four non-
malignant normal lung tissue samples.  Samples were taken from both male and female patients 
ranging in age from 33 to 75 years of age.  The slide was sent for immunohistochemical 
staining for Lyn protein at the Saskatoon City Hospital, using the sc-7274 anti-Lyn antibody.  
In addition, the slide was counterstained with hematoxylin in order to visualize cells.  Slides 
were examined for the percent of cells that were positive for Lyn expression and categorized as 
follows: no Lyn expressed (%), <25% of cells expressed Lyn (+/-), 25% to 50% of cells 
expressed Lyn (+), 50% to 75% of cells expressed Lyn (++), >75% of cells expressed Lyn 
(+++). 
 
3.10. Tyrosine Kinase Assay 
3.10.1. Immunoprecipitation 
     The protein concentration of cell lysates harvested in RIPA buffer was determined using a 
Lowry Assay and samples were made up to 1 µg/mL in RIPA buffer containing 1 x Protease 
Inhibitor Cocktail (PIC), 1 mM dithiothreitol (DTT), and 100 µM sodium orthovanadate 
(Na3VO4). Ten µL of antibody was added and samples were nutated overnight at 4°C.  
Following incubation, 20 µL of Protein G Agarose was added to each sample before being 
nutated for an additional 1 hour and 15 minutes at 4°C.  Samples were centrifuged at 2300 x g 
for 1 minute at 4°C and the beads washed twice with RIPA buffer prior to being washed once 
with 1 X Kinase Reaction Buffer (1 mM ATP, 10 mM MgCl2, 25 mM Tris and 5 mM "-
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glycerophosphate) containing 2 mM DTT and 100 µM Na3VO4.  Assays were carried out 
directly on immunoprecipitated proteins. 
 
3.10.2. Kinase assay 
     The kinase activity of the immunoprecipitated Src family members was determined using 
the Chemicon Tyrosine Kinase Activity Assay kit according to the manufacturer’s instructions.  
The kinase reaction was allowed to proceed for 45 minutes. 
 
3.11. Cellular Proliferation Assays 
3.11.1. MTS assay 
 Cellular Proliferation Assays were carried out using the CellTitre 96 Aqueous One 
Solution Cell Proliferation Assay. Briefly, HepG2 cells were seeded and reverse transfected in 
triplicate in 96 well plates, while the stable knockdown HT29, SW480, or HCT116 cells were 
trypsinized, counted using a Coulter Counter ZM and equivalent cell numbers seeded in each 
well.  Identical plates were seeded for each 24 hour time point (up to 120 hours), and cells 
allowed to grow under normal conditions. For the assays testing the effects of SFK inhibitors 
on proliferation, the media was replaced after 24 hours with media containing the inhibitors or 
the control DMSO at concentrations of 2 µ&, 10 µ&, 'r 30 µ&, or the control DMSO at the 
corresponding volumes.  To asses the number of live cells present in each well, 20 µL of the 3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethonyphenol)-2-(4-sulfophenyl)-2H-tetrazolium 
(MTS) reagent was added to each well using a multichannel pipettor and allowed to incubate 
for 1 hour at 37°C and 5% CO2 before the absorbance was read at 490 nm using a microplate 
reader.  Background was corrected for by including wells containing media without cells. To 
determine cellular proliferation over time MTS assays were performed every 24 hours for up to 
96 hours. 
 
3.11.2. Cellular growth curve experiments 
     Stable shRNA-transduced HT29 cells were starved for 24 hours in DMEM containing 
0.05% FCS prior to being trypsinized, counted using a Coulter Counter ZM, and seeded in 
duplicate at 1.0 x 10
5
 cells per 35 mm well (9.6 cm
2
) in media containing 10% FCS.  Cells were 
allowed to grow under normal conditions and were trypsinized and counted in PBS every 24 
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hours for five days using the Coulter Counter ZM.  Growth curves of the HCT116 and SW480 
knockdown cells were also determined; however, 1.0 x 10
5
 HCT116 and 2.0 x 10
5 
SW480 cells 
were seeded initially.  
 
3.12. Adhesion Assay 
     Adhesion Assays were carried out in 96 well plates coated overnight with either 2.5 µg 
fibronectin or 2.5 µg collagen I.  Following coating, wells were washed twice with PBS before 
being blocked with 0.5% bovine serum albumen (BSA) in PBS for 1 hour at 37°C, washed 
three times in PBS and chilled at 4°C for up to a week.  To perform the adhesion assays, cells 
were trypsinized, counted using a Coulter Counter ZM and the cells seeded directly into the 
wells.  5.0 x 10
4
 HepG2 and HCT116, 1.0 x 10
5
 HT29, or 1.5 x 10
5
 SW480 cells were seeded 
per well and incubated at 37°C for 1 hour.  To assess the adhesion of the stable shRNA 
expressing cells, a suspension of cells in 100 µL was seeded directly into the wells.  To assess 
the effect of SFK inhibitors on cellular adhesion, the inhibitors or DMSO were diluted to 
concentrations of 4 µ&, 20 µ&, 'r 60 µ& in 100 µL and 50 µL added to each well.  The above 
numbers of cells were then seeded into the wells in 50 µL for a final inhibitor concentration of 
2 µM, 10 µ&, 'r 30 µ&.  Following incubation, wells were washed with PBS to remove 
unadherent cells from the wells before the adherent cells were fixed with 4% paraformaldehyde 
for 10 minutes at room temperature.  Following two washes with PBS, cells were stained with 
crystal violet (5 mg/mL in 2% ethanol) for 10 minutes.  After washing with water, wells were 
allowed to dry before 2% SDS was added.  Following a 30 minute incubation at room 
temperature, absorbance was read at 550 nm with a microplate reader. 
 
3.13. Wound Healing Assay 
3.13.1. Tissue culture 
     Confluent HT29, SW480, or HepG2 cells were trypsinized, counted using a Coulter Counter 
ZM, and 1.0 x 10
6
 HT29, 1.5 x 10
6
  SW480, or 6.0 x 10
5
 HepG2 cells seeded into 35 mm wells 
containing a sterile etched glass slide.  The cells were allowed to grow for 24 hours (HT29 and 
HepG2) or 48 hours (SW480) until they reached 80 to 90% confluency.  Once the cells had 
reached this confluency, the media was changed to starvation DMEM containing 0.5% FCS 
and the cells allowed to grow for a further 24 hours.  To assess migration, a sterile 10 µL 
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pipette tip was used to score three separate lines into the monolayer, the well washed at least 
twice with PBS to remove debris, and DMEM containing 10% FCS added to the well.  The 
plates were placed on a Nikon Eclipse TE300 microscope and 0 hour photographs were taken 
using a Nikon Coolpix 990 digital camera at distinct locations under 10x magnification.  Cells 
were placed under normal growth conditions and allowed to grow for 24 or 48 hours before 
photographs were taken at the same locations as the 0 hour photographs.  Six photographs, two 
from each wound, were taken for each well.  In order to determine the effect of SFK inhibitors 
on cellular migration wound healing assays were carried out exactly as described, except that 
following wounding the complete media added to the cells contained the indicated inhibitors at 
the given concentration.   
 
3.13.1. Quantification of migration 
     In order to quantify migration, the width of the wound was measured at the same locations 
of the slide at both 0 hours and 24 or 48 hours.  Image J software was used to measure the 
width of the wound at three locations for each photograph, using the slide etchings as a guide.  
Subsequently, the distance migrated in pixel width was calculated, and corrected to the pixel 
width migrated by the control cells. 
 
3.14. Colony Forming Assay 
3.14.1. Seeding 
Bottom agarose layers were formed by plating 0.6 % agarose made up in 2 X DMEM plus 20 
% FCS and allowing the agarose to set.  Cells were counted using the Coulter Counter ZM and 
5000 HT29, HepG2, or HCT116 cells or 10 000 SW480 cells were resuspended in 0.3 % 
agarose containing 10 % FCS.  This cell suspension was layered over the bottom agarose layer, 
allowed to set, and the cells placed at 37°C plus 5 % CO2  for 14 days for HepG2 cells to 21 
days for HT29.  Every three to four days fresh 0.3 % agarose in DMEM was layered over the 
wells.  To assess SFK Inhibitor effects on colony forming ability, cells were seeded in the 
presence of 2 µM, 10 µM, or 30 µM of each inhibitor.  In these assays, the inhibitors were also 
present at the indicated concentrations every time additional agarose was overlayed throughout 
the course of the assay. 
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3.14.2. Counting colonies formed 
Colonies were counted manually, using a grid.  Four random areas of each well were counted 
under a microscope and the average number of colonies determined for each well.  All 
experiments were carried out in duplicate. 
 
3.15.  Statistical Analysis 
Data is presented as the mean ± standard deviation.  One-way analysis of variance was 
performed on all data using GraphPad Prism, version 5.0d for Mac OS X (GraphPad Software, 
San Diego, CA, www.graphpad.com).  Dunnett’s multiple comparisons post test was performed 
to compare the mean of each sample to the mean of a control sample; either cells treated with 
the corresponding volume of DMSO for experiments looking at the effects of Src kinase 
inhibitor treatments, or those transduced with the empty shRNA control vector (pGIPZ), or 
transfected with a scrambled control siRNA, for experiments examining the effects of 







4.1.  SRC FAMILY KINASE EXPRESSION AND ACTIVITY IN A PANEL OF CELL 
LINES  
4.1.1. Src family kinase mRNA expression in a panel of colon cancer cell lines 
     In order to investigate the mRNA expression of the SFKs in a panel of colon cancer cell 
lines, mRNA was isolated from each cell line and Northern Blots carried out.  In the nine colon 
cancer cell lines initially examined by Dr. Calley Hirsch, five SFKs (Src, Yes, Fyn, Lyn, and 
Lck) were found to be expressed at the mRNA level in at least a subset of the cell lines 
investigated, while Blk, Fgr, and Hck showed no mRNA expression (Figure 4.1).  Furthermore, 
it was found that the different colon cancer cell lines examined each expressed only a subset of 
the SFKs, and that these combinations differed between cell lines.  In addition, the SFKs were 
expressed at different levels in the different cell lines.  To expand on this finding, a further 
seven colon cancer cell lines were examined for SFK mRNA expression, and were similarly 












Figure 4.1.  mRNA expression of the Src family kinases in different cancer cell lines.  
Total mRNA was harvested from confluent plates of sixteen colon cancer cell lines, the HepG2 
hepatocellular cell line, and the U937 myeloid cell line. The mRNA expression of the Src 
family members was examined by Northern Blot using probes specific for Src, Lck, Fyn, Lyn, 
or Yes.  Blk, Fgr, and Hck were not detected.  
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4.1.2. Src family kinase protein expression in a panel of colon, breast and lung cancer cell 
lines 
     Upon determining the levels of SFK mRNA expression in a panel of colon cancer cell lines, 
it was of interest to examine the protein expression of these kinases as well.  Therefore, the 
protein expression of the SFKs was investigated in the same panel of colon cancer cell lines, as 
well as in a panel of five breast cancer cell lines, six lung cancer cell lines and two normal lung 
cell lines, the hepatocellular carcinoma cell line HepG2, and the myeloid cell line U937.  At 
confluence, when the cells covered the maximum percentage of the tissue culture plate 
attainable by each given cell line, each of the cell lines was harvested for protein, and Western 
Blots carried out to determine the level of protein expression of each of the SFKs.  The level of 
protein expression correlated to what was observed at the mRNA level in most cell lines, and 
the Western Blots similarly demonstrated that Src, Yes, Fyn, Lck and Lyn proteins are 
expressed by the various cell lines at different levels and in different combinations (Figure 4.2).  
For example, HT29 cells express both Src and Yes at relatively high levels, and Fyn at a lower 
level, when compared to other cell lines.  In contrast, SW480 cells express Src and Yes at lower 
levels and Lck and Fyn at relatively high levels.  The majority of the cell lines examined also 
expressed Lyn.  From these observations, the colon cancer cell lines HT29, SW480, and 
HCT116 were chosen for further study, as they are representative of the different combinations 
of SFKs expressed in the panel of cell lines.  The hepatocellular carcinoma cell line HepG2 was 
also included in further studies as it expresses high levels of Src and has been used extensively 
in our laboratory. 
 
4.1.3. Src family kinase activity in selected cancer cell lines 
     Following the observation that a given cell line may express multiple SFKs at the mRNA 
and protein level, the kinase activity of the SFKs was examined in selected cell lines using a 
commercially available Tyrosine Kinase Activity Assay kit (Millipore) that can be used to 
assess the kinase activity of specifically immunoprecipitated proteins.  Following 
immunoprecipitation, the tyrosine kinases are incubated with a synthetic peptide, and the level 
of the resulting phosphorylation measured colourimetrically using an HRP-conjugated 
phosphotyrosine antibody.  As the SFKs can be immunoprecipated using specific antibodies, 




















Figure 4.2.  Protein expression of the Src family kinases in different cell lines.  Protein was 
harvested from confluent cells and Western Blots carried out using Src, Lck, Fyn, Lyn, or Yes 
specific antibodies to detect Src family member expression in A.  Sixteen colon cancer cell 
lines, the HepG2 hepatocellular cell line, and the U937 myeloid cell line, and B.  Four breast 
cancer cell lines. 
 
 
were found to be expressed at the protein level in a given cell line, not all of the SFKs 
expressed exhibited kinase activity (Figure 4.3).  For instance, although Lyn is expressed in 
HCT116 cells, Lyn kinase activity above the level observed in control samples that were not 
incubated with immunoprecipitated protein was not detected.  In general, Src was found to have 
the highest level of kinase activity, although Yes activity was also detected in HT29 cells and, 
to a lesser extent, HepG2 cells.  The relative Src kinase activity also differed between cell lines, 
with HT29 having the highest activity.  In SW480 cells, only Src and Fyn were found to have 











Figure 4.3.  Src family member kinase activity in HepG2, HT29 and HCT116 cells.  Src 
family members were immunoprecipitated from cell lysates of each cell line using antibodies 
specific for each of the five Src family members expressed, as indicated, and the kinase activity 
of each detected using a non-radioactive kinase assay kit.  Error bars are representative of the 
standard deviation of three independent experiments carried out in duplicate. 
 
cells when compared to the other cell lines examined, the level of Src kinase activity in SW480 
cells was relatively low.  In addition to SW480 cells, the SW620 cell line, which is derived 
from the lymph node metastasis of SW480 cells, was also assayed for SFK kinase activity.  
Much like the SW480 cells, SW620 showed Src and Fyn kinase activity; however, the level of 










Figure 4.4.  Src family member kinase activity in SW480 and SW620 colon cancer cells.  
Src family members were immunoprecipitated from cell lysates of each cell line using 
antibodies specific for each of the five Src family members expressed, as indicated, and the 
kinase activity of each detected using a non-radioactive kinase assay kit.  Error bars are 
representative of the standard deviation of four (SW480) or two (SW620) independent 
experiments carried out in duplicate. 
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4.1.4.  Src family kinase protein expression and kinase activity in a panel of lung cancer 
cell lines 
     In addition to colon and breast cancers, SFKs have also been found to be overexpressed and 
activated in lung cancer (Mazurenko et al., 1992; Masaki et al., 2003; Zhang et al., 2007).  
Therefore, in addition to the colon cancer and breast cancer cell lines previously examined, a 
panel of normal lung and lung cancer cell lines was examined for both SFK protein expression 
and Src and Lyn kinase activity.  In agreement with previous findings in the other cell lines 
examined, the lung cell lines all expressed multiple SFKs at different levels; the majority of the 
lung cell lines, including the two normal lung lines CCD-16Lu and CCD-19Lu, were found to 
express Src, Yes and Fyn (Figure 4.5 A).  Src was expressed at similar levels in all but two of 
the cell lines, and all of the cell lines showed similar levels of Yes protein expression.  Fyn was 
also detected in all but one of the lung lines.  Similar to what was observed in the panel of 
colon cancer cell lines, where Lck was expressed in only a small subset of the cell lines, Lck 
was detected at very low levels in only the NCI-H727 lung cancer cell line.  Although the 
majority of the colon and breast cancer cell lines examined were found to express Lyn, this 
protein was detected in only four of the eight lung lines.  Therefore, to determine if Src and/or 
Lyn kinase were active in these lung cell lines, the same kinase assay previously used to detect 
SFK kinase activity in HT29, HCT116, SW480, SW680 and HepG2 cells was employed.  Src 
activity was detected in all of the cell lines examined (Figure 4.5 B), while the NCI-H2009 and 
HCC-827 cell lines were also observed to have Lyn activity.  No significant Lyn activity was 
detected in the H23 and H727 cell lines, which correlates with the lower levels of Lyn protein 
expressed in these cell lines, when compared to NCI-H2009 and HCC-827 cells.      
 
4.1.5.  Lyn expression in a lung cancer tissue array 
     Lyn has previously been found to be expressed in lung tissue (Holtrich et al., 1991; Pertel et 
al., 2006; Zhao et al., 2006); however, the involvement of Lyn in lung cancers has not been 
studied extensively.  Therefore, as Lyn was found to have kinase activity in the lung cancer cell 
lines in which it was expressed, it was of interest to examine Lyn expression in samples of lung 
cancer tissue.  To this end, a lung cancer tissue microarray was obtained from US Biomax that 
contained duplicate samples of ten adenocarcinoma and ten squamous cell carcinomas,  




















Figure 4.5.  Src family member protein expression and Src and Lyn kinase activity in a 
panel of lung cancer cell lines.  A.  Confluent plates of normal lung and lung cancer cell lines 
were harvested in 2 X Sample Buffer and 30 µg of protein electrophoresed in an SDS-PAGE 
gel.  Western blots were carried out using antibodies against Src, Yes, Fyn, Lck, Lyn and "-
Actin, as indicated.  B.  Src or Lyn were immunoprecipitated from total protein harvested from 
the indicated cell lines and the kinase activity of these proteins determined using the Chemicon 
Tyrosine Kinase Assay kit.  Data presented is the average of at least two independent 
experiments carried out in duplicate. 
 
 
lung cancers.  Four non-malignant normal lung specimens were also included.  Following 
DAB-immunohistochemical staining using a Lyn specific antibody, which is visualized as a 
brown stain, and counterstaining with hematoxylin, which non-specifically stains cells blue and 
allows the visualization of cells, cases were examined for Lyn expression in order to determine 
if any patterns of expression were notable.  When examined, the majority of cases showed 
some Lyn expression, although generally at low levels, and often in fewer than 50% of the cells 
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within the sample.  However, some histological types of lung cancer showed higher levels of 
Lyn expression, both in terms of the number of cells positive for Lyn expression, as well as in 
Lyn protein levels.  In particular, the large cell carcinoma and atypical carcinoid samples 
showed high Lyn expression, with many of the cells in these cases expressing Lyn.  A high 
percentage of cells in the squamous cell carcinoma samples also expressed relatively high 
levels of Lyn.  In contrast, the majority of the adenocarcinoma samples showed no or very low 
levels of Lyn expression.  Within these cases, where the stage of cancer was known, no 
correlation between Lyn expression and the stage of cancer was observed.  The number of 
cases of each lung cancer pathology with a certain percentage of cells expressing Lyn is given 
in Table 4.1, while representative slides of adenocarcinoma, squamous cell carcinoma, small 
cell and large cell lung carcinomas, as well as papillary adenocarcinomas, alveolar cell 
carcinoma, papillary adenocarcinomas, atypical carcinoid, and non-malignant normal lung 
tissue are shown in Figure 4.6. 
 
Table 4.1. The number of cases of a lung cancer tissue array that show positive staining 
for Lyn protein expression.  Following immunohistochemical staining with a Lyn specific 
antibody, each case of a lung cancer tissue array obtained from US Biomax was examined and 
the percent of cells within each sample that were positive for Lyn expression determined.  The 
number of cases within each lung cancer type that were positive for Lyn expression in the 










































Figure 4.6.  Lyn expression in a panel of lung cancer tissue specimens.  
Immunohistochemistry was carried out on a lung cancer tissue microarray using a Lyn specific 
antibody (brown) and a hematoxylin counter stain (blue).  Representative samples of each lung 
cancer type are given as follows: A.  Adenocarcinoma, B.  Squamous cell carcinoma, C.  Small 
Cell, D.  Large Cell, E.  Atypical, F.  Papillary Adenocarcinoma, G.  Alveolar, and H.  Normal 
lung tissue. 
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4.1.6.  Summary   
     When the expression and kinase activity of the individual SFKs was examined in a panel of 
cancer cell lines it was found that although each cell line expressed multiple SFKs, the 
particular subset of SFKs expressed differed between cell lines.  In addition, the level of protein 
expression of each SFK varied between cell lines.  When selected cell lines were examined for 
SFK kinase activity it was found that Src itself exhibited kinase activity in all of the cell lines 
examined.  Yes or Fyn activity was also detected in selected colon cancer or hepatocellular 
carcinoma cell lines, while Lyn activity was detected in both of the lung cancer cell lines that 
expressed high levels of Lyn protein.  When Lyn expression was examined in lung cancer 
tissue present on a tissue microarray it was found that many of the samples expressed some 
level of Lyn protein, although in most cases weakly.   
 
4.2. OPTIMIZATION OF SILENCING INDIVIDUAL SRC FAMILY KINASES  
4.2.1. Identification of individual siRNA sequences that effectively silence single Src 
family kinases 
     In order to investigate the contributions of the individual SFKs to different cellular 
phenotypes, it was necessary to be able to decrease the expression of each SFK without 
affecting the activity or expression of the other family members.  In order to do this, individual 
siRNA sequences able to target each of the ubiquitously expressed SFKs, Src, Fyn, and Yes, 
were identified.  Initially, pools of four chemically synthesized siRNAs targeting each 
individual SFK, known as SMART Pools, were obtained from Dharmacon.  Following initial 
optimization using this pool of four sequences, the most effective individual sequence in each 
was identified by transfecting a cell line that expressed the given protein at high levels with the 
individual sequences and monitoring for decreases in protein expression 48 hours following 
transfection.  The siRNA sequence that was most effective in decreasing the protein expression 
of Src, Fyn, or Yes was then used in further experiments in HepG2 cells (Figure 4.7). 
 
4.2.2. Time courses of siRNA silencing 
     As siRNA silencing using chemically synthesized siRNAs is a transient event, it was 
necessary to demonstrate that the protein expression of the target SFKs remained at low levels 





















Figure 4.7.  Western Blots showing the relative efficiencies of individual siRNA sequences 
to silence the Src family kinases.  Representative blots are given for A.  Src siRNA in HepG2 
cells, B.  Yes siRNA in HT29 cells, and C.  Fyn siRNA in SW480 cells.  Cells were transfected 
with the indicated concentrations of the four numbered individual siRNA sequences, the 
SMARTpool siRNA (Pool), the scrambled control siRNA (siCtrl), or were left untransfected 
(#).  Western blots with the indicated antibodies, or "-actin as a loading control were 
performed using lysates harvested 48 hours following transfection.  For each Src family 
member the single sequence that resulted in the greatest silencing was identified (indicated with 
arrow).   
 
mediated knockdown of the SFKs were carried out in order to determine if SFK levels were 
significantly decreased for long enough to allow changes in cellular phenotypes to be detected.  
The length of knockdown was determined by harvesting protein samples at 24 hour intervals 
following transfection with siRNA and performing Western Blots to detect protein expression 
(Figure 4.8).  It was demonstrated in HepG2 cells that Src levels were knocked down by 24 
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hours post-transfection, and that by 48 hours there was nearly complete knockdown, which was 
maintained for a minimum of six days.  The level of Yes expression was not decreased to the 
same extent as the level of Src; however, expression also remained decreased past six days 
post-transfection.  In addition to transfecting HepG2 cells with siRNAs targeting either Src or 
Yes, cells were transfected with siRNAs targeting both Src and Yes together, in order to 
knockdown the expression of both of these proteins within single cells.  As was observed when 
these SFKs were silenced individually, Src levels were decreased nearly completely by 48 
hours, while Yes knockdown was less significant.  However, both Src and Yes protein levels 
were again found to be decreased for over six days (Figure 4.8).  This duration should provide 
enough time to monitor a number of cellular phenotypes following siRNA transfection, 















Figure 4.8.  Time courses of siRNA-mediated knockdown of Src and Yes expression in 
HepG2 cells.  HepG2 cells were seeded and reverse transfected in 35 mm wells with the 
indicated siRNAs, and cell lysates harvested in 2x SDS Sample Buffer every 24 hours for 144 
hours. Thirty µg of the resulting lysates were then separated on an SDS-PAGE gel, and 
Western blots carried out using either Src or Yes specific antibodies, to determine the extent of 




4.2.3. Generation of stable cell lines with decreased Src, Fyn, or Yes expression 
     As siRNA silencing proved to be inconsistent in HT29, HCT116, and SW480 cells, and 
often did not result in a significant decrease in SFK levels, it was necessary to achieve 
knockdown using an alternate method.  To this end, stable cell lines were created using shRNA 
vectors targeting individual SFKs.  Pre-designed pGIPZ vectors containing shRNA sequences 
targeting either Src, Fyn, or Yes, were purchased directly from Open Biosystems and 
transfected into HEK 293T cells along with the two viral packaging vectors psPAX2 and 
pMD2.G.  The HEK 293T cells subsequently produced lentivirus packaged with vectors 
containing specific shRNA sequences targeting either Src, Fyn, Yes, or the empty pGIPZ 
vector, as a control.  Following the production of lentivirus, HT29, HCT116, and SW480 cells 
were transduced with the shRNA vectors.  In an attempt to target multiple SFKs, cells were 
also transduced with combinations of lentivirus produced from HEK 293T cells that were 
transfected with a single shRNA vector, or with lentivirus from HEK 293T cells that were 
transfected with multiple shRNA vectors targeting different SFKs.  Once our cell lines of 
interest were transduced, the cells were  allowed to recover for four to six days before selection 
with puromycin was carried out.  A puromycin kill curve was initially carried out to determine 
the minimum required concentration of puromycin required to kill a given cell line; however, a 
higher concentration was necessary in order to select for cells that contained multiple vectors.  
Selection for cells expressing shRNAs was carried out for several weeks, with media 
containing fresh puromycin changed every four days.  As the puromycin selection resulted in 
significant cell death, cells were allowed to grow until they appeared healthy and confluent, at 
which point they were harvested, and Western Blots carried out in order to determine if the 
knockdown of the SFKs was successful (Figure 4.9 A, B, C).  The percent knockdown was 
determined using the Odyssey software, available from Li-Cor, which measures the intensity of 
protein bands.  After correcting for differences in the concentration of protein loaded in each 
well using the intensity of the "-actin band as a loading control, the level of knockdown was 
assessed quantitatively by comparing the intensities of protein bands from cells in which Src, 
Fyn, or Yes were knocked down to those of the pGIPZ control cells.  Although multiple 
shRNA sequences targeting each of the SFKs were tested for effective knockdown, only a 
single sequence for each SFK was found to result in significant knockdown (data not shown).  





















Figure 4.9.  Stable cell lines with decreased Src, Fyn, or Yes expression.  A.  HT29, B.  
HCT116, and C.  SW480 cells were transduced with shRNA vectors targeting Src, Yes, or Fyn.  
Following selection with puromycin, protein was harvested and Western blots carried out using 
the indicated antibodies to determine the level of protein knockdown.  The level of "-actin 
expression was also determined for all blots as loading controls; a sample blot is shown for 
each cell line.  At least three separate protein harvests and Western blots were carried out for 
each cell line, and the intensities of the protein bands measured quantitatively using the 
Odyssey software available from Li-Cor.  The percentage by which the expression of the 
indicated SFKs was decreased when compared to the pGIPZ control cells is given.  
 
 
knockdown of any of the SFKs (Figure 4.9).  Although the level of knockdown varied between 
cell lines, Src levels were decreased the most significantly of the three SFKs in all of the cell 
lines tested, with a minimum knockdown of 70% when compared to the Src levels expressed in 
the control cells.  Unfortunately, the decreases in Fyn and Yes expression were not as 
significant as that of Src in any of the cell lines, with Fyn being knocked down by 60 to 70%, 
 83 
and Yes expression being decreased by approximately 60%.  The level of knockdown achieved 
also depended upon cell line, with the greatest knockdown of all three of the SFKs occurring in 
HCT116 cells, while less significant SFK knockdown was observed in HT29 cells.  
Furthermore, as SW480 cells express very low levels of Yes protein, it was not possible to 
determine if Yes levels were further decreased in this cell line by the expression of a Yes-
specific shRNA.  SW480 cells that had been transduced with lentivirus containing the Yes 
specific siRNA were, however, used in subsequent experiments for the sake of completeness, 
and may be viewed as a further control.  HepG2 cells stably expressing the shRNAs, as 
evaluated by decreased SFK expression, were not successfully produced (data not shown).  
Therefore, SFK expression was transiently decreased in HepG2 cells using chemically 
synthesized siRNAs in further experiments. 
 
4.2.4.  Summary 
     As transfection of chemically synthesized siRNAs did not result in significant or consistent 
enough knockdown of the SFKs in HT29, HCT116, and SW480 cells, it was necessary to move 
to an shRNA approach in which cells with stable knockdown of Src, Fyn, or Yes were 
produced.  Although the transduction of HepG2 cells with shRNA vectors did not result in SFK 
knockdown, the transfection of siRNAs targeting Src into this cell line resulted in nearly 
complete knockdown of Src and this method was therefore used to decrease SFK expression in 
HepG2 cells in further experiments.  Although the level of knockdown achieved varied 
between both cell line and the SFK being targeted, a decrease in protein expression of at least 
55% was observed for all.  Although this is less than ideal silencing, we judged this sufficient 
to observe if SFK knockdown results in changes in cellular phenotypes. 
 
4.3. INVOLVEMENT OF SRC FAMILY KINASES IN CANCER CELL PHENOTYPES  
     Once HT29, HCT116, and SW480 cells with stably decreased Src, Fyn, or Yes expression 
were created, they were used to investigate the involvement of these proteins in the 
proliferation, adhesion, migration, and colony-forming ability of these cell lines.  HepG2 cells 
with siRNA-mediated knockdown of the SFKs were also examined.  By comparing the 
phenotypes of cells with decreased SFK expression to those of parental control cells and cells 
containing an empty control vector or scrambled siRNA control sequence it was possible to 
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determine which phenotypes the individual SFKs were involved in.  In addition, cells in which 
the kinase activity of all of the SFKs was inhibited through treatment with one of four different 
SFK inhibitors were examined for phenotypic changes.  Each inhibitor was used at three 
different concentrations representative of the concentrations used in the literature (2 µM, 10 
µM, and 30 µM), in order to examine the effects of both low and high concentrations.  By 
comparing the phenotypic changes resulting from SFK inhibition to those that occurred in 
response to the decreased expression of a single SFK it was possible to assess which SFKs in 
particular are involved in a given phenotype, and whether multiple SFKs must be targeted in 
order to cause significant effects on selected cellular phenotypes.   
 
4.3.1. Cellular Proliferation 
       One cellular phenotype that Src and the other SFKs have been implicated in is cellular 
proliferation.  In our investigations, cellular proliferation was initially determined using a 
commercially available MTS assay, which gives a representation of the number of 
metabolically active cells present in a well through the conversion of the MTS reagent to a 
colourimetrically detectable product.  In order to assess proliferation, cells were seeded in 
triplicate and an MTS assay carried out every 24 hours from 0 to 72 hours, at which time the 
cells reached confluency.  The proliferation of HepG2 cells was measured over 48 hours, as 
confluency was reached at this time.  In the experiments examining the effects of SFK 
inhibition, cells were grown in the presence of the SFK inhibitors over the course of the 
experiment.  The proliferation of cells in which Src, Fyn, or Yes levels were decreased was also 
examined, both by using the MTS assay, as well as by manually counting the number of cells 
present every 24 hours following seeding in order to create a growth curve.  This allowed the 
effects of inhibiting the kinase activity of multiple SFKs on proliferation to be compared to 
those of decreased Src, Fyn, or Yes expression. 
 
4.3.1.1.  Effects of Src family kinase inhibitor treatment on cellular proliferation 
     In order to determine the effect of SFK inhibition on cellular proliferation, HT29, HCT116, 
SW480, and HepG2 cells were treated with a range of concentrations of the commercially 
available SFK inhibitors PP2, SU6656, SKI I and SKI II, which all inhibit multiple SFKs.  It 
was found that not only were the four inhibitors disparate in their effects on the proliferation of 
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the cell lines tested, but that these effects were also cell line-specific.  As expected, the ability 
of the SFK inhibitors to inhibit cellular proliferation was also concentration specific, with 
higher concentrations of the inhibitors generally having a greater effect.  For example, the 
proliferation of HT29 cells treated with 30 µM of both PP2 and SKI I was reduced by 
approximately 45% and 25%, respectively, which was a greater decrease than was observed 
when cells were treated with either 2 µM or 10 µM of these inhibitors.  Neither SU6656 nor 
SKI II treatment resulted in a significant effect on HT29 proliferation (Figure 4.10 A-D).  
When the effect of SFK inhibitor treatment on the proliferation of HCT116 was examined, it 
was found that the proliferation of these cells was decreased by 40% when treated with the 
highest concentration of PP2, 30% when treated with SU6656, and 15% when treated with SKI 
II.  SKI I had no effect on HCT116 proliferation (Figure 4.11 A-D).  In contrast, none of the 
SFK inhibitors tested had a significant effect on the proliferation of SW480 cells (Figure 4.12 
A-D) or HepG2 cells (Figure 4.13 A-D).  Although the proliferation of cells treated with 
DMSO presented represents the proliferation of cells treated with a volume of DMSO 
equivalent to that of the 10 µM inhibitor samples, three separate DMSO controls were utilized 
and showed no significant difference in their effect on proliferation. 
 
4.3.1.2.  Effects of decreased Src, Fyn, or Yes expression on cellular proliferation 
     Once the effect of SFK inhibition on proliferation was determined, the proliferation of 
HT29, HCT116, SW480, and HepG2 cells with decreased Src, Fyn, or Yes expression was 
investigated, in order to compare the effects of inhibiting multiple SFKs to those when the 
activity of a single SFK was decreased.  Initially, the MTS assay was again used to measure 
proliferation.  However, due to the difficulty in ensuring that the same number of cells was 
seeded in every experiment, and the small number of cells seeded, the results obtained using 
this assay were quite variable, with a large statistical error between replicates.  When the fold 
growth of the cells was determined, which corrects for the number of cells seeded per well, the 
data obtained from all replicates was less variable.  Although no effect on proliferation was 
observed in HT29 cells when using the MTS assay (Figure 4.14 A), HT29 cells expressing 
lower levels of both Src and Yes were qualitatively observed to reach confluency more slowly 
than the cells containing the control pGIPZ vector, those with decreased Fyn expression, or the 

























Figure 4.10.  The proliferation of HT29 cells in the presence of Src family kinase 
inhibitors. HT29 cells were serum starved for 24 hours, following which 5000 cells were 
seeded per well of a 96 well plate.  After 24 hours, cells were treated with the indicated 
concentrations of A.  PP2, B.  SU6656, C.  SKI I, and D.  SKI II, and MTS proliferation assays 
carried out at the time of treatment (0 hours), and at 24, 48, and 72 hours post-treatment.  The 
graphs shown represent the average of three independent experiments done in triplicate, with 
the standard deviation given as error.  Statistical significance with a P value of less than 0.05 


























Figure 4.11.  The proliferation of HCT116 cells in the presence of Src family kinase 
inhibitors.  HCT116 cells were serum starved for 24 hours, following which 5 000 cells were 
seeded per well of a 96 well plate.  After 24 hours, cells were treated with the indicated 
concentrations of A.  PP2, B.  SU6656, C.  SKI I, and D.  SKI II, and MTS proliferation assays 
carried out at the time of treatment (0 hours), and at 24, 48, and 72 hours post-treatment.  The 
graphs shown represent the average of three independent experiments done in triplicate, with 
the standard deviation given as error.  Statistical significance with a P value of less than 0.05 


























Figure 4.12.  The proliferation of SW480 cells in the presence of Src family kinase 
inhibitors.  SW480 cells were serum starved for 24 hours, following which 20 000 cells were 
seeded per well of a 96 well plate.  After 24 hours, cells were treated with the indicated 
concentrations of A.  PP2, B.  SU6656, C.  SKI I, and D.  SKI II, and MTS proliferation assays 
carried out at the time of treatment (0 hours), and at 24, 48, and 72 hours post-treatment.  The 
graphs shown represent the average of three independent experiments done in triplicate, with 


























Figure 4.13.  The proliferation of HepG2 cells in the presence of Src family kinase 
inhibitors.  Cells were serum starved for 24 hours, following which 10 000 cells were seeded 
per well of a 96 well plate.  After 24 hours, cells were treated with the indicated concentrations 
of A.  PP2, B.  SU6656, C.  SKI I, and D.  SKI II, and MTS proliferation assays carried out at 
the time of treatment (0 hours), and at 24 and 48 hours post-treatment.  The graphs shown 
represent the average of three independent experiments done in triplicate, with the standard 
deviation given as error.  
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proliferation, whereby the number of cells present in each well was counted every 24 hours for 
120 hours.  A growth curve demonstrated that HT29 cells with decreased Src, Fyn, or Yes 
expression did indeed have reduced proliferation when compared to the control cells (Figure 
4.14 B).  Interestingly, both Src and Yes knockdown resulted in a decrease in cell number of 
approximately 50% by 120 hours, when compared to the control cells, while Fyn knockdown 
resulted in a decrease of 30%.  This approach was then also used to examine the growth of 
HCT116 and SW480 cells. 
     When MTS assays were carried out on HCT116 cells, there appeared to be an increase in the 
proliferation of the parental HCT116 cells over the cells containing shRNA vectors.  This 
difference in proliferation may, however, have been an artifact of being represented as fold 
growth, as fewer untransduced cells were present in the 0 hour timepoint in every assay.  There 
was no statistically significant difference observed between the pGIPZ control cells and any of 
the shRNA expressing cells, however.  Similar results were obtained when a cellular growth 
curve was made, as there was no significant difference in the growth of any of the cells (Figure 
4.15 B). 
     Although SW480 cells with stable Src knockdown appeared to have a reproducible decrease 
in proliferation when compared to that of the parental SW480 cells and control pGIPZ cells, as 
measured with the MTS assay, this was not statistically significant (Figure 4.16 A).  Similarly, 
no significant differences in proliferation were observed in any of the other knockdown cell 
lines.  However, when a growth curve was created, SW480 cells with decreased Src expression 
were found to have decreased numbers of cells after 72 hours when compared to both the 
pGIPZ and parental control cells.  The number of pGIPZ cells present at 120 hours was 
significantly fewer than the number of parental control cells, however.  Therefore, although the 
growth of SW480 cells with decreased Fyn expression was significantly reduced when 
compared to the parental cells and cells with decreased Yes expression, between which there 
was no difference in proliferation, no significant difference in proliferation was observed 
between cells with decreased Fyn expression and the pGIPZ control cells (Figure 4.16 B). 
      In order to assess the proliferation of HepG2 cells with decreased SFK expression, they 
were transiently transfected with chemically synthesized siRNAs targeting the SFKs at the time 
of seeding, 24 hours prior to beginning the MTS assay.  This was sufficient time to decrease 


























Figure 4.14.  The proliferation of HT29 cells with decreased Src, Fyn, or Yes expression.  
A.  Untransduced control HT29 cells (Ctrl), and HT29 cells transduced with an empty control 
vector (pGIPZ), or an shRNA vector targeting Src, Fyn, or Yes were serum starved for 24 
hours, following which 5000 cells were seeded per well of a 96 well plate.  MTS assays were 
carried out at the time of seeding (0 hour), and every 24 hours for five days.  The graph shown 
represents the average fold growth of three independent experiments done in triplicate, with the 
standard deviation given as error.  B.  HT29 cells stably transduced with shRNA vectors, or 
untransduced HT29 control cells (Ctrl) were serum starved for 24 hours prior to 1.0 x 10
5
 cells 
being seeded per 35 mm plate.  Cells were trypsinized and counted every 24 hours using a 
Coulter Counter ZM for five days.  The graph shown represents the average of two independent 
experiments done in duplicate, with the standard deviation given as error.  Statistical 

























Figure 4.15.  The proliferation of HCT116 cells with decreased Src, Fyn, or Yes 
expression.  A.  Untransduced control HCT116 cells (Ctrl), and HCT116 cells transduced with 
an empty control vector (pGIPZ), or an shRNA vector targeting Src, Fyn, or Yes were serum 
starved for 24 hours, following which 5000 cells were seeded per well of a 96 well plate.  MTS 
assays were carried out at the time of seeding (0 hour), and at 24, 48, and 72 hours after 
seeding.  The graph shown represents the average fold growth of four independent experiments 
done in triplicate, with the standard deviation given as error.  Statistical significance with a P 
value of less than 0.05 (*) versus the pGIPZ control is shown.  B.  HCT116 cells stably 
transduced with shRNA vectors, or untransduced HCT116 control cells (Ctrl) were serum 
starved for 24 hours prior to 1.0 x 10
5
 cells being seeded per 35 mm plate.  Cells were 
trypsinized and counted using a Coulter Counter ZM every 24 hours up to 72 hours.  The graph 
shown is the average of four independent experiments done in duplicate, with the standard 
























Figure 4.16.  The proliferation of SW480 cells with decreased Src or Fyn expression.  A.  
Untransduced control SW480 cells (Ctrl), and SW480 cells transduced with an empty control 
vector (pGIPZ), or an shRNA vector targeting Src, Fyn, or Yes were serum starved for 24 
hours, following which 5000 cells were seeded per well of a 96 well plate.  MTS assays were 
carried out at the time of seeding (0 hour), and every 24 hours for five days.  The graph shown 
represents the average fold growth of three independent experiments done in triplicate, with the 
standard deviation given as error.  B.  SW480 cells stably transduced with shRNA vectors, or 
untransduced SW480 control cells (Ctrl) were serum starved for 24 hours prior to 1.0 x 10
5
 
cells being seeded per 35 mm plate.  Cells were trypsinized and counted every 24 hours using a 
Coulter Counter ZM for five days.  The graph shown represents the average of three 
independent experiments done in duplicate, with the standard deviation given as error.  
Statistical significance with a P value of less than 0.05 (*) or 0.01 (**) versus the pGIPZ 
control is shown. 
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until approximately 72 hours.  No significant differences in proliferation were observed 
between the transfected and control cells, which corresponds with the finding that none of the 
SFK inhibitors tested had any effect on the proliferation of this cell line.  A HepG2 growth 
curve was therefore not created.  In addition to Src and Yes siRNA being used to reduce the 
expression of these proteins individually, HepG2 cells were also transfected with both siRNAs 
together in order to determine if their proliferation would be affected when Src and Yes levels 















Figure 4.17.  The proliferation of HepG2 cells with decreased Src, Fyn, or Yes expression.  
HepG2 cells were trypsinized, counted, and seeded at the time of reverse transfection with no 
siRNA (Mock), a scrambled control siRNA (siCtrl), or siRNAs targeting either Src, Yes, or 
Fyn individually, or Src and Yes together, in wells of a 96 well plate.  MTS assays were carried 
out every 24 hours until 72 hours after seeding, at which time the cells had reached confluency.  
Data presented is the average of three independent experiments done in triplicate, with the 







4.3.1.3.  Summary 
     Although multiple SFKs have been implicated in proliferation, results in the literature have 
been variable, and changes in SFK expression level or SFK inhibitor treatment have been found 
to affect the proliferation of some cell lines and not others.  Our findings also suggest that the 
SFKs may affect proliferation in only a subset of cell lines, as the inhibitors used in these 
studies were found to significantly reduce the proliferation of only HT29 and HCT116 cells 
(Table 4.2).  The ability of the SFK inhibitors to affect proliferation was also dependent upon 
the inhibitor being used.  When the effects of SFK knockdown were examined, it was found 
that HT29 cells expressing Src, Yes and Fyn shRNA sequences had decreased growth when 
compared to control cells.  In contrast, HCT116 cells, which had decreased proliferation when 
grown in the presence of the SFK inhibitors, showed no significant differences in growth when 
any one of the SFKs was knocked down.  Furthermore, although none of the SFK inhibitors 
tested had an effect on the proliferation of SW480 cells, SW480 cells with decreased Src 
expression proliferated more slowly than the control cells.  In HepG2 cells, however, neither 
decreases in Src or Yes expression nor Src kinase inhibition had an effect on proliferation.  
SFK involvement in the proliferation of cancer cell lines, therefore, appears to be cell line 
dependent. 
 
Table 4.2.  Summary of the effects of Src family kinase inhibitor treatment or decreased 
Src, Fyn, or Yes expression on the proliferation of selected cancer cell lines.  Relative 
levels of inhibition of proliferation are given as follows: # No effect, +/# less than 20%, but 












4.3.2. Cellular Adhesion to Fibronectin and Collagen 
     The adhesive properties of cancer cells to both other cells and the extracellular matrix 
(ECM) are generally altered, which contributes to their ability to spread.  Although cell-cell 
adhesion was not investigated in this work, adhesion to both fibronectin and collagen, which 
are important components of the ECM, was investigated.  In order to assess the adhesion of our 
cell lines of interest, cells were seeded into tissue culture wells that had previously been coated 
with either fibronectin or collagen.  After allowing the cells to adhere to the wells for an hour, 
unadherent cells were washed from the wells, and the adherent cells fixed and stained so that 
the level of cellular adhesion could be assessed colourimetrically.  Both cells that had been 
treated with SFK inhibitors and those with decreased Src, Fyn, or Yes expression were assessed 
for their ability to adhere to both fibronectin and collagen. 
 
4.3.2.1.  Effects of Src family kinase inhibitor treatment on cellular adhesion 
     In order to determine the effect of SFK inhibition on cellular adhesion to both fibronectin 
and collagen, HT29, SW480, HCT116, and HepG2 cells were treated with SFK inhibitors and 
examined for their ability to adhere to these ECM components.  The four SFK inhibitors: PP2, 
SU6656, SKI I, and SKI II, were used at three different concentrations to inhibit the SFKs, as 
indicated.  As three different concentrations were used from a single stock solution, this 
resulted in cells being exposed to different volumes of the DMSO solvent, depending on the 
concentration of inhibitor used.  It was discovered in our adhesion assays that higher volumes 
of DMSO alone increased the adhesion of some of our cell lines of interest.  To control for this 
effect, three different DMSO controls were used in each assay, whereby cells were treated with 
volumes of DMSO equivalent to those that were used to deliver each of the three 
concentrations of inhibitors.  When analyzing data, it was therefore necessary to compare the 
adhesion of cells in the presence of a given concentration of inhibitor to the control cells treated 
with the corresponding volume equivalent of DMSO.  Data is therefore presented as the percent 
migration of each sample in relation to its respective DMSO control.    
     In HT29 cells, it was found that treatment with the highest concentrations of PP2, SU6656, 
and SKI I decreased the adhesion of these cells to both fibronectin and collagen by at least 
40%, while no decrease in adhesion was observed following SKI II treatment (Figure 4.18 A, 

























Figure 4.18.  The adhesion of HT29 cells to fibronectin or collagen in the presence of Src 
family kinase inhibitors.  HT29 cells were trypsinized, counted, and 1.0 x 10
5
 cells seeded per 
well of a 96 well plate coated with either A.  fibronectin or B.  collagen in the presence of the 
indicated concentrations of the Src kinase inhibitors PP2, SU6656, SKI I or SKI II, or in the 
volume of DMSO equivalent to those concentrations.  Following a one hour incubation, 
unadhered cells were washed from the plate, and the remaining cells fixed and stained with 
crystal violet for colourimetric analysis.  The data presented are the mean of the percent level 
of adhesion, relative to the control cells treated with DMSO, of three independent experiments 
done in triplicate, with the standard deviation given as error.  Statistical significance with a P 




adhesion to both fibronectin and collagen, the effects of SU6656 and SKI I treatment were 
concentration dependent, with the greatest decrease observed using the highest concentration of 
inhibitor.  Unexpectedly, the adhesion of HT29 cells to fibronectin was significantly increased 
by treatment with the lower concentrations of both SKI I and SKI II. 
     When the adhesion of HCT116 cells was examined, it was found that although treatment 
with 2 µM of SKI I or SKI II resulted in an increase in the adhesion of this cell line to 
fibronectin, no effects were observed when they were treated with either the higher 
concentrations of these inhibitors, or PP2 or SU6656 (Figure 4.19 A).  In contrast, the adhesion 
of HCT116 cells to collagen was affected by treatment with three of the inhibitors investigated, 
whereby treatment with 30 µM of PP2, SKI I, and SKI II reduced the adhesion of these cells to 
collagen by 40%, 25%, and 25%, respectively.  An increase in the adhesion of HCT116 cells to 
collagen in response to treatment with 2 !M of SKI I and SKI II was also observed.  SU6656 
treatment did not significantly affect HCT116 adhesion to collagen (Figure 4.19 B).   
     When the effect of SFK inhibition on the adhesion of SW480 cells was examined it was 
found that treatment with the highest concentration of PP2 tested resulted in a 50% decrease in 
adhesion to fibronectin, while none of the other inhibitors tested had any effect (Figure 4.20 A).  
Rather, as was seen in HT29 cells, treatment with 2 !M of SKI I or SKI II resulted in an 
increase in adhesion to fibronectin, although this effect was not observed when higher 
concentrations of these inhibitors were used.  When the adhesion of SW480 cells to collagen 
was examined, 30 !M of PP2 was again found to reduce the adhesion of these cells by 35% 
(Figure 4.20 B).  This was also observed in cells treated with 30 !M of SKI I, whereby their 
adhesion to collagen was decreased by 30%.  The adhesion of SW480 cells to collagen was 
increased by treatment with all three concentrations of SU6656, while only the lowest 
concentration of SKI II significantly increased the adhesion of these cells.  
     Finally, the treatment of HepG2 cells with PP2, SU6656, and SKI I resulted in significant, 
concentration dependent decreases in the adhesion of these cells to fibronectin, with 30 µM of 
these inhibitors reducing adhesion by 40%, 35%, and 70%, respectively.  In contrast, SKI II 
was not observed to have any statistically significant effect on the adhesion of HepG2 cells to 
fibronectin (Figure 4.21 A).  PP2 and SKI I were also able to significantly reduce HepG2 
adhesion to collagen by 20%, although only at the highest concentration used (Figure 4.21 B).  

























Figure 4.19. The adhesion of HCT116 cells to fibronectin or collagen in the presence of 
Src family kinase inhibitors.  HCT116 cells were trypsinized, counted, and 5.0 x 10
4
 cells 
seeded per well of a 96 well plate coated with either A.  fibronectin or B.  collagen in the 
presence of the indicated concentrations of the Src kinase inhibitors PP2, SU6656, SKI I or SKI 
II, or in the volume of DMSO equivalent to those concentrations.  Following a one hour 
incubation, unadhered cells were washed from the plate, and the remaining cells fixed and 
stained with crystal violet for colourimetric analysis.  The data presented are the mean of the 
percent level of adhesion, relative to the control cells treated with DMSO, of three independent 
experiments done in triplicate, with the standard deviation given as error.  Statistical 



























Figure 4.20.  The adhesion of SW480 cells to fibronectin or collagen in the presence of Src 
family kinase inhibitors.  SW480 cells were trypsinized, counted, and 1.5 x 10
5
 cells seeded 
per well of a 96 well plate coated with either A.  fibronectin or B.  collagen in the presence of 
the indicated concentrations of the Src kinase inhibitors PP2, SU6656, SKI I or SKI II, or in the 
volume of DMSO equivalent to those concentrations.  Following a one hour incubation, 
unadhered cells were washed from the plate, and the remaining cells fixed and stained with 
crystal violet for colourimetric analysis.  The data presented are the mean of the percent level 
of adhesion, relative to the control cells treated with DMSO, of three independent experiments 
done in triplicate, with the standard deviation given as error.  Statistical significance with a P 


























Figure 4.21.  The adhesion of HepG2 cells to fibronectin or collagen in the presence of Src 
family kinase inhibitors.  HepG2 cells were trypsinized, counted, and 5.0 x 10
4
 cells seeded 
per well of a 96 well plate coated with either A.  fibronectin or B.  collagen in the presence of 
the indicated concentrations of the Src kinase inhibitors PP2, SU6656, SKI I or SKI II, or in the 
volume of DMSO equivalent to those concentrations.  Following a one hour incubation, 
unadhered cells were washed from the plate, and the remaining cells fixed and stained with 
crystal violet for colourimetric analysis.  The data presented are the mean of the percent level 
of adhesion, relative to the control cells treated with DMSO, of three independent experiments 
done in triplicate, with the standard deviation given as error.  Statistical significance with a P 




treatment with 2 µM of SKI II.  Therefore, the effects of the SFK inhibitors on the adhesion of 
the different cancer cell lines depended both upon both the inhibitor and cell line being 
investigated. 
 
4.3.2.2.  Effects of decreased Src, Fyn, or Yes expression on cellular adhesion 
     As the adhesion of all of our cell lines of interest to both fibronectin and collagen was 
decreased in response to treatment with at least one of the SFK inhibitors, we next examined 
the effects of Src, Fyn, and Yes knockdown on adhesion in order to determine if the inhibition 
of multiple SFKs results in greater effects on adhesion than decreases in the expression of a 
single SFK.  Although the level of adhesion of HT29 cells with decreased Src or Yes 
expression to fibronectin was reduced by 35% when compared to that of cells containing the 
pGIPZ control vector, no effect was observed in HT29 cells with decreased Fyn expression 
(Figure 4.22 A).  Furthermore, although SFK inhibitor treatment resulted in a significant 
reduction in the adhesion of HT29 cells to collagen, no such effect was observed as a result of 
decreased Src, Fyn, or Yes expression in these cells (Figure 4.22 A).  Likewise, neither the 
adhesion of HCT116 (Figure 4.22 B), nor SW480 cells (Figure 4.22 C) with decreased Src, 
Fyn, or Yes expression to either fibronectin or collagen was significantly reduced when 
compared to that of the cells transduced with the pGIPZ control vector.   
     HepG2 cells transiently transfected with a control scrambled siRNA, or siRNAs targeting 
Src, Yes, or Fyn were also assayed for their ability to adhere to fibronectin and collagen.  The 
adhesion of HepG2 cells with decreased Src and Yes expression to fibronectin was reduced by 
30% and 25%, respectively, when compared to that of the control cells transfected with the 
scrambled siRNA (Figure 4.23 A).  Similarly, the adhesion of HepG2 cells to collagen was 
reduced by 40% in response to decreased Yes expression, although decreases in Src expression 
did not have a statistically significant effect on the adhesion of these cells to collagen (Figure 
4.23 B).  When the adhesion of HepG2 cells expressing decreased levels of both Src and Yes in 
conjunction was investigated, it was found that there was no significant effect on the adhesion 




























Figure 4.22.  The adhesion of HT29, HCT116, and SW480 cells with decreased Src, Fyn, 
or Yes expression to fibronectin or collagen.  Stably transduced A.  HT29, B.  HCT116, or 
C.  SW480 cells were trypsinized, counted, and 1.0 x 10
5
 HT29 cells, 5.0 x 10
4
 HCT116 cells, 
or 1.5 x 10
5
 SW480 cells seeded per well of a 96 well plate coated with either fibronectin or 
collagen.  Following a one hour incubation, unadhered cells were washed from the plate, and 
the remaining cells fixed and stained with crystal violet for colourimetric analysis.  The data 
presented are the mean of the percent level of adhesion, relative to that of the pGIPZ control 
cells, of at least three independent experiments done in triplicate.  The standard deviation is 
given as error.  Statistical significance with a P value of less than 0.05 (*) versus the pGIPZ 











Figure 4.23.  The adhesion of HepG2 cells with decreased Src, Fyn, or Yes expression to 
fibronectin or collagen.  HepG2 cells were transfected with either a scrambled control siRNA 
(siCtrl), or siRNAs targeting Src, Fyn, or Yes individually, or Src and Yes in conjunction.  
Cells were grown for five days before 5.0 x 10
4
 cells were seeded in a 96 well plate coated with 
either A.  fibronectin or B.  collagen.  Following a one hour incubation, unadhered cells were 
washed from the plate, and the remaining cells fixed and stained with crystal violet for 
colourimetric analysis.  The data presented are the mean of the percent level of adhesion, 
relative to that of the scrambled control cells, of four (fibronectin) or three (collagen) 
independent experiments done in triplicate, with the standard deviation given as error.  
Statistical significance with a P value of less than 0.05 (*) or 0.01 (**) versus the control is 
shown.   
 
 
4.3.2.3.  Summary 
     The effect of SFK inhibition on adhesion appears to be dependent upon both the inhibitor 
and cell line being investigated, as well as upon the adhesion molecule being assayed (Table 
4.3).  In particular, HT29 cells had the most significantly decreased adhesion to both 
fibronectin and collagen when treated with SFK inhibitors, as well as when Src and Yes protein 
levels were decreased.  While the adhesion of the majority of the cell lines to both fibronectin 
and collagen was inhibited by treatment with either PP2 or SKI I, SU6656 and SKI II only 
inhibited the adhesion of HCT116 cells.  Furthermore, treatment with a number of the 
inhibitors resulted in the increased adhesion of given cell lines to either fibronectin or collagen.  
In particular, this was observed when cells were treated with the lowest concentration of the 
inhibitors investigated in this study, and although this was observed mostly in response to SKI I 
and SKI II treatment, SU6656 also had this effect on SW480 cells.  Although the adhesion of 
all four of the cell lines investigated to either fibronectin or collagen was inhibited by at least 
one SFK inhibitor, decreases in the expression of individual SFKs did not have as significant 
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an effect.  Only HT29 and HepG2 cells with decreased Src and Yes expression had reduced 
adhesion to fibronectin, while only HepG2 cells with decreased Yes expression had 
significantly reduced adhesion to collagen.  Decreases in the expression of both Src and Yes in 




Table 4.3. Summary of the effects of Src family kinase inhibitor treatment or decreased 
Src, Fyn or Yes expression on the adhesion of selected cancer cell lines to fibronectin and 
collagen. Relative levels of inhibition of adhesion to A. Fibronectin and B. Collagen in the 
presence of 30 !M of the indicated inhibitors are given as follows: # No effect, + 20-35% 
inhibition, ++ 35-50% inhibition, +++ more than 50% inhibition.  Increased adhesion due to 


















4.3.3. Cellular Migration 
     Many of the SFKs have been strongly implicated in cellular migration.  It would therefore 
be expected that cellular migration would be inhibited following either treatment with an SFK 
inhibitor, or in response to decreased SFK expression.  The migratory capacity of cells that 
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were either treated with SFK inhibitors or had decreased Src, Fyn, or Yes expression was 
therefore assessed by performing wound healing assays.  In these assays, cells were grown on 
etched glass cover slips until they were nearly confluent, at which time a wound was created in 
the monolayer.  The wound was photographed at distinct locations on the cover slip both at the 
time of wounding, and again after the cells had been allowed to grow into the wound; the extent 
to which the cells had migrated into the wound was determined by measuring the width of the 
wound at both the time of wounding and following incubation.  Representative images of SFK 
inhibitor treated HT29 cells showing wounds at 0 hours and 48 hours are shown in Figure 4.24.  
Due to the time consuming nature of the quantification, only one concentration of each 
inhibitor was used in the wound healing assays: 30 µM PP2, 2 µM SU6656, 10 µM SKI I, and 
20 µM SKI II, as these concentrations are typically used in the literature (Jones et al., 2002; 
Golubovskaya et al., 2003; Boyd et al., 2004; Chiang et al., 2005; Matsumoto et al., 2010).  
Control cells treated with DMSO were also included in every assay, and the data presented as 
the percent of the wound that had closed following incubation, in relation to these control cells.  
HCT116 migration was not investigated using this assay because it was not possible to make a 
uniform, thin wound in a confluent monolayer of these cells.   











Figure 4.24.  Representative images of an HT29 wound healing assay carried out in the 
presence of Src family kinase inhibitors.  HT29 cells were seeded on etched glass cover slips 
in six well plates and grown to confluency.  Upon reaching confluency, the cells were serum 
starved for 24 hours prior to being wounded using a 10 µL pipette tip.  Photos were taken of the 
wound widths at the time of wounding (0 h) and the cells grown in media containing serum in 
the presence of DMSO or the Src kinase inhibitors at the following concentrations: 30 µM PP2, 
2 µM SU6656, 10 µM SKI I, and 20 µM SKI II for 48 hours.  Following 48 hours, photos were 
taken at the same locations as the 0 h photos, as indicated by the etched grid position (48 h).   
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4.3.3.1. Effects of Src family kinase inhibitor treatment on migration 
     When the effect of SFK inhibition on migration was investigated, it was found that the four 
different SFK inhibitors affected cellular migration in a cell line and inhibitor specific manner.  
In the case of HT29 cells, PP2 completely prevented the migration of the cells into the wound; 
instead, it caused a change in the morphology of the cells that resulted in a wider wound at the 
later time point than was initially made in the monolayer.  SU6656 treatment did not result in a 
statistically significant decrease in HT29 migration when compared to the control cells treated 
with DMSO.  Treatment with SKI I was found to cause a 50% decrease in HT29 migration 
when compared to the control cells, while treatment with SKI II did not cause any significant 
differences in migration (Figure 4.25 A).  Similar to what was observed with HT29 cells, the 
migration of SW480 cells was found to be completely inhibited by PP2 treatment, while SKI I 
treatment inhibited the migration of these cells into wounds by 60%.  Treatment with either 
SU6656 or SKI II did not statistically inhibit SW480 migration (Figure 4.25 B). 
     The different SFK inhibitors also inhibited the migration of HepG2 cells.  PP2 was once 
again found to reduce migration to the greatest extent; however, PP2 inhibited HepG2 
migration by only 70%, compared with the complete inhibition of the other cell lines examined.  
SU6656 and SKI I treatment both inhibited HepG2 migration by 30%, while SKI II treatment 
did not result in a significant change in the migration of these cells in relation to the control 
cells treated with DMSO (Figure 4.25 C).  Although the extent to which the SFK inhibitors 
reduced migration depended upon cell line, the migration of all of the cell lines investigated 
was inhibited by both PP2 and SKI I treatment. 
 
4.3.3.2. Effects of decreased Src, Fyn, or Yes expression on migration 
     After investigating the effects of SFK inhibition on migration, we next examined the effects 
of decreasing the expression of individual SFKs.  The migration of HT29 cells with decreased 
Src, Fyn, or Yes expression was reduced by 30% to 45% when compared to the pGIPZ control 
cells (Figure 4.26 A).  In SW480 cells, it was found that while decreased Src expression 
resulted in a reduction in migration of approximately 40%, neither decreased Fyn nor Yes 
expression had any significant effect on the migration of these cells (Figure 4.26 B).  Finally, 
the migration of HepG2 cells was not affected by decreased Src, Fyn, or Yes expression, or 

























Figure 4.25.  The migration of HT29, SW480, and HepG2 cells in the presence of Src 
family kinase inhibitors.  A. HT29, B.  SW480, or C.  HepG2 cells were trypsinized, counted, 
and seeded into six well plates containing etched glass slides.  Cells were grown to near 
confluency before being serum starved for 24 hours prior to three wounds being made in each 
monolayer.  Each wound was photographed at two distinct locations at the time of wounding, 
and at the same locations after the cells had been grown under normal cell culture conditions 
for 24 to 48 hours.  The width of the wound was measured at both timepoints to determine 
migration.  The data is presented as the percent of the wound width that had closed during 
incubation, in relation to that of the DMSO control cells.  Error bars are the standard deviation 
of at least two (HT29 and SW480) or three (HepG2) independent experiments.  Statistical 

























Figure 4.26.  The migration of HT29, SW480, and HepG2 cells with decreased Src, Fyn, 
or Yes expression.  A.  HT29 or B.  SW480 cells stably transduced with shRNA vectors 
targeting Src, Fyn, Yes, or the control vector pGIPZ were trypsinized, counted, and seeded into 
six well plates containing etched glass slides.  C. HepG2 cells were seeded and transfected 
concurrently with chemically synthesized siRNAs targeting Src, Fyn, Yes, or a scrambled 
control siRNA (siCtrl).  Cells were grown to near confluency before being serum starved for 24 
hours prior to three wounds being made in each monolayer.  Each wound was photographed at 
two distinct locations at the time of wounding, and at the same locations after the cells had been 
grown under normal cell culture conditions for 24 to 48 hours.  The width of the wound was 
measured at both timepoints to determine migration.  The data is presented as the percent of the 
wound width that had closed during incubation, in relation to that of the pGIPZ or siCtrl control 
cells, with the standard deviation given as error.  Statistical significance with a P value of less 
than 0.05 (*) or 0.01 (**) versus the pGIPZ or siCtrl controls is shown.  
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4.3.3.3. Summary 
     Of the SFK inhibitors tested, PP2 elicited the greatest inhibition of migration in all of the 
cell lines investigated, as it completely prevented any growth into the wound area in both HT29 
and SW480 cells, and decreased the migration of HepG2 cells by 70%.  SKI I treatment also 
resulted in decreases in cellular migration in all three of the cell lines tested, while SU6656 
inhibited the migration of HepG2 cells.  SKI II did not inhibit the migration of any of the cell 
lines investigated.  In addition, the migration of HepG2 cells was, in general, not affected by 
SFK inhibitor treatment to the same extent as HT29 and SW480 cells (Table 4.4).  Therefore, 
while the extent to which the SFK inhibitor treatment reduced migration depended upon cell 
line, SFK inhibition resulted in reduced migration of all of the cell lines investigated. 
     When compared to the decreases in migration observed in the cell lines treated with SFK 
inhibitors, the effects on migration observed when the expression of a single SFK was 
decreased were small.  While decreases in the expression of Src, Fyn, and Yes inhibited the 
migration of HT29 cells, when compared to the pGIPZ control cells, only decreased Src 
expression inhibited the migration of SW480 cells.  Interestingly, despite the effects of SFK 
inhibition in HepG2 cells, no significant changes were observed in the migration of HepG2 
cells with decreased Src, Fyn, or Yes expression (Table 4.4), suggesting that multiple SFKs 
may need to be targeted in order to inhibit migration in some cell lines. 
 
 
Table 4.4. Summary of the effects of Src kinase inhibitor treatment or decreased Src, Fyn, 
or Yes expression on the migration of selected cancer cell lines. Relative levels of inhibition 
of proliferation are given as follows: # No effect,  +  25-50% inhibition, ++ 50-75% inhibition, 











4.3.4. Colony Forming Ability 
     Only cells that are able to grow in the absence of adhesion, as well as with a lack of contact 
inhibition are able to form colonies in soft agar from a single cell suspension.  As these 
characteristics are an indication of transformation, soft agar colony forming assays can be used 
to assess the number of transformed cells within a population.  In order to investigate the role 
of the SFKs in the ability of HT29 and HepG2 cells to form colonies, cells that were either 
treated with SFK inhibitors or expressed decreased levels of Src, Fyn, or Yes were seeded into 
soft agar and allowed to form colonies over three weeks for HT29 cells and two weeks for 
HepG2 cells.  The number of colonies formed was then counted using a grid under a light 
microscope.  Only HT29 and HepG2 cells were examined for the ability to form colonies in 
soft agar, as only these cell lines were found to form significant numbers of colonies. 
 
4.3.4.1. Effects of Src family kinase inhibitor treatment on colony forming ability 
     The ability of HT29 and HepG2 cells to form colonies in soft agar in the presence of SFK 
inhibitors was investigated in order to examine the involvement of the SFKs in this process.  As 
increasing amounts of DMSO resulted in an increase in the number of HT29 colonies formed, 
the different inhibitor concentrations were compared to the DMSO controls corresponding to 
the volume of inhibitor used, and the data presented as the percent of colonies formed when 
compared to the DMSO treated cells.  It was found that the presence of 30 µM PP2 completely 
inhibited the formation of HT29 colonies, while 2 µM and 10 µM did not result in a decrease in 
colony number; rather, there was a statistically significant increase in colony number in the 
presence of low concentrations of PP2.  Treatment with all concentrations of SU6656 
significantly inhibited colony formation, however, with essentially no colonies able to grow in 
the presence of 10 µM or 30 µM of this inhibitor.  SKI I was also able to significantly inhibit 
colony formation by HT29 cells, while the presence of SKI II had no statistically significant 
effect (Figure 4.27 A). 
     Unlike HT29 cells, the colony forming ability of HepG2 cells was not affected by the 
amount of DMSO present, as all of the control wells contained equal numbers of colonies.  In 
this cell line, PP2 was able to inhibit the formation of colonies in a concentration dependent 
manner, with 2 µM having no effect and 30 µM causing the greatest inhibition.  Likewise, 
although treatment with 2 µM of SU6656 was sufficient to produce a significant decrease in 
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colony formation, higher concentrations of this inhibitor decreased colony formation to a 
greater extent.  As in HT29 cells, SU6656 had a greater effect on HepG2 colony formation than 
PP2.  No effect on the colony forming ability of HepG2 cells was observed in the presence of 
either SKI I or SKI II (Figure 4.27 B).  Therefore, as with the other cellular phenotypes 
investigated, the ability of the SFK inhibitors to reduce colony formation depended upon the 





















Figure 4.27.  The colony forming ability of HT29 and HepG2 cells in the presence of Src 
family kinase inhibitors.  A.  HT29 and B.  HepG2 cells were trypsinized, counted, and 5000 
cells seeded in 0.3% soft agarose in the presence of the indicated concentrations of PP2, 
SU6656, SKI I or SKI II.  Cells were allowed to grow for at least two weeks, with agarose 
containing fresh inhibitor added to the wells every three to four days.  Colonies were counted 
manually using a grid under 10 x magnification. The data presented are the mean of the number 
of colonies grown, relative to the control cells treated with DMSO, of three independent 
experiments done in duplicate.  Standard deviation is given as error.  Statistical significance 
with a P value of less than 0.05 (*) or 0.01 (**) versus the DMSO control is shown. 
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4.3.4.2. Effects of decreased Src, Fyn, or Yes expression on colony forming ability 
     The colony forming ability of HT29 and HepG2 cells with decreased Src, Fyn, or Yes 
expression was also examined.  Although HT29 cells with decreased Src expression may have 
a reduced ability to form colonies in soft agar, the results of this assay were extremely variable, 
and no concrete conclusions can be drawn from this data (Figure 4.28 A). 
     In the case of HepG2 cells, transfection with siRNAs targeting Src resulted in a significant 
decrease in the number of colonies formed when compared to cells transfected with a 
scrambled control siRNA.  Decreased expression of both Src and Yes in conjunction also 
inhibited HepG2 colony formation to the same extent as was observed for cells with decreased 
Src expression alone.  In contrast, decreased Fyn or Yes expression did not significantly affect 







Figure 4.28.  The colony forming ability of HT29 and HepG2 cells with decreased Src, 
Fyn, or Yes expression.  A.  HT29 cells stably expressing decreased levels of Src, Fyn or Yes, 
or B.  HepG2 cells transfected with siRNAs targeting the Src family members were trypsinized, 
counted and 5000 cells seeded per well of a six well plate in agarose.  Cells were allowed to 
grow for at least two weeks before colonies were counted manually using a grid under 10 x 
magnification.  The data presented are the mean of the number of colonies grown, relative to 
the pGIPZ or siCtrl control cells, of five (HT29) or three (HepG2) independent experiments 
done in duplicate, with the standard deviation given as error.  Statistical significance with a P 





4.3.4.3.  Summary 
     Although the presence of at least two of the SFK inhibitors was sufficient to significantly 
inhibit the ability of both HT29 and HepG2 cells to form colonies in soft agar, the data obtained 
for HT29 cells with decreased expression of the individual SFKs was extremely variable and is 
not conclusive.  In HepG2 cells, decreased expression of either Src alone, or Src and Yes 
together, resulted in fewer colonies than were formed from cells transfected with a scrambled 
control siRNA.  Decreases in Fyn or Yes expression had no statistically significant effect on the 
colony forming ability of these cells (Table 4.5).  In any case, the SFKs appear to play an 
important role in the colony forming ability of at least some cell lines. 
 
 
Table 4.5. Summary of the effects of Src family kinase inhibitor treatment or decreased 
Src, Fyn, or Yes expression on the colony forming ability of selected cancer cell lines.  No 
statistically significant change in colony forming ability following treatment or due to 
decreased protein expression is indicated by the – symbol; +++ indicates greater than 75% 
inhibition.  Increased colony forming ability following treatment with the lower doses of 
inhibitors is indicated by an arrow.  No conclusions can be drawn from assays examining the 









     The SFKs are overexpressed and activated in a number of human cancers, including those of 
the colon and breast, and contribute to cancer progression leading to metastasis through their 
involvement in a number of cellular phenotypes (Summy and Gallick, 2003).  However, past 
studies have most commonly investigated the effects of Src expression alone on these 
phenotypes, or have inhibited multiple SFKs using SFK inhibitors.  The goal of this study was 
therefore to examine the contributions of the individual SFKs to various cancer cell 
phenotypes, including proliferation, adhesion, migration, and colony forming ability, and to 
thereby identify if other SFKs besides Src itself are involved in these processes.  In order to do 
this, two approaches were used.  Namely, the kinase activity of multiple SFKs was inhibited by 
treating our cell lines of interest with four different commercially available SFK inhibitors, or 
the expression of individual SFKs was knocked down in these cell lines using either shRNA in 
HT29, HCT116, and SW480 cells, or siRNA in HepG2 cells, and the resulting phenotypic 
changes examined.  This allowed the involvement of individual SFKs in selected cancer cell 
phenotypes to be assessed and compared to the cellular effects of inhibiting multiple SFKs. 
 
5.1. Src family kinase expression and activity in cancer cells 
     The SFKs, which play important roles in various cancer cell phenotypes, are overexpressed 
in a wide variety of different cancers (Summy and Gallick, 2003).  SFK mRNA expression was 
therefore investigated in a panel of colon cancer cell lines, while their protein expression was 
examined in the colon cancer cell lines, as well as in several breast cancer cell lines, lung 
cancer cell lines, the myeloid cell line U937, and the hepatocellular carcinoma cell line HepG2.  
It was found that Src, Yes, Fyn, Lyn, and Lck were all expressed at the mRNA and protein 
level in at least a subset of the cell lines investigated, and that the level of expression of a given 
SFK varied between cell lines (Hirsch et al., 2006).  Furthermore, it was found that all of the 
cell lines investigated expressed at least one of the SFKs, and that different cell lines expressed 
different combinations of the family members.  This was also found in a more recent study 
examining SFK expression in a panel of cell lines (Barraclough et al., 2007).  Not surprisingly, 
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the other SFKs, namely Blk, Fgr, and Hck, which are generally thought to have expression 
restricted to cells of hematopoietic origin, were not observed (Hirsch et al., 2006).      
     Interestingly, while both Lyn and Lck are also generally regarded to be expressed mainly in 
hematopoietic cells, both of these proteins were expressed in the cell lines that we examined; 
Lyn in the majority of the cell lines, and Lck in a small subset of colon and lung cancer cell 
lines.  This was likewise observed in another investigation of SFK expression in a large panel 
of colorectal cancer cell lines (Emaduddin et al., 2008).  Lck has also previously been found to 
be expressed in some lung cancer cell lines (Veillette et al., 1987).  As Lck is not generally 
expressed in normal epithelial tissue, its expression in certain cancers may indicate a role for 
this protein in epithelial cancers, as well as in hematopoietic cancers.   
     In addition to Src itself, other SFKs have also previously been found to have kinase activity 
in colon cancer cell lines (Park et al., 1993).  Therefore, four cell lines representative of the 
combinations of SFKs expressed in the wider panel of cell lines were chosen for further study, 
and the kinase activity of the SFKs in these cells investigated using a commercially available 
tyrosine kinase assay kit.  As this kit detects the total kinase activity of specifically 
immunoprecipitated proteins, it was possible to assess the activity of the individual SFKs.  
When HT29, HCT116, SW480, and HepG2 cells were examined for SFK kinase activity, not 
all of the SFKs expressed at the protein level within a given cell line were found to have 
significant kinase activity.  However, the level of activity of those SFKs that were active 
roughly corresponded to the level of protein expression of that family member within a cell 
line.  For instance, HT29 cells, with the highest level of Src protein observed, also had the 
highest level of Src kinase activity.  In contrast, SW480 cells, which express a relatively lower 
level of Src protein, exhibited lower Src kinase activity.  These findings support the idea that 
the high levels of Src activity observed in these cell lines are due to increased protein 
expression, which agrees with the findings that Src kinase activity correlates with the level of 
Src mRNA (Dehm et al., 2004) and protein (Iravani et al., 1998) expressed by a cell.  
Furthermore, different SFKs had kinase activity in different cell lines, and in addition to Src, 
both Yes and Fyn had detectable kinase activity in select cell lines.  For instance, both Src and 
Yes kinase activity was observed in HT29 and HepG2 cells, while Src and Fyn activity was 
detected in the SW480 cell line.   
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     In addition to SW480 cells, the kinase activity of the SFKs was also examined in SW620 
cells.  Although both cell lines showed Src and Fyn activity, with no Yes activity detected, the 
level of kinase activity of both Src and Fyn was increased in the SW620 cell line when 
compared to that of SW480 cells, whereby a moderate increase in Src activity and a greater 
increase in Fyn activity were observed.  As the SW620 cell line is derived from a lymph node 
metastases from the tumour from which SW480 cells are derived, this supports the finding that 
Src activity increases with tumour progression (Talamonti et al., 1993).  It also suggests that 
Fyn may also be involved in colon cancer progression, at least in a subset of colon cancers.  
Indeed, it has been reported that there is more SFK activity in a number of colon cancer cell 
lines than can be accounted for by the level of kinase activity of Src itself, suggesting that other 
family members may also have significant kinase activity in these cells (Emaduddin et al., 
2008).  As Src, Fyn, and Yes are all expressed and exhibit kinase activity in at least some of the 
colon cancer cell lines investigated, it is possible that all three of these proteins are involved in 
at least some cancer cell phenotypes in certain cell lines. 
     It was of interest that Lyn was expressed at the protein level in the majority of the cell lines 
investigated, as this SFK has traditionally been thought to be mainly expressed in 
hematopoietic cells.  However, Lyn has previously been found to be expressed at the mRNA 
level in lung tissue (Holtrich et al., 1991), as well as in cultured airway smooth muscle cells 
(Pertel et al., 2006), and human bronchial epithelial cells (Zhao et al., 2006).  Despite having 
been reported to be expressed in the lung, the involvement of Lyn in lung cancers has not been 
extensively studied.  In contrast, Src has been found to be highly expressed at the protein level 
in lung cancers (Mazurenko et al., 1992), and is significantly activated in NSCLCs, where the 
level of Src activity is correlated with tumour size (Masaki et al., 2003).  The kinase activity of 
both Lyn and Src was therefore investigated in selected lung cancer cell lines.  Although all of 
the cell lines examined exhibited Src activity, Lyn activity was detected only in the two cell 
lines with the highest Lyn protein expression, the level of which was proportional to the level 
of Lyn protein expressed in these cell lines.  When a tissue microarray containing samples of 
various types of lung cancer was examined, it was found that although Lyn was expressed in 
the majority of the samples, in most cases the level of expression was low.  However, the 
majority of the squamous cell carcinomas, large cell carcinomas, and atypical carcinoids 
represented on the slide showed high levels of Lyn protein expression in the majority of the 
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cells in the sample.  This suggests that Lyn expression and activity may be significant in some 
histological types of lung cancer but not others, and that Lyn, as well as Src, may contribute to 
the cancerous phenotypes of certain lung cancers.   
 
5.1.4. Summary 
     Our work has demonstrated that although all of the cancer cell lines investigated expressed 
multiple SFKs, the particular SFKs that are expressed and active in a given cell line vary 
significantly.  Furthermore, not all of the SFKs expressed in a given cell line necessarily have 
significant kinase activity, at least under our assay conditions.  For instance, while Src was 
found to have kinase activity in all of the cell lines investigated, both Fyn and Yes had 
detectable kinase activity in only a subset of the colon cancer cell lines, while Lyn kinase 
activity was detected in a subset of the lung cancer cell lines.  This suggests that more than one 
SFK may be involved in the cancer phenotypes of these cells.  Lyn in particular may have a 
role in lung cancer, as it was found to be expressed in many of the lung cancer cases present on 
a tissue microarray stained for Lyn protein expression.  Furthermore, as the squamous cell 
carcinomas, large cell carcinomas, and atypical carcinoids represented on the slide showed 
relatively high levels of Lyn protein expression in some of the cells in the sample, Lyn may be 
involved in certain histological types of lung cancer in particular.  Although we did not 
investigate the roles of the SFKs in normal colon cells, our findings point to the potential 
involvement of a number of the SFKs in different cancers, and indicate that the particular SFKs 
involved may vary between cell lines. 
 
5.2. RNA interference-mediated silencing of the Src family kinases 
     In order to examine the involvement of the individual SFKs in cancer cell phenotypes it was 
necessary to be able to target these proteins individually, without affecting the expression or 
activity of the other family members.  As the SFK inhibitors currently available inhibit multiple 
SFKs (Hanke et al., 1996; Liu et al., 1999; Blake et al., 2000), a sequence based RNAi 
approach was used to target these proteins, which allowed the expression of a single SFK to be 
knocked down without affecting the expression of the other SFKs.  Both chemically 
synthesized siRNA and a vector based shRNA approach were used.   
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     The siRNA approach involves the introduction of 21 nucleotide long, chemically 
synthesized siRNAs into cells using a lipid based transfection reagent.  For four hours 
following transfection, siRNAs accumulate in the cytoplasm in both an intact and disassociated 
form (Rao et al., 2009).  Once in the cytoplasm, the siRNAs direct the sequence-based 
degradation of the complementary mRNA; this activity reaches a peak at around 24 hours 
following introduction into the cell.  However, as the majority of the siRNAs transfected into a 
cell will have been degraded by 48 hours following transfection, siRNA produces only a 
temporary silencing of the targeted protein (Rao et al., 2009), the length of which is related to 
the rate of cell division (Dykxhoorn et al., 2003).  The level of silencing elicited by transfected 
siRNAs also depends greatly on transfection efficiency, which can be variable, particularly in 
difficult to transfect cell lines.  Therefore, large variations in the level of silencing may occur, 
both between experiments and cell lines (Amarzguioui et al., 2005).  In our experiments, the 
transfection of HepG2 cells with siRNAs targeting the SFKs resulted in a significantly higher 
level of knockdown than was achieved in HT29 cells.  The level of knockdown in HT29, 
HCT116, and SW480 cells also varied greatly between replicates (data not shown).  Therefore, 
although the siRNA approach was initially used to silence the expression of the SFKs both 
individually and in combination in all four of our cell lines of interest, it was preferable to use 
the vector based shRNA approach in order to decrease the expression levels of the SFKs in a 
stable manner. 
     In contrast to the transient knockdown of protein expression observed following the 
transfection of siRNAs into cells, stable knockdown can be achieved by using a vector based 
approach.  In this method, sequences coding for shRNAs are cloned into an expression vector 
(in our case, of lentiviral origin) and introduced into target cells.  This results in the production 
of the shRNA by the cell itself, as it is transcribed by either RNA polymerase II or III (Rao et 
al., 2009).  The transcript produced contains a hairpin stem-loop structure that can be processed 
in the nucleus to produce individual shRNAs with a two-nucleotide 3’ overhang.  Following 
transport to the cytoplasm, the hairpin loop is cleaved, forming a double-stranded siRNA that 
mediates the degradation of the target mRNA.  As the shRNAs are synthesized by the cell into 
which it has been introduced, a stable knockdown is achieved.  Indeed, fewer than five copies 
of an shRNA vector are sufficient to result in the continuous knockdown of a target protein 
(Rao et al., 2009).  Vectors containing an shRNA sequence targeting Src, Fyn, or Yes, as well 
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as an empty control vector, were therefore introduced into our cell lines of interest in order to 
stably decrease the expression levels of these proteins.   
     Although HT29, HCT116, and SW480 cells with stable knockdown of Src, Fyn, or Yes 
were successfully produced, the shRNA approach was unsuccessful in generating HepG2 cells 
with stable knockdown of the SFKs.  However, it was possible to examine the effects of 
decreased SFK expression in HepG2 cells using siRNA, as the transfection of this cell line 
consistently resulted in a significant level of knockdown.  Although there was a near complete 
siRNA-mediated knockdown of Src in these cells for over 144 hours post transfection, the Yes 
siRNA was not as efficient, and resulted in less significant knockdown.  However, Yes levels 
also remained decreased for over 144 hours.  Although the HepG2 colony forming assays were 
performed over two weeks, this length of knockdown allowed differences in colony forming 
ability to be observed.  Results obtained from siRNA knockdown in the other cell lines 
produced extremely variable levels of knockdown between experiments, and are therefore not 
presented in this work (data not shown). 
     Both siRNA and shRNA can result in off-target effects, whereby they cause effects other 
than those due to the degradation of the target mRNA.  These effects are sequence related, as 
RNAi mediated by the same sequence in both siRNA and shRNA protocols results in the same 
off-target effects in multiple cell lines (Jackson et al., 2006).  For instance, partial sequence 
complementarity of the siRNA sequence to mRNAs other than the target, or partial 
complementarity to the guide strand of the RNAi construct, can result in the suppression of 
genes other than the intended gene (Rao et al., 2009).  The severity of off-target effects appears 
to be unrelated to the ability of an siRNA to silence its target, however (Jackson et al., 2003).  
Other non-specific effects on cellular behaviour may occur due to the delivery of chemically 
synthesized siRNAs or vectors into a cell, or due to the expression of the shRNA construct 
itself (Rao et al., 2009).   
     In addition to having different off-target effects, the efficiency at which different siRNA and 
shRNA sequences are able to silence the expression of a single protein also varies greatly.  This 
can depend on the sequence used, as not all sequences to a given target are able to silence the 
expression of a protein to the same degree (Dykxhoorn et al., 2003).  For this reason, multiple 
siRNA and shRNA sequences targeting each SFK were tested for the ability to silence their 
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each SFK, in order to control for any non-specific effects exerted by a given sequence.  
However, only one of the shRNA sequences examined for each protein produced a significant 
level of knockdown.  All further experiments were therefore carried out using the single most 
effective siRNA or shRNA sequence to decrease the expression of Src, Fyn, or Yes.            
     Unfortunately, complete knockdown of the SFKs was not achieved even when using the 
most effective shRNA sequence to target each SFK, and, in some cases, was very poor.  The 
level of knockdown achieved following the introduction of Src, Fyn, or Yes shRNA vectors 
into HT29, HCT116, and SW480 cells was assessed quantitatively using the Odyssey software 
(Li-Cor), which determines the intensity of protein bands on Western blots.  The level of Src 
protein was decreased significantly in all of the cell lines investigated, with knockdown from 
70% to 80%; however, the knockdown of Fyn and Yes was less effective.  Although Fyn 
expression was decreased by 70% in HCT116 cells, the level of Fyn knockdown was closer to 
60% in both HT29 and SW480 cells.  The expression of Yes in particular proved to be difficult 
to knock down using both shRNA and siRNA; Yes levels were decreased by only 55% to 60% 
in the stable cell lines created.  While it is possible that the remaining protein was sufficient to 
mask any involvement of these proteins in the cellular processes investigated in this work, the 
level of knockdown achieved should have allowed differences between the phenotypes of 
parental cells and those with decreased SFK expression to be observed.   
 
5.2.4. Summary 
     In order to inhibit the protein expression of individual SFKs within a cell line, an RNAi 
approach was used to decrease the expression of Src, Fyn, or Yes in HT29, HCT116, SW480, 
and HepG2 cells.  While siRNA was used to transiently reduce SFK expression in HepG2 cells, 
an shRNA approach was used to achieve stable knockdown of the SFKs in HT29, HCT116, 
and SW480 cells.  Although multiple siRNA and shRNA sequences were initially tested for 
their ability to reduce SFK expression, only one sequence for each of Src, Fyn, and Yes was 
found to result in significant knockdown.  Had more than one sequence targeting each SFK 
resulted in successful knockdown the presence of off-target effects could have been controlled 
for to some degree; however, as only one sequence effectively knocked down each SFK it is 
possible that off-target effects may have affected the results of our assays.  Cell lines in which 
different combinations of SFKs were knocked down would have also been useful in 
 122 
determining if the SFKs are able to compensate for a loss of expression of one of the family 
members in given cellular functions.  However, as all of the vectors used contained the same 
selective marker, the knockdown of multiple SFKs in single cells was not achieved.  Therefore, 
further experiments examined the effects of decreasing the expression of only a single SFK on 
selected cellular phenotypes.   
     As SFK knockdown was not complete in the stable cell lines produced, the effects of 
decreased Src, Fyn, or Yes expression on the cellular processes investigated in this work are 
likely not as pronounced as if complete knockdown had been achieved.  In particular, Fyn and 
Yes were more resistant to knockdown than was Src, despite a number of sequences being 
assessed for their ability to decrease the expression of these proteins.  Between 20% and 30% 
of normal Src levels remained even in the cells expressing shRNAs targeting Src, while those 
in which Fyn or Yes were knocked down expressed up to 40% of the normal levels of these 
proteins.  As this was the case, the level of Src, Fyn, or Yes protein remaining in a cell 
following incomplete knockdown could be sufficient to carry out the normal cellular functions 
of these proteins, thereby masking their involvement in given cellular phenotypes.  However, 
while the differences in cellular behaviour between the control cells and those with decreased 
SFK expression may have been less significant than would have been observed had complete 
knockdown occurred, the level of knockdown achieved likely allowed some of the major 
differences in proliferation, adhesion, migration, and colony formation to be detected.   
 
5.3. Involvement of Src family kinases in cancer cell phenotypes 
      A large number of studies have investigated the involvement of the SFKs in various cancer 
cell phenotypes, and changes in the expression and activity of these proteins have been 
implicated in altered cellular adhesion, apoptosis, angiogenesis, tumour growth, and metastasis 
(reviewed in Irby and Yeatman, 2000).  However, many of these studies have only used a 
single chemical SFK inhibitor to examine the involvement of the SFKs in various cellular 
phenotypes.  As chemical inhibitors may have significant off-target effects, four different SFK 
inhibitors were used in the studies described herein so that their effects could be compared.  
Furthermore, RNAi was used to specifically decrease the expression of Src, Fyn, or Yes in 
selected cell lines in order to examine the involvement of individual SFKs in our selected 
cellular phenotypes.  Examining the phenotypic changes of cells in which the expression of a 
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single SFK was decreased in conjunction with those of cells in which the kinase activity of all 
of the SFKs was inhibited was undertaken in order to provide a clearer picture of the actual 
involvement of these proteins in selected cancer cell phenotypes. 
 
5.3.1. Cellular Proliferation 
     In order to examine the involvement of the SFKs in the cellular proliferation of HT29, 
HCT116, SW480, and HepG2 cells, the effects of either SFK inhibition or decreases in the 
expression level of individual SFKs were examined.  To assess the proliferation of our cell 
lines of interest, two different approaches were undertaken.  A method that is commonly used 
to assess cellular proliferation is the use of tetrazolium salts, which gives an indication of the 
number of metabolically active cells in a sample (Mosmann, 1983; Cory et al., 1991).  This 
method can be used to determine cell numbers, as actively proliferating cells will reduce 
tetrazolium salts, such as MTS and 3-(4,5-dimethyethiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT), to a formazan product that can be measured colourimetrically.  As the amount 
of formazan formed correlates directly with the number of metabolically active cells present in 
a culture, this assay can be used to monitor cellular proliferation.  There are, however, 
disadvantages to this technique.  For instance, the use of tetrazolium salts gives a measure of 
the number of only healthy, metabolically active, cells within a population.  MTS assays are 
also not as sensitive in samples with few cells (Huang et al., 2004).  Since this is the case, small 
differences in the number of cells seeded may significantly impact results.  In our 
investigations, this may have prevented an effect on proliferation from being observed since, as 
the populations of knockdown cell lines were counted separately before seeding, there were 
likely differences in the number of cells seeded.  Although the MTS assay did not show 
significant decreases in proliferation, HT29 cells with decreased Src or Yes expression were 
observed qualitatively to grow more slowly than either the parental cell line or the cells 
transduced with the pGIPZ control vector.  Therefore, it was necessary to manually count the 
numbers of cells present within a larger sample in order to examine the proliferation of cells 
with decreased SFK expression.  Unlike assays using tetrazolium salts, counting cells is a 
measure of the number of all of the cells in a sample, and is therefore a direct measure of 
cellular proliferation.  The colourimetric MTS assay was therefore used in conjunction with 
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counting cells in order to examine the effect of decreased SFK expression or activity on cellular 
proliferation. 
     By examining four cell lines in conjunction, it was possible to identify differences in the 
involvement of the SFKs in cellular proliferation between cell lines.  Indeed, our findings 
suggest that the effects of SFK inhibition on proliferation are both cell line and inhibitor 
specific.  For instance, PP2 treatment significantly inhibited the proliferation of only HT29 and 
HCT116 cells, and did not affect that of SW480 or HepG2 cells.  Furthermore, HCT116 cells 
were more susceptible to the SFK inhibitors than the other cell lines, as PP2, SU6656, and SKI 
II all reduced the proliferation of this cell line.  Conversely, the SFK inhibitors had no effect on 
the proliferation of SW480 and HepG2 cells.  This suggests that SFK inhibition affects 
proliferation in a cell line-specific manner.  Although this was the case in our findings, many of 
the studies that have used SFK inhibitors to inhibit the activity of the SFKs in a variety of cell 
lines have found that SFK inhibition results in decreased cellular proliferation.  For instance, 
the treatment of CML (Golas et al., 2003), osteosarcoma (Spreafico et al., 2008), pancreatic 
(Nagaraj et al. 2010), and breast cancer cell lines (Moasser et al., 1999) with SFK inhibitors 
has been shown to inhibit the proliferation of these cells.  Many of the investigations that have 
used PP2 to inhibit the SFKs have also reported effects on proliferation: treatment with this 
inhibitor has been found to both inhibit the proliferation and increase the apoptosis of a 
medulary thyroid cancer cell line (Liu et al., 2004), as well as to inhibit the anchorage-
dependent and independent growth of three different breast cancer cell lines (Ishizawar et al., 
2004).  Finally, in an investigation of a number of colorectal cancer cell lines, it was found that 
all of the sixteen cell lines investigated were sensitive to both PP2 and SU6656 treatment, 
whereby proliferation was inhibited in a concentration dependent manner (Emaduddin et al., 
2008).  In contrast, a further study investigating the proliferation of several colon cancer cell 
lines following treatment with the clinically relevant SFK inhibitor dasatinib found that this 
inhibitor only inhibited the proliferation of two out of the twelve cell lines investigated, and had 
no effect on the proliferation of the other ten cell lines (Serrels et al., 2006).  Taken together, 
these studies, as well as our own, suggest that the effects of SFK inhibitors on cellular 
proliferation are variable. 
     In addition to differences in susceptibility to SFK inhibitors between cell lines, differences 
in the effects of SFK inhibitor treatment on proliferation observed between studies could be due 
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to incomplete inhibition of the SFKs at lower concentrations, or because of increased non-
specific effects due to higher concentrations of inhibitor.  That at least some of the effects of 
these inhibitors on proliferation are due to non-specific effects is suggested by our finding that 
not all of the SFK inhibitors affected proliferation in a given cell line.  For instance, the 
proliferation of HT29 cells was inhibited by PP2 and SKI I, while treatment with SU6656 and 
SKI II had no effect.  Similarly, the proliferation of HCT116 cells was not affected by 
treatment with SKI I, but was inhibited to some extent by the other three SFK inhibitors.  If the 
effects of these drugs on proliferation were due solely to the inhibition of the SFKs, it would be 
expected that all of the SFK inhibitors would affect proliferation similarly.  However, the large 
number of off-target effects that these inhibitors may elicit could result in either increased or 
decreased proliferation, or in no effect on proliferation being observed.  Taken together, our 
results suggest that the effects of SFK inhibitors on the proliferation of various cell lines are 
complex, and likely depend on both cell line and the inhibitor being used.   
     In addition to SFK inhibition, the proliferation of cells expressing decreased levels of Src, 
Fyn, or Yes was examined.  As was found when the SFKs were inhibited, the effects of 
decreasing the expression of the individual SFKs on proliferation appear to depend upon cell 
line.  For instance, decreased Src expression inhibited the proliferation of HT29 and SW480 
cells, but had no effect on the proliferation of HCT116 or HepG2 cells.  By examining the 
effects of decreasing the expression of all three of the ubiquitously expressed SFKs 
individually in our study, we also demonstrated that not only Src, but also Yes, and to a lesser 
extent, Fyn, likely play a role in cellular proliferation.  For instance, the proliferation of HT29 
cells was equally inhibited in cells with decreased Src or Yes protein levels.  HT29 cells with 
decreased Fyn levels were also found to proliferate more slowly than the control cells, although 
not to the extent of the cells in which either Src or Yes were knocked down.  This suggests that, 
at least in this cell line, all three of the ubiquitously expressed SFKs are involved in regulating 
proliferation.  This corresponds to the more dramatic decrease in proliferation observed when 
HT29 cells were treated with SFK inhibitors, which inhibit the kinase activity of multiple 
SFKs.  In contrast, the proliferation of HCT116 cells was not affected by decreased levels of 
Src, Yes, or Fyn, as measured by either an MTS assay or in direct cell counts.  As HCT116 
proliferation was inhibited by SFK inhibitor treatment, this may indicate that multiple SFKs 
must be targeted in order for an effect on proliferation to be observed in some cell lines.  As 
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there is evidence that the SFKs are able to compensate for a loss in activity of one or more 
family members, this could be the case (reviewed in Lowell and Soriano, 1996).  Interestingly, 
although the proliferation of SW480 cells was not significantly affected by SFK inhibitor 
treatment, a growth curve revealed that SW480 cells with decreased Src expression had 
significantly slower proliferation than the control cells.  Although SW480 cells with decreased 
Fyn expression also had significantly decreased proliferation when compared to either 
untransduced control cells or those that had been transduced with an shRNA targeting Yes, the 
proliferation of these cells was not significantly different than that of the control pGIPZ cells, 
which had a reproducible decrease in proliferation when compared to the control parental cells.  
The involvement of Fyn in the proliferation of SW480 cells therefore remains inconclusive.  It 
appears that SFK activity is not necessary for the proliferation of HepG2 cells, as no change in 
proliferation was observed upon treatment with SFK inhibitors, or when Src or Yes protein 
levels were decreased either individually or in concert.  Therefore, our results suggest that the 
involvement of the SFKs in cellular proliferation is cell line specific, and that more than one 
SFK may be involved in this process within a given cell line.   
     The involvement of the SFKs in the proliferation of cancer cell lines has previously been 
investigated by varying the expression levels of these proteins, either through the use of siRNA 
or antisense, or through overexpression.  For instance, HT29 cells in which Src has been 
silenced through the use of antisense have decreased proliferation (Staley et al., 1997), which 
corresponds to our findings in this cell line.  Similarly, siRNA mediated decreases in Src 
expression have been found to result in the reduced proliferation of MCF7 breast cancer cells 
(González et al., 2006).  It has also been shown in primary CML blasts, as well as in myeloid 
cell lines, that there is a decrease in cellular proliferation coupled with an increase in apoptosis 
when Lyn is specifically silenced using siRNA (Ptasznik et al., 2004).  However, Src antisense 
was found to have no effect on the proliferation of an ovarian cancer cell line (Wiener et al., 
1999), thereby supporting the idea that the SFKs affect cellular proliferation in a cell line 
specific manner.  In contrast to most findings obtained by decreasing SFK expression, the 
overexpression of Src has been found to have little effect on proliferation.  For instance, no 
effects on proliferation were observed in response to elevated Src kinase activity in KM12C, 
HCT116, or SW480 cells, either in vitro, or when injected into mice (Jones et al., 2002; 
Welman et al., 2006).  Similarly, the proliferation of colon cancer cell lines was not affected by 
 127 
the overexpression of Yes, either in vitro or in vivo (Barraclough et al., 2007).  However, the 
finding that increased SFK protein levels and activity do not have a significant effect on 
cellular proliferation may simply indicate that the cells being assayed already express the SFKs 
at a level that results in the maximum amount of proliferation signalling being achieved; in this 
case, having surplus amounts of the SFKs would not result in an effect on proliferation.  The 
disparate findings of investigations examining the effects of SFK activity on cellular 
proliferation suggest that the SFKs may be involved in the proliferation of some cell lines and 
not others.  Our results also support the idea that the effects of the SFKs on proliferation are 
cell line specific, as both treatment with SFK inhibitors and decreases in SFK expression 
inhibited the proliferation of only a subset of the cell lines investigated.  
 
5.3.2. Cellular Adhesion 
     In addition to cellular proliferation, the SFKs have also been implicated in a variety of 
signalling pathways involved in cellular adhesion to both the extracellular matrix (ECM) and to 
other cells.  The adhesion of cells to the ECM is important to the growth of most non-cancerous 
cells, as it not only provides support to the cells embedded within it, but also influences the 
growth, adhesion, and motility of these cells (reviewed in Frantz et al., 2010).  The ECM is 
composed primarily of polysaccharides and fibrous proteins that have been secreted by nearby 
cells and organized into a network.  The major scaffolding protein of the ECM is collagen, 
which is involved in stabilizing, strengthening, and organizing other components of the ECM 
(Rozario and DeSimone, 2010).  Although there are a number of different collagens, Type I 
collagen is the most abundant (Di Lullo et al., 2002).  Fibronectin, in contrast, is a large 
glycoprotein that is involved in cellular adhesion and migration, as well as in organizing the 
ECM, through its interactions with integrins and collagen (reviewed in Pankov and Yamada, 
2002; Singh et al., 2010).  The ability of our cell lines of interest to adhere to both collagen I 
and fibronectin following treatment with SFK inhibitors or decreases in Src, Fyn, or Yes 
expression was investigated.     
     Our results indicate that although SFK inhibition was able to decrease the level of cellular 
adhesion to fibronectin and collagen I, this was dependent upon the inhibitor being used, the 
concentration of the inhibitor, and the cell line being investigated.  Although PP2 and SKI I 
inhibited the adhesion of the majority of the cell lines examined to both fibronectin and 
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collagen I, the extent of this inhibition was cell line specific.  For instance, the adhesion of 
HT29 cells to fibronectin was inhibited to the greatest extent, with greater than 50% inhibition 
by three of the four SFK inhibitors investigated.  The adhesion of HepG2 cells to fibronectin 
was also significantly reduced by the majority of the inhibitors.  In contrast, none of the 
inhibitors decreased the adhesion of HCT116 cells to fibronectin, while only PP2 inhibited the 
adhesion of SW480 cells.  Furthermore, although the treatment of HT29 cells with SU6656 
resulted in a decrease in adhesion to both fibronectin and collagen I of more than 50%, SU6656 
and SKI II generally had much weaker effects on the adhesion of the cell lines examined.  This 
clearly demonstrates that the effects of the different SFK inhibitors on adhesion are variable.                 
     The effect of SFK inhibition on adhesion also depended upon the adhesion molecule being 
assayed, as the adhesion of our cell lines of interest to both fibronectin and collagen was 
affected to different extents by the SFK inhibitors, with the exception of HT29 cells.  For 
instance, the adhesion of HepG2 cells to fibronectin in the presence of PP2 was decreased by 
approximately 40% while their adhesion to collagen I was inhibited by only 20%.  In contrast, 
none of the inhibitors tested impacted the adhesion of HCT116 cells to fibronectin, although 
PP2 treatment reduced the adhesion of these cells to collagen following PP2 treatment by 40%.  
The adhesion of this cell line to collagen I was also inhibited by the presence of SKI I and SKI 
II by 25%.  That the SFKs are involved in cellular adhesion to different components of the 
ECM to different extents has previously been suggested by the finding that although the 
adhesion of src
-/-
 cells to fibronectin was reduced when compared to Src expressing cells, no 
difference in the adhesion of these cells to collagen was observed (Kaplan et al., 1995).  This 
indicates that the SFKs may be involved in cellular adhesion to different components of the 
ECM.  Furthermore, our results suggest that this may be cell line dependent.   
     Interestingly, all of the inhibitors examined, with the exception of PP2, caused a dose-
dependant increase in the adhesion of at least one cell line to either fibronectin, collagen I, or 
both.  Interestingly, this increase in adhesion was observed only when cells were treated with 2 
!M the of the inhibitors.  This was particularly evident with SKI II, as treatment with this 
inhibitor increased the adhesion of all of the cells lines investigated to collagen I and three of 
the four cell lines to fibronectin.  In contrast, treatment with low concentrations of SU6656 and 
SKI I resulted in an increase in adhesion of only a subset of the cell lines.  Despite the increase 
in cellular adhesion when the cells were exposed to low doses of inhibitor, higher 
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concentrations of these inhibitors either did not statistically impact adhesion to either 
fibronectin or collagen I, or resulted in a decrease in adhesion.  One possibility for this is that 
these inhibitors may have unexpected effects on other proteins at lower concentrations that 
result in an increase in adhesion.  The possible incomplete inhibition of the SFKs at lower 
doses of inhibitor may also be a factor.  As this increase in adhesion was observed following 
treatment with most of the inhibitors used in these studies, it may indicate that SFK inhibitors 
elicit different effects upon their targets depending upon the concentration used, which may be 
an important consideration when using these drugs as anti-cancer agents.   
     Despite the ability of the SFK inhibitors to inhibit cellular adhesion to both fibronectin and 
collagen I, only HT29 and HepG2 cells with decreased Src and Yes expression were observed 
to have reduced adhesion to these molecules.  Furthermore, decreases in Src and Yes 
expression only inhibited the adhesion of HT29 cells to fibronectin; no effect on the adhesion 
of these cells to collagen I was observed.  The adhesion of HepG2 cells to fibronectin was also 
reduced in response to decreases in Src and Yes expression, while decreased Yes expression 
also reduced the adhesion of these cells to collagen I.  In contrast, HCT116 and SW480 cells 
with decreased SFK expression did not show any difference in adhesion to either fibronectin or 
collagen I, suggesting that more than one of the SFKs may be involved in adhesion in these 
cells, and that the loss of a family member can be compensated for by the remaining SFKs.  If 
this were the case, the loss of an individual SFK would not result in any observable change in 
adhesion.  This could also explain the finding that, although the adhesion of src
-/-
 fibroblasts to 
a fibronectin matrix is inhibited somewhat, these cells retain the ability to adhere, suggesting 
that although Src may be required for maximum adhesion, it is not necessary for adhesion to 
occur (Kaplan et al., 1995).  As src
-/-
 cells express other SFKs this could be due to 
compensation by other family members.  Our finding that treatment with all of the SFK 
inhibitors reduced the adhesion of at least a subset of the cell lines examined to a greater extent 
than was observed when single SFKs were knocked down also suggests that the SFKs are able 
to compensate for the loss of activity of other family members.  Indeed, the finding that the 
knockdown of individual SFKs did not affect the adhesion of two of the cell lines investigated 
in this work to either fibronectin or collagen I, while SFK inhibition significantly impacted 
their adhesion to both of these adhesion molecules, suggests that multiple SFKs are involved in 
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this process.  However, it is also possible that the level of knockdown of the SFKs achieved in 
this work was not sufficient to observe effects on cellular adhesion. 
     In agreement with our findings, the SFKs have previously been shown to be involved in 
cellular adhesion to the ECM.  For example, while elevated Src expression has been found to 
result in the increased adhesion of KM12C colon cancer cells to fibronectin, this adhesion was 
inhibited by treatment with either PP2 or SU6656 (Jones et al., 2002).  Furthermore, the 
expression of a kinase-deficient, dominant-negative Src prevented KM12C cells from 
extending and retracting protrusions required for adhesion to collagen (Brunton et al., 2005).  
Indeed, the major effect of abnormal Src signalling in the KM12C colon cancer cell line has 
been found to be on both cell-cell and cell-ECM adhesion, rather than on proliferation 
(Avizienyte et al., 2002; Jones et al., 2002; Brunton et al., 2005).  The expression of a 
dominant-negative Src has also been shown to result in a significant reduction in the adhesion 
of MCF7 breast cancer cells to fibronectin (González et al., 2005), while the adhesion of 
prostate cancer cells to fibronectin was inhibited by the SFK inhibitor dasatinib (Nam et al., 
2005).  These studies, along with our work, demonstrate that the SFKs are involved in the 
adhesion of cancer cell lines to components of the ECM.   
 
5.3.3. Cellular Migration 
     The SFKs have strongly been implicated in cellular migration, as the loss of their activity 
either due to SFK inhibitor treatment or through decreased expression has been found to result 
in a reduced ability of cells to migrate.  In agreement with previous studies, we found that the 
migration of all three of the cell lines examined was significantly reduced by treatment with 
both PP2 and SKI I.  Furthermore, we demonstrated that the level of inhibition depended upon 
both the cell line and inhibitor being investigated.  For instance, PP2 treatment inhibited the 
migration of all of the cell lines to the greatest extent, with the migration of both HT29 and 
SW480 cells being completely inhibited, and that of HepG2 cells being decreased by 70%.  
Similarly, PP2 treatment has been reported in the literature to result in the decreased motility of 
osteosarcoma cells (Azuma et al., 2005), prostate carcinoma cell lines (Slack et al., 2001), and 
a murine melanoma cell line with high metastatic potential in which Fyn is selectively activated 
of the SFKs (Huang et al., 2003).  Similar results have been found with other SFK inhibitors as 
well, including the clinically relevant SKI-606 and dasatinib; SKI-606 has been found to inhibit 
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the motility and invasion of breast cancer cell lines (Vultur et al., 2008), while dasatinib has 
been shown to inhibit the migration of melanoma cells (Buettner et al., 2008), prostate cancer 
cell lines (Nam et al., 2005), and malignant pleural mesothelioma cells (Tsao et al., 2007), as 
well as several human sarcoma cell lines from both bone and soft tissue (Shor et al., 2007).  
Taken together, these studies strongly implicate the SFKs in cellular migration.   
     In addition to investigating the effects of inhibiting all of the SFKs on cellular migration, the 
effects of decreased Src, Fyn, and Yes expression were also examined.  Our investigations 
found that not only are several of the SFKs involved in cellular migration, but that more than 
one SFK may be involved in this process in a given cell line.  For instance, HT29 cells with 
decreased expression of Src, Yes, and Fyn all had reduced migration when compared to control 
cells; the migration of HT29 cells with decreased Src and Fyn expression was inhibited by 
30%, while that of cells with decreased Yes expression was inhibited by 45%, when compared 
to the pGIPZ control cells.  This suggests that all three of the ubiquitously expressed SFKs may 
play a role in migration in this cell line.  However, when shRNA expressing SW480 cells were 
examined for changes in cellular migration, only the migration of cells with decreased Src 
expression was inhibited, while no effect was observed in SW480 cells with decreased Fyn 
expression.  This was surprising, as Fyn, which has been implicated in cellular migration in 
both cancer and normal cells, was found to have kinase activity in SW480 cells.  In contrast, no 
statistically significant effect was observed on the migration of HepG2 cells when Src, Yes, or 
Fyn were knocked down, or when Src and Yes were knocked down simultaneously.  This again 
suggests that the involvement of the individual SFKs in migration is cell line specific.  Further 
evidence supporting this idea comes from a study that found that when cells lacking Src, Yes, 
and Fyn were reconstituted with Src, Yes, or Fyn individually, only Src was required for villin-
induced regulation of migration (Mathew et al., 2008), despite other findings implicating Yes 
and Fyn in the migration of various other cell lines (Mariotti et al., 2001; Huang et al., 2003; 
Azuma et al., 2005; Barraclough et al., 2007).   
     A number of the SFKs have previously been implicated in cellular migration by studies that 
have varied their level of expression.  For instance, both Src siRNA and the expression of a 
dominant-negative Src have been shown to inhibit the migration of MCF7 breast cancer cells 
(González et al., 2006).  The motility of KYN-2 hepatocellular carcinoma cells, which have 
high levels of Src activity and are normally highly motile, has likewise been shown to be 
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inhibited by the expression of a dominant-negative Src (Sakamoto et al., 2001).  Furthermore, 
siRNA-mediated decreases in the expression of both Src and Fyn have been found to inhibit the 
EGFR-dependent motility of glioblastoma cells (Lu et al., 2009).  Of the SFKs, Fyn in 
particular has often been implicated in cellular migration.  For instance, the expression of a 
dominant-negative form of Fyn in squamous carcinoma cells was shown to result in a decrease 
in the ability of these cells to migrate both in vivo and in vitro (Mariotti et al., 2001).  A further 
study found that the upregulation of Fyn, but not other SFKs, corresponded to an increase in 
cell motility and cell spreading in a murine melanoma cell line with high metastatic potential 
(Huang et al., 2003).  Similarly, the overexpression of Fyn in a subline of HuO9 osteosarcoma 
cells with low metastatic potential has been shown to result in increased cell motility (Azuma et 
al., 2005).  In contrast, increased Fyn activity did not have a significant effect on the migration 
of glioblastoma cells (Stettner et al., 2005), although Lyn siRNA was able to significantly 
inhibit the migration of these cells (Ding et al., 2003).  Yes has also been implicated in 
migration, as the expression of an active Yes in LS174T colon cancer cells resulted in the 
increased motility of these cells (Barraclough et al., 2007).  Taken together, these studies 
indicate that multiple SFKs are involved in cellular migration, at least in some cell types, which 
corresponds to our finding that an RNAi-mediated decrease in Src, Fyn, or Yes expression is 
capable of inhibiting the migration of certain cell lines.  That the migration of these cells was 
not reduced to the same extent as it was when multiple SFKs were inhibited could be either due 
to the incomplete knockdown of the SFKs, or could indicate that multiple SFKs need to be 
targeted in order for the full involvement of these proteins in migration to be observed.  As we 
found that the knockdown of Src, Fyn, and Yes in HT29 cells all decreased migration this may 
be the case.  
 
5.3.4. Colony Forming Ability 
     In addition to examining the effects of decreased SFK expression and activity on the cellular 
proliferation, adhesion, and migration of our cell lines of interest, the colony forming ability of 
HT29 and HepG2 cells was also assessed, as these two cell lines were found to form significant 
numbers of colonies.  Since cells must have certain characteristics of transformed cells in order 
to grow in a soft agar matrix, the ability of cells to form colonies is viewed as a measure of 
transformation.  For instance, they must be able to grow with a lack of contact inhibition and in 
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the absence of anchorage (Hanahan and Weinberg, 2000).  As cellular motility is impeded 
when cells are grown in soft agar, single cells with a transformed phenotype will form colonies, 
which may be counted in order to assess the colony forming ability of a given cell line. 
     When HT29 and HepG2 cells were examined for colony forming ability in the presence of 
SFK inhibitors it was again found that the effects observed were inhibitor, concentration, and 
cell line specific.  For instance, PP2 and SU6656 were able to inhibit the colony formation of 
both cell lines, while SKI I was able to prevent HT29 cells, but not HepG2 cells, from forming 
colonies.  Similarly, both SU6656 and SKI-606 have previously been found to prevent HT29 
cells from forming colonies in soft agar (Laird et al., 2003; Golas et al., 2005). 
     When the ability of HT29 and HepG2 cells with decreased Src, Fyn, and Yes expression to 
form colonies was examined, it was observed that the colony formation of HepG2 cells with 
decreased Src expression was significantly inhibited.  In contrast, although cells with decreased 
Yes expression were observed to form larger colonies than the control cells, the number of 
colonies formed was not affected significantly.  It is, however, possible that the involvement of 
Yes in this process may have been masked by the incomplete knockdown of Yes in these cells.  
The colony forming ability of HepG2 cells with decreased expression of both Src and Yes 
together was inhibited to the same extent as cells with decreased Src expression alone.  
Although it appeared that decreased Src expression may also reduce the colony forming ability 
of HT29 cells, the number of colonies formed from this cell line was extremely variable 
between experiments, and no conclusive conclusions may be drawn from these results.  This 
was likely due to differences in seeding, as each cell line with decreased Src, Fyn, or Yes 
expression needed to be counted and seeded separately.  In contrast, cells were seeded from a 
single dilution in the experiments examining the effects of SFK inhibitor treatment, thereby 
increasing the likelihood that an identical number of cells was seeded in every well.  However, 
the observation that decreased Src expression in HepG2 cells, and potentially HT29 cells, 
impedes colony formation agrees with the finding that an siRNA-mediated reduction in Src 
expression decreased the ability of four breast cancer cell lines and two colon cancer cell lines, 
including HT29, to form colonies in soft agar (Zheng et al., 2008).  Taken together, these 
results suggest that SFK expression is required for cells to be able to undergo anchorage-




     Although our investigations into the involvement of the SFKs in cellular proliferation, 
adhesion to fibronectin and collagen, migration, and colony forming ability do not clearly 
implicate a single SFK in these processes, findings from all of these studies share particular 
characteristics.  Firstly, this work clearly demonstrates that the involvement of the SFKs in all 
of the cellular processes examined is cell line specific (Table 5.1 A-D).  Perhaps not 
surprisingly, the greatest effects of both SFK inhibitor treatment and decreased Src, Fyn, and 
Yes expression were observed in HT29 cells, which have the highest level of Src and Yes 
kinase activity of the cell lines examined in these studies (Table 5.1 A).  This work also 
demonstrates that Src, Fyn, and Yes may all be involved in a given phenotype within a single 
cell line.  For example, the proliferation of HT29 cells was inhibited when the expression of 
any one of these SFKs was decreased.  However, as SFK knockdown was not complete in any 
of the cell lines investigated, and, in some cases, was quite poor, it is likely that these proteins 
may be more significantly involved in given cellular phenotypes than was observed.  For 
instance, while decreases in Src, Fyn and Yes expression resulted in phenotypic changes in 
HT29 and HepG2 cells, it is possible that they may also be involved in cellular processes in 
HCT116 and SW480 cells, or that the involvement of all three of these proteins is more 
significant than was observed in these studies.  This may be due to the incomplete knockdown 
of the SFKs achieved, as the levels of Src, Fyn, and Yes remaining in our cell lines of interest 
following transduction with shRNA vectors or transfection with siRNAs may have been 
sufficient to fully carry out their functions, thereby potentially masking their involvement in 
certain cellular processes.  The possibility of compensation by other SFKs following the loss of 
expression or activity of other family members may have also led to less significant effects 
being observed.  Therefore, although decreased Src expression was found to have a greater 
effect on the cancer cell phenotypes investigated in this work than decreased Fyn or Yes 
expression, this may have been due to the more significant knockdown of Src achieved.  
Similarly, differences in the effects of SFK knockdown between cell lines could also 
potentially be due to the differing levels of Src, Fyn, and Yes knockdown in the four different 




Table 5.1.  Summary of the effects of Src family kinase inhibitor treatment or decreased 
Src, Fyn, or Yes expression on the proliferation, adhesion, migration, and colony forming 
ability of selected cancer cell lines.  A. HT29, B. HCT116, C.  SW480, and D. HepG2 cells 
were examined.  No statistically significant change in a phenotype following treatment or due 
to decreased protein expression is indicated by the – symbol; + to +++ indicates increasing 
levels of inhibition of the indicated cellular phenotype.  Arrows indicate an increase in the 
cancer cell phenotype when treated with low concentrations of inhibitors, while n/a signifies 




























     This work also shows that the effects of SFK inhibitor treatment on cellular processes are 
inhibitor specific, as the four inhibitors used in these studies were found to have different 
effects on multiple cancer cell phenotypes.  In general, PP2 and SKI I had the greatest effects 
on the cellular phenotypes of all of the cell lines examined, while SU6656 also had significant 
effects in HT29 and HepG2 cells, and SKI II only impacted HCT116 cells (Table 5.1 A-D).  In 
addition, the consequences of SFK inhibitor treatment were also concentration-dependent, 
whereby the greatest inhibition of proliferation, adhesion, migration, and colony forming ability 
was, not surprisingly, observed to occur when cells were treated with the highest concentration 
of the inhibitors.  Interestingly, the adhesion of all four of our cell lines of interest to 
fibronectin, collagen, or both, was increased following treatment with the lowest concentration 
of at least one of the SFK inhibitors, as was the colony forming ability of HepG2 cells when 
treated with low concentrations of PP2.  This highlights the importance of determining 
effective doses of these drugs, as they may have very different effects on certain phenotypes, 
depending on the concentrations being used.  That the inhibitors elicited such varying responses 
between cell lines may also suggest that at least some of the changes in cellular phenotypes 
observed could be due to effects that these inhibitors have on proteins other than the SFKs.  
Finally, as the inhibition of the kinase activity of multiple SFKs using SFK inhibitors generally 
had a greater effect on all of the cellular processes examined than the individually decreased 
expression of Src, Fyn, or Yes, this work also suggests that multiple SFKs likely need to be 
targeted in order to elicit the most significant effects on cancer cells.  In all, the involvement of 
the SFKs in various cancer cell phenotypes was shown in this work to be extremely complex. 
 
5.4. Scope and Significance 
     The experiments presented in this work examined the involvement of the SFKs in cancer 
cell phenotypes such as proliferation, adhesion, migration, and colony formation.  As the SFKs 
are a valid therapeutic target in a number of different cancers, it is important to investigate the 
involvement of these proteins in cellular processes in order to understand the consequences of 
their inhibition.  This work clearly demonstrated that not only are multiple SFKs expressed 
within a cell line, but that more than one of the SFKs expressed may have kinase activity.  It 
has also shown that the involvement of the SFKs in particular cellular processes is not clear-
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cut, and, importantly, appears to be cell line specific.  Furthermore, although decreased Src 
expression was found to result in the greatest effects on all of the cancer cell phenotypes 
investigated, Fyn and Yes were also implicated in certain phenotypes, suggesting that multiple 
SFKs may need to be targeted in order to achieve the greatest effects on cancer cells possible.  
In particular, and not surprisingly, targeting the SFKs in cell lines with relatively higher Src 
expression and activity, such as HT29 cells, was found to have a greater effect than in cells 
with lower Src activity, such as SW480 cells.  This is important, as it suggests that the 
treatment of cancer cells with lower Src expression with SFK inhibitors may not be effective, 
and that other cancer therapies may be more useful in these cases.  Also of note is the finding 
that the effects of SFK inhibitor treatment on the cancer cell lines investigated appear to be not 
only inhibitor specific, but that the effects of treatment with a given SFK inhibitor vary 
significantly depending on the concentration of inhibitor used.  Although no clinically relevant 
SFK inhibitors were examined in this study, this may also potentially complicate the use of 
other SFK inhibitors as cancer therapies.  Therefore, it will be important in the future to 
determine which cancers will benefit from treatment with SFK inhibitors, particularly as it is 
becoming increasingly evident that different cancers are best targeted by different therapeutic 









6. CONCLUSIONS AND FUTURE STUDIES 
     An extensive body of work investigating the cellular functions of Src has accumulated since 
the observation of Peyton Rous that a filterable agent was capable of causing cancer in 
chickens nearly a century ago.  More recently, it has been found that there is a whole family of 
similar proteins that also have important cellular functions.  Significantly, the SFKs have also 
been implicated in a number of human diseases, including many cancers (Engen et al., 2008).  
As these proteins have been found to be involved in a variety of cancer cell phenotypes, 
including proliferation, adhesion, migration, angiogenesis, and metastasis, they are of 
significant clinical interest, and there are currently a number of SFK inhibitors in clinical trials 
or in use as cancer therapies (Wheeler et al., 2009).  As such, it is important to understand the 
involvement of the different SFKs in cancer cell phenotypes.  Although a large number of 
studies have examined the role of Src in these processes, far fewer investigations into the 
involvement of the other ubiquitously expressed SFKs, Fyn and Yes, have been carried out.  
This work outlines the findings that multiple SFKs are expressed in given cancer cell lines, and 
that the levels of protein expression and combinations of the SFKs expressed vary between cell 
lines.  It also shows that not only Src, but also Yes and Fyn have detectable kinase activity in a 
subset of cancer cell lines.  By examining four different cell lines using both chemical SFK 
inhibitors and an shRNA/siRNA approach to specifically decrease the expression of Src, Fyn, 
and Yes individually, this work in particular demonstrates that the effects of SFK expression 
are not clear-cut.  Significantly, it suggests that the involvement of the SFKs in proliferation, 
adhesion, migration, and colony forming ability is cell line specific, and that multiple SFKs 
need to be targeted in order for significant effects on these cellular processes to occur. 
     Although this work examined the effects of decreasing the expression of Src, Fyn, or Yes 
individually, the level of knockdown achieved was less than ideal and may have prevented the 
involvement of these proteins in cancer cell phenotypes from being observed.  It would also 
have been useful to examine the effects of knocking down different combinations of SFKs in 
order to more fully understand the involvement of these proteins in various cellular processes.  
Such studies could be used to determine if multiple SFKs are involved in given cancer cell 
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phenotypes, and if they have complementary and/or compensatory functions.  Furthermore, 
cells in which the expression of specific combinations of SFKs were decreased would provide 
an important tool that could be used to determine if the effects of SFK inhibitors on cancer cells 
are due to the inhibition of these proteins or are instead due in part to non-specific effects on 
other proteins.  This is likely the case, as many of the SFK inhibitors currently in clinical trials 
target other proteins, in particular Abl kinase, in addition to the SFKs (Wheeler et al., 2009).  
As Src and the other SFKs are likely to remain attractive targets in cancer therapy in the future, 
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